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DELTA-AMINOLEVULINIC ACID (ALA) IN LEAD POISONED AND
TUMOR BEARING ANIMALS
The data based on research of ALA in lead-poisoned and tumor bearing
animals is divided into three major sections.
The first section concerns data obtained from the modification of the
dual piggyback unit for urinary ALA to a one-column unit for screening a pediatric population for early detection of exposure to lead.

The data from the

present experiments indicate that recovery of ALA from the one-column unit
averaged 94 percent. In parallel with the modification studies, methods and
data is presented for the isolation and quantitation of human urinary porphobilinogen (PBG) anrl urinary urea utilizing a color chromophore formed with
modified Ehrlich's reagent.

Data is presented indicating that a triad of

quantitative tests could be rapidly obtained from one 0. 50 ml. aliquot of
urine--namely ALA, PBG, and urea.
The second section concerns the effect of lead poisoning on rabbits
especially in regard to accumulation of ALA in the tissues.

The data of the

present experiments indicates that one gram of tissue is sufficient for the
analysis of tissue ALA levels. Recovery of ALA from normal tissue averaged
92 percent and of the 21 tissues isolated and studied the greatest accumulation
of ALA occurred in the bone marrow and kidney approximately a 100 and 27 fold
increase over control, respectively.

Studies were completed showing ALA

accumulation in the bone marrow and kidney were dose-nependent on the lead
acetate injected. It is concluded that the methods described would be most
useful in determining ALA levels in the post-mortem diagnosis of lead poisoning
The third section presents data on a tumor-host interaction. This
involves greatly elevated levels of delta-aminolevulinic acid dehydrase (ALAD)
with a concomitant increase in reticulocyte formation.

The tumor studied was

the Walker 256 Carcinosarcoma and the host species was the Sprague-Dawley

iii

rat. A study of basic hematology parameters was also initiated-- to determine
red and white cell counts, hemoglobin, hematocrit, body weight, tumor volume,
and percent reticulocytes. The most significant factor determined was the
reticulocyte count. The data indicates that immediately after transplantation
and 4 days before the transplanted tumor becomes palpable, ALAD activity
increases over control values in conjunction with the increased reticulocyte
count. ALAD activity increased ll7 percent over control within 24 hours after
transplantation. The count rose to 619 percent by day 4, the first day of palpable tumor growth.

The reticulocytes increased to l, 440 percent by day 16,

the last day of accurate tumor measurement, and rose to 2, 000 percent over
control on day 20, the final day of the experiment.
After transplantation the reticulocyte count increased over control was as
follows:

70 percent at 24 hours, 387 percent at 4 days, l, 822 percent at day

16, and 2, 300 percent at day 20.
Two significant results are noted from these data about the growth of
the Walker tumor in vivo: 1) the similarity and parallelism of ALAD activity
with the percent reticulocyte formation and 2) the immediate and rapid elevation
of these two parameters before any growth of the tumor could be detected as
well as their persistence throughout the time of the growth of the tumor.
These data indicate that the Walker tumor stimulates reticulocytosis
with a concomitant increase in ALAD activity suggesting a unique early
tumor-host interaction.
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INTRODUCTION
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CHAPTER I
INTRODUCTION
A.

UNIFYING THEME OF THE DISSERTATION

The main theme, or unifying concept, of studies based on deltaaminolevulinic acid (ALA) in lead poisoned and tumor bearing animals should
be briefly explained at the beginning of this dissertation, later to be developed
in more detail.
The heme precursor delta-aminolevulinic acid (ALA), the first product
in heme synthesis is excreted in significant amounts in the urine of a child
or an adult having a blood lead concentration over 50 µgrams/100 ml
(Selander and Cramer, 1970).

This excreted precursor is quantitatively

determined to indicate how severe the exposure to lead was and how severe
the toxicity is that is borne by the hematopoietic system.

The inhibition by

inorganic lead (Gibson et al, 19 55, Lichtman and Feldman, 19 63, de Bruin
and Hoolboom, 19 67 and de Bruin, 19 65) of one of the enzymes in the heme
biosynthetic pathway, namely ALA dehydrase (Chisolm, 1964), is thought to
be responsible for the spilling over of ALA into the urine.

This enzyme is

dependent on the presence of free sulfhydryl (SH) groups for its activity
(Chisolm, 19 64).

The SH - groups of the active center of ALA dehydrase are

part of the protein structure of the enzyme molecule.

The interaction of lead

3

with ALA dehydrase is complex because of the presence of many factors including reactive ligands which have not been studied to date.
The enzyme ALA dehydrase catalyzes the condensation of two molecules
of the substrate ALA by a Knorr type of reaction to form one molecule of
porphobilinogen (PBG), the second product in the heme biosynthetic pathway.'
The enzyme is found in the mature red blood cell and is measured by taking a
peripheral blood sample. As previously described, lead binds to the free SH
groups of the dehydrase molecule P.reventing the formation of PBG.

The ALA

dehydrase enzyme which is inhibited in lead poisoning is elevated in the
animal bearing a Walker 256 carcinosarcoma tumor.

This unique finding will

be thoroughly discussed in this dissertation.
Therefore, the substrate delta-aminolevulinic acid and its enzyme deltaaminolevulinic acid dehydrase, which is inhibited in the lead poisoned animal
and elevated in the animal bearing a Walker tumor, is the unifying concept of
this dissertation.
B.

HISTORY OF LEAD POISONING
It has been known. since antiquity that lead poisoning may occur when

the metal gains access to the body tissues by inhalation, ingestion, or skin
contact. The first descriptions of the clinical picture of such intoxication
date back to the middle of the seventeenth century (Stockhausen, 1656). Its
toxic properties were first recognized by Hippocrates (Hunter, 19 62) and over
the centuries more has been written about the causation and symptomatology

.
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of poisoning by lead than by any other toxic agent (Johnstone, 19 66).
Tanquerel des Planches in 1839 published an epoch-making treatise
containing an accurate clinical description of lead poisoning and since
Tanquerel' s time, little has been added to our clinical knowledge of lead
poisoning.

This treatise was responsible for the initiation of a period of

intensive clinical and experimental investigation of lead poisoning and this
research is presently continuing.
Lead is a normal and ubiquitous constituent of the earth's crust being
present in an average concentration of about 16 parts per million (Swaine, 1955)
Because of its ubiquitous nature, lead is absorbed along with other trace
elements by plants and animals v..1 hich in turn form the diet of man.

Since this

has been true for many millions of years, it seems reasonable to conclude
that man has always had a level of lead within his body which has derived
largely from the diet and was not the result of man's industrial activities.

This

level of lead constitutes a "background" body burden which is always present,
although varying in amount from place to place on the earth's surface, depending upon the local concentration of lead in the soil and water.
There is much evidence that lead wastes have been accumulating
during the past century, particularly in congested urban areas.

Increased

exposure to lead has been shown in populations exposed to lead as an air
pollutant.

Postmortem examinations show a higher lead content in the organs

of individuals in highly industrialized societies than in organs of most

---------------------"··-·. .
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individuals in primitive populations. Although no population group is apparently yet being subjected to levels of exposure associated with the symptoms of
lead poisoning, it is clear that a continued rise in the pollution of the human
environment with lead could eventually produce levels of exposure that could
have adverse effects on human health.
C.

CHILDHOOD LEAD POISONING

The immediate and urgent problem is to control the exposure to lead
of well-defined groups that are known to be directly at risk - especially young
children who live in dilapidated housing where they can nibble chips of
leaded paint.
There is a large group of children between one and five years of age
who live in deteriorating buildings who have the habit of eating nonfood substances including peeling paint, plaster and putty containing lead (Bradley
et al, 1956 and Griggs et al, 1964).
la tin word for magpie).

(This behavior is termed pica, after the

The epidemiological data are still incomplete but

large scale screening programs now in progress in Chicago and Ne'I!'! York City
indicate that between 5 and 10 percent of the children tested show evidence of
asymptomatic increased lead absorption and that between 1 and 2 percent have
unsuspected plumbism (Davis, 19 68

).

The causative factors for childhood lead poisoning are commonly a
triad: a dilapidated old house, a toddler with pica aad parents with inadequate
resources (emotional, intellectual, informational and/or economic) to cope

b

with the family's needs (Chisolm, 197 O).

The three factors interact to increase

the liklihood that the child will eat chips of leaded paint. A chip of paint
about the size of an adult's thumbnail can contain between 50 and 100 milligrams of lead (Chisolm and Harrison, 195 6), so a child eating a few small
chips a day easily ingests 100 or more times the tolerable adult intake of the
metal.

Pica for leaded paint results in genuinely massive exposures and when

the abnormal intake ceases it may be several months or years before bloodlead levels return to normal (Kehoe, 19 61). Kehoe (19 61) measured the rate at
which the excessive burden of lead is excreted after experimental ingestion
is terminated.

The data indicates that it takes twice as long for the adult to

excrete a given burden of lead as it does for him to accumulate it. Kehoe (19 61)
has shown that bone is the chief storage depot for lead.
over has considerable influence on lead turnover in man.

The rate of bone turnSince the rate of bonE

turnover differs between children and adults, these adult data cannot be
strickly applied to the lead-turnover rates in the growing child. The data
indicated as presented by Kehoe, does establish the validity of blood lead and
urinary AI.A as indices of the body burden of lead.
Whole blood-lead measurements require careful interpretation, and
serial measurements are necessary to ascertain trends. The following factors
must be considered in accessing the significance of a given value: hematocrit,
intercurrent infection, coincident bone disease, current or recent administration of chelating agents, current or recent excessive absorption of lead and

-4-

the time interval since excessive absorption ceased.

About 90 percent of the

lead in whole blood is transported attached to the red-cell surface (Clarkson
and Kerch, 1958).

Chelating agents have only a transient effect on the dis-

tribution of lead between plasma and red cells (Hammond and Aronson, 1960).
Thus, the quantity of circulating red cells largely determines the blood's
carrying capacity for lead.
Chelating agents temporarily disturb the equilibrium between bone and
soft tissues because they remove lead from the soft tissues only.

Thereafter,

several weeks may be required for bone and soft tissue lead to be equilibrated
once again.

During this time, the blood lead will rise to a new plateau from

the temporarily depressed val':1e seen at the end of treatment with chelating
agents. When chelating agents and intensive absorption cause such fluctuations in blood lead concentrations other parameters of lead' s metabolic
toxicity such as urinary excretion of delta-aminolevulinic acid (ALA) (HaegerAronson, 19 60)

_g_~ a

more accurate index of the biologic

effects~ead.

It is apparent from recently published data that previous concepts of

"normal" blood-lead concentrations should be revised downward (Jacobziner,
19 66 H. and Rennert, O. M. et al, 1970).

Beyond infancy there is general

agreement that the median value in unexposed subjects is approximately 27
µgrams and that the upper limit is 40 µgrams lead per 100 ml of whole blood.
In the past, 50 to 60 µ grams has been cited as the upper limit of "normal".
In part, this old higher limit was based on the observation that clinically -

overt acute plumbism is virtually always associated with values greater than
The higher value was based on the use of 11 normal 11 samples

6 0 µ grams.

containing a large proportion of young children drawn from old urban housing
areas (Kaplan and McDonald, 194 2).

T\11 1enty or thirty years ago the extent of

lead exposure in such an environment was not fully appreciated.

More recently,

a random sample of 333 children drawn from a low-income area of Baltimore,
Maryland gave a mean value for whole blood lead of 4 3 ± 14 µ grams (Bradley

-

et al, 19 56).
Therefore, in a child with pica, the rep·eated ingestion of leaded-paint

chips for about 3 months or longer can lead to clinical symptoms and eventually
to the absorption of potentially lethal body burden of lead.

During the first

four to six weeks of abnormal ingestion there are no symptoms.

After a few

weeks minor symptoms such as decreased appetites, irritability, clumsiness,
unwillingness to play, fatigue, headache, abdominal pain and vomiting begin
to appear,

These, of course, are all quite nonspecific symptoms, easily

ignored as behavior problems or blamed on various childhood diseases.

In a

few weeks the lassitude may progress to intermittent drowsiness and stupor;
the vomiting may become persistent and forceful; brief convulsions may occur.
If exposure to lead continues, the course of the disease can culminate abruptly

in coma, intractable convulsions and sometimes death.
This picture of fulminating encephalopathy is commonest in children
between 15 and 30 months of age; older children tend to suffer recurrent but

less severe acute episodes and are usually brought to the hospital 'l/ltith a
history of sporadic convulsions, behavior problems, hyperactivity or mental
retardation.

The symptoms tend to wax and wane

severe in summer.

usually becoming more

Some 85 percent of all lead-poisoned cases are reported

from May through October.
It is certain that acute lead encephalopathy in early childhood produces

irreversible injury to the brain (Blockman, 1937).

Byers and Lord (1943) were

the first to suggest that lead might produce mental deficiency, and clinical
and experimental evidence has since supported this idea.

Moncrieff et al,

(1964) showed that the frequency of blood lead levels greater than 36 µgram
per 100 ml in 122 mentally retarded children was 45 percent, and Gibson (19 67)
noted an increased incidence of blood lead levels greater than 40 µgrams
per 100 ml in a group of children who were mentally retarded but in v.•hom no
etiological factor for their mental deficiency was known, compared with normal
children or mentally retarded children of known etiology.
Today public attention is finally being focused on childhood lead
poisoning, although the difficult task of eradicating it has just begun.

I

believe it is impermissible for ~ humane society to fail to do Vl.·ha t is so
necessary to eliminate a wholly preventable disease.
D.

LABORATORY METHODS USED TO DETECT INCREASED LEAD EXPOSURE

1.

Number of basophilic stippled cells in perpheral blood

Behrend in 1899 was the first to report that lead causes stippling of the

erythrocyte. Today, we recognize that two different types of granulations may
be present in the erythrocytes of lead-intoxicated patients and animals (Griggs,
19 64). The first type of granulation is due to an accumulation of excessive
iron unusable for hemoglobin formation and the second type represents damaged
mitochondria that do not contain iron.
Stippling, however, is generally considered an unreliable criterion of
lead intoxication because it also occurs in a large number of blood diseases
such as various types of hemolytic anemia, post hemorrhogic anemia, leukemia,
and after exposure to benzene, aniline, carbon monoxide, arsenic, copper,
and bismuth (Haeger-Arons en, 19 60). The upper limit of normal is approximate
and the values cited vary considerably, ranging from 1 per 10, 000 RBC
(Schmidt, 1919) to 90 per 10, 000 (Sanders, 1943). Therefore, the method can
hardly be more than an "adjunct to other more specific and sensitive methods"
(Kehoe, 19 4 9) •
2.

Determination of coproporphyrin III in the urine

Urinary coproporphyrin III excretion has been shown to be elevated in
lead ·poisoning (Wyllie, 19 55; Holeck, 19 57; Benson and Chisolm, 19 60; and
Haeger-Aronsen, 19 60). However, coproporphyrin levels are also increased in
various forms of anemia, particularly hemolytic anemias, in jaundice whether
due to diffuse liver damage or to biliary obstruction, in some infectious diseases such as pneumonia and acute poleomyelitis, and in several types of intoxication including mercury, bismuth, sulfonal, and sulfonamide poisoning
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(Haeger-Arons en, 19 60).

The upper limit of normal for urinary coproporphyrin

is 15 µ grams per 100 ml of urine.
3.

Determination of lead in blood and urine

Most investigators agree that an increased level of lead in the blood
and urine is the most specific sign of increased lead absorbance. It must be
remembered, however, that the blood is rapidly cleared of lead and blood
lead levels are considered of value only in acute cases of lead intoxication.
Berman (19 66) has reported that the blood lead levels in chronic cases of lead
poisoning are not remarkable.
The drawing of blood samples and the analytical procedures for determining the lead levels in blood and urine are time consuming processes requiring
skilled personnel and it therefore appears that the determination of lead in
the blood and urine is not practical as a screening test for early detection of
increased lead absorption.
4.

Determination of urinary delta-aminolevulinic acid (ALA) and the
rational for its use

In 19 5 6 Mauzerall and Granick developed a sensitive colorimetric method
for the quantitative determination of urinary ALA.

Using this method one

takes an aliquot of random urine (pH 5 to 7) containing porphobilinogen
(PBG), urea, and ALA and places this on a column of Dowex 2 resin in the
acetate form.

The PBG is retained by the anion-exchanger Dowex 2. The ALA

is then placed on a cation-exchanger Dowex 50 in the hydrogen form, and

I

L

washed well with distilled water to wash out the urea.
After elution from the ion-exchangers, PBG and ALA are demonstrated by
means of p-dimethylaminobenzaldehyde (DMAB), the former substance directly;
l

the latter, after quantitative conversion to 3-acetyl-2-methylpyrrole 4-(3 )
propionic acid by heating with acetylacetone. With DMAB in acid solution,
PBG as well as the pyrrole obtained on condensation of ALA and acetylacetone,
forms colored complexes which are spectrophotometrically determined.
Haeger in 1957 using Mauzerall and Granick's technique, reported that
workers exposed to inorganic lead have considerably elevated ALA levels in
urine. Since then, numerous other investigators have shown elevated urinary
ALA levels in cases of clinical adult plumbism and in adult workers exposed to
lead (Haeger-Arons en, 19 60; de Kretzer and Waldron, 19 63, Klein stein et al,
1963; Efe, 1964; Cramer and Selander, 1965; Cramer et al, 1966; de Bruin and
Hoolboom, 1967; Cramer and Selander, 1967; Williams and Few, 1967; Gibson
et al, 1968; Wada et al, 1969; Selander and Cramer, 1970; Davis, 1970; and
Haeger-Aronsen, 19 71).
Urinary ALA levels have been reported to have a positive correlation with
blood lead levels (Selander et al, 1966 and Davis, 1970), urinary lead excretion
(Haeger-Aronsen, 1960; Cramer and Selander, 1965), and clinical impression of
lead intoxication (Craemer and Selander, 19 65). Raised ALA levels in the urine
have also been found to be closely correlated to raised ALA levels in serum
(Saita and Moreo, 1961; Chiesura and Brugnone, 1963).

Blood and urinary ALA
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levels remain significantly increased for up to three x_ec:i:r_§ 9Jter cessation of
lead exposure (Saita and Moreo, 1964).
An increased ALA excretion has been reported to be an earlier sign of
lead exposure than an increased coproporphyrin excretion (Singerman, 1964;
Djuric et al, 19 6 6) and several investigators have stated that an increased
ALA excretion is the earliest sign of an increased lead absorbance (Efe, 19 64
and Djuric et al, 19 66). An increased urinary ALA level also appears to be
pathognomonic of elevated lead absorption since the only other conditions
known to result in an increased ALA excretion are acute intermittent porphyria
and certain liver diseases.

Haeger-Aron sen (19 60) determined the urinary

ALA content of patients with either biliary disease, acute hepatitis, cirrhosis
of the liver, hemolytic anemia, pernicious anemia, malignant tumor, leukemia,
diabetes mellitus, nephropa thy, or drug intoxication.

The concentration of

ALA in the urine was normal in all cases except three.

Two of these were

patients with acute hepatitis and one was a man with bronchial cancer.
Schlenker et al {19 64) determined the urinary ALA content of patients with
Hodgkin's disease, cirrhosis, leukemia, multiple myeloma, sickle cell anemia,
or cancer and the only patient showing a minor elevated urinary ALA level was
the one with cirrhosis.

Griggs (19 64) compared the urinary ALA levels of

patients with lead toxicity, acute intermittent porphyria, iron deficiency
anemia, hemolytic anemia, pernicious anemia, or liver disease and found
that elevated levels are seen only in patients with lead poisoning, acute
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intermittent porphyria, and occasionally liver disease.
E.

HEME BIOSYNTHESIS
l.

Normal heme biosynthesis

The biosynthetic sequence of heme has been elucidated as a result of
the research conducted mainly in the laboratories of Shemin and Granick in
the United States and Neuberger and Rimington in Great Britian. As early as
1948 it was found that avian red blood cells can synthesize heme in vitro
(She min et al, 19 48) and soon after, cell free extracts of duck erythrocytes
were found to synthesize heme from the proper substrates (Shemin et al, 1955).
When chicken cells, rabbit reticulocytes, and human red cells from erythroblas
tosic fetalis are hemolyzed, a number of the enzymes of the heme biosynthetic
pathway are found to be soluble and can be separated from each other by zone
electrophoresis on starch (Granick and Mauzerall, 19 58). These soluble
enzymes are localized in the cytoplasm and include delta-aminolevulinic acid
dehydrase (ALAD}, porphobilinogen (PBG) deaminase, uroporphyrinogen (UPG)
isomerase, and uroporphyrinogen decarboxylase.

The insoluble enzymes are

loca1ized in the mitochondria and include ALA synthetase, coproporphyrinogen
(CPG) oxidase, and heme synthetase (Sano and Granick, 19 61).
The first step in heme synthesis is the condensation of succinyl Co A
with glycine (Shemin et al, 1955; Gibson et al, 1958; and Kikuchi et al, 1958)
to form

-amino-

-keto adipic acid which readily decarboxylates yielding

delta-aminolevulinic acid (Shemin et al, 1955 and Neuberger, 1961). This
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reaction is catalyzed by the enzyme ALA synthetase and requires pyridoxal
phosphate as a co-factor (Lascelles, 1957; Schulman and Richert, 1957; and
Kikuchi et al, 1958). The enzyme ALA dehydrase condenses two molecules of
ALA forming one molecule of porphobilinogen (PBG) and water (Gibson et al,
19 55). Three molecules of PBG then combine under the influence of PBG
deaminase to form tripyrryl methane and this in the presence of UPG isomerase
is converted to uroporphyrinogen III (Bogorad, 19 58a and Cornford, 19 64). The
four acetic acid side chains of uroporphyrinogen III are then decarboxylated
by UPG decarboxylase to produce coproporphyrinogen III (Mauzerall and
Granick, 19 58).

Two propionic acid side chains of coproporphyrinogen III are

oxidatively decarboxylated to form vinyl groups by CPG oxidase and this results in the formation of protoporphyrinogen IX (Sano and Granick, 19 61).
Protoporphyrinogen IX is then autoxidized to form protoporphyrin IX (Sano and
Granick, 19 61) and hemesynthetase inserts one ferous ion into each molecule
of protoporphyrin IX forming heme (Goldberg et al. 195 6 and Labbe and Hubbard,
19 60).

This total scheme is shown in figure 8.
2.

Effect of lead on heme synthesis

Perhaps the first note relative to an effect of lead upon the synthesis
of heme was that of Binnedijk (1895) in his report of the occurence of porphyrin
in the urine of a patient with lead intoxication (cit. Haeger, 1960). However,
it was Watson (1936) who first suggested that this porphyrinuria might be a

manifestation of an effect of lead upon the synthesis of hemoglobin. It is

l
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now known that the urine of patients with lead intoxication consistently contains abnormally large quantities of coproporphyrin, as well as its immediate
precursor, uroporphyrin (Bashour, 1954).

More recently it has been observed

in elegant studies by Haeger-Aron sen (19 60) that urine from such patients contains large amounts of delta-aminolevulinic acid, although the simultaneous
rate of excretion of porphobilinogen is normaL As previously discussed, ALA
has been and is now used widely as a screening test for lead exposure.

In

fact, it is probably the most frequently used test in urban pediatric practice
for the detection of lead poisoning in children.
Heme is necessary in the synthesis of cytochrome oxidase as well as
in the production of red cell hemoglobin.

Because the synthesis of heme is

an essential biochemical pathway for all cells, the effects of lead poisoning
are much more significant and far reaching than the anemia alone (Avent, 1972).
A synopsis of the salient features of the influence of lead on heme
synthesis may be described by the following diagram and paragraphs which
follow.

SUCCINYL CoA
Glycine
Pyridoxal-p

l

cS-ALA

l

Pb

Excessive Excretion
in Urine

0 -ALAD

•...

PORPHOBILINOGEN
UROPORPHYRINOGEN III

Pb

COPROPORPHYRINOGEN III__.. Excessive Excretion
llJt
in Urine
PROTOPORPHYRINOGEN

+
+
PROTOPORPHYRIN IX _

Pb ------•lllt

+

___,_..

Excessive Accumulation in Erythrocytes

HEME
INHIBITORY EFFECTS OF LEAD IN THE BIOSYNTHESIS OF HEME
As can be seen from the above diagram lead exerts an inhibitory effect
on several of the enzymes necessary for heme synthesis e.g. ALA dehydrase,
CPG oxidase, and heme synthetase. ALA dehydrase (Gibson et al, 19 55) and
heme synthetase (Schwartz et al, 1959) both contain essential sulfhydryl
groups and a blockage of such groups by lead maybe the cause of the inhibition
of their activity.
a.

ALA dehydrase

Several authors have reported that the activity of this enzyme is
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decreased in erythrocytes from lead-intoxicated patients (Lichtman and
Feldman, 19 63; Bonsignore, 19 66; and de Bruin and Hool boom, 19 67).
Gibson (1955) isolated and purified ALA dehydrase and demonstrated
the inhibitory effect of lead upon the enzyme in vitro.

Bonsignore (19 65) and

de Bruin (1968) were able to demonstrate that in adults occupationally exposed
to lead, red cell ALA dehydrase activity was reduced appreciably below that of
control groups.

Nakao et al (19 68) found evidence of decreased red cell ALA

dehydrase activity in adults with clinically evident lead poisoning and also in
asymptomatic lead workers.

Hernberg and his co-workers (1970 a, b) observed

.an increased correlation between blood lead levels and red cell ALA dehydrase
activity in adults.

Similar correlations between blood lead and rerl cell ALA

dehydrase have been demonstrated in children by Millar and Battistini (1970).
Recently Weissberg et al (1971) introduced a micromethod to screen for lead
poisoning using ALA dehydrase.
ALA dehydrase is functionally significant when blood lead concentration
is approximately 10-50 µ gram per 100 ml. It is especially useful because
it indicates biochemical effects on the general population at exposures

induced by environmental polluation with lead (Hernberg, 1970 a).

Frank

lead poisoning is considered to be any blood lead level over 60 µ gram per
100 ml.
Previous studies concerned with the interrelationship between different
Parameters indicative of lead absorption have dealt with a rather high exposure
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level, or even with clinical poisoning. At these levels of absorption (over 60
P. grams blood lead per 100 ml) the concentration of ALA in urine gives a

quantitive measurement of the response of the organism to surplus lead (Haeger
Arons en, 19 60; Davis and Andelman, 19 67; Davis, J. R • .§! al, 19 68; Selander
and Cramer, 1970, Davis, 1970; and Haeger-Aronsen 1971).
b.

CPG oxida se

An increased urinary excretion of coproporphyrin from individuals with
lead intoxication has been known for years.

Coproporphyrinogen III is the

compound that is excreted in the urine, however, it is rapidly oxidized to
coproporphyrin III (Watson et al, 1951 and Weatherall, 1952).

The increased

urinary excretion of coproporphyrin III in lead poisoning has been postulated
to be due to destruction in the bone marrow of younq red blood cells containing
large amounts of coproporphyrinogen III (Schmid et al, 1950).

This increased

amount of coproporphyrinogen III in the young red blood cells is a result of the
inhibition of the enzyme CPG oxidase by lead.
c.

Heme synthetase

Erythrocyte protoporphyrin IX levels have been found by
(1958) to be elevated in 21 of 22 patients with lead poisoning.

Rubino.§!~

Increased

amounts of protoporphyrin IX in the erythrocytes of lead poisoned patients have
also been found by Vigliani and Waldenstrom (1937). Whitaker and Vietti (1958)
have shown that children with lead intoxication also have increased amounts of
Protoporphyrin IX in the erythrocytes.

Lead inhibits the in vitro synthesis of
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heme from protoporphyrin IX and iron of chicken, rabbit, and human erythrocytes
(Rimington, 19 51 and Jandl et al, 19 59). It has been reported that in humans,
elevated levels of protoporphyrin IX persist in the erythrocytes up to nine
years after cessation of lead exposure (Saita and Moreo, 19 64).
F.

BIOSYNTHESIS OF DELTA-AMINOLEVULINIC ACID
Prior to 1946 little was known about the chemical building blocks

from which the body synthesizes porphyrins and heme.

In that year Shemin

and Rittenberg observed that after administration of isotopically labeled glycine
the concentration of the label in the circulating hemoglobin heme rose rapidly,
remained more or less steady for about 100 days, and then rapidly declined.
The disappearance of the label from the circulating heme was accompanied by
a marked though temporary increase in the fecal excretion of labeled urobilinogen (London, et al, 1949 and Gray et al, 1950). These observations permitted
the conclusions that (1) glycine is a specific precursor of heme; (2) hemoglobin
of the circulating erythrocytes remains outside the general metabolic pool of
protein interchange; (3) most of the normal red cells have a mean life span of
about 120 days; (4) a large fraction of the fecal urobilinogen is derived from
the breakdown of circulating red blood cells; and (5) the metabolites of heme
protoporphyrin are not reutilized for the synthesis of hemoglobin in newly formed erythrocytes.
These results of synthesizing labeled heme from glycine _l4c and the
classic work of the intermediate, which is formed by the condensation of
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glycine and succinate, is the five-carbon aminoketone - ALA.
The condensation of glycine with "active" succinate to form ALA
requires the enzyme ALA synthetase.

This reaction has been demonstrated

in vitro in systems containing some particulate matter which is present in
nucleated avian red cells and in mammalian reticulocytes, liver, and kidney
(Granick and Urata, 1963, Granick, 1963, Shemin and Russel, 1955, Laver et
al,

1958, Gibson et al, 1958, Granick, 1958, and Sano et al, 1959) but is

absent from mature mammalian erythrocytes (London, 1950).

These observations

strongly suggest that the enzyme ALA synthetase is bound to mitochondria
(Granick and Urata, 1963 and Granick, 1963). Synthesis of ALA synthetase
can be induced in mammalian liver cells by a variety of compounds, which
are also known to produce experimental porphyria in animals (Granick and
Urata, 1963 and Granick, 1963).
The primary product obtained on condensation of succinyl CoA with
glycine would be expected to be o<.-amino-,8-ketoadipic acid (Shemin, 1955,
Shemin and Russell, 1953, and Neuberger and Scott, 1953). Although the
ease with which this compound undergoes spontaneous decarboxylation has
prevented its isolation (Gibson, et al, 1958), the observed conversion of its
diethyl ester to PBG in vivo is in line with this concept (Weliky and Shemin,
19 57).
The condensation of glycine with succinyl CoA maybe the prototype of
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a more general reaction involving glycine metabolism (Shemin, 1955).

Distinct

mitochondrial enzymes appear to catalyze the condensation of glycine with
other acyl CoA substrates such as acetyl CoA and propionyl CoA, forming
aminoacetone and other aminoketones (Urata and Granick, 1963).

Thus it

became of great interest to determine the aminoacetone in the urine and tissues
of the lead poisoned rabbits.
The biosynthetic pathway of ALA formation can be summarized briefly
by saying that ALA synthetase catalyzes the condensation of succinyl CoA
with glycine to form ALA.

The initial reaction of this pathway requires a

functioning tricarboxylic acid cycle and thus is oxygen - dependent; the
condensing enzyme sys tern is operative under anaerobic conditions.

The lack

of mitochondria in mature mammalian erythrocytes precludes formation of
succinyl CoA and of ALA.
G.

BIOSYNTHESIS OF PORPHOBILINOGEN
The establishment of ALA as an obligatory intermediate in porphyrin

and heme biosynthesis has allowed studies of the subsequent enzymatic
steps to be greatly facilitated.

The enzyme ALA dehydrase was found to

catalyze the condensation of 2 moles of ALA to form a precursor pyrrole
(Granick, 1954, Schmid and Shemin, 1955 and Gibson, et al, 1955).

The

theoretical formulation of the structure of this pyrrole (Shemin and Russell,
19 53) yielded the same structure as porphobilinogen (PBG), the chromogen
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excreted in the urine of patients with acute porphyria (Waldens tram, 193 7).
PBG was first isolated by Westall in 1952.
The soluble enzyme ALA dehydrase has been purified from a number of
sources, including duck erythrocytes (Schmid and Shemin, 1955), chicken
erythrocytes (Dresel and Falk, 1956) and ox liver (Gibson, et al, 1955, and
Gibson, 19 5 5).

SH-group inhibitors such as iodoacetamide and p-chloromer-

curibenzoa te have an inhibitory effect (Gibson, 19 5 5) which can be reversed
by the addition of reduced glutathione (Gibson, et al, 1955 and Gibson, 1955).

Two molecules of ALA are required for formation of one mole of PBG
(Shemin, 1955 and Schmid and Shemin, 1955). Heme synthesized from labeled
ALA has twice the specific activity of that formed from an equimolar amount
of PBG with the same radioactivity (Shemin, 1955 and Schmid and Shemin, 1955).
These findings confirmed the earlier reports by Falk et al (19 53) and by
Bogorad and Granick (1953) that PBG is a specific precursor and an obligatory
intermediate in the biosynthesis of porphyrins and of heme.
H.

METABOLISM OF ALA AND PBG IN THE INTACT ORGANISM
In man, approximately 2 mg of ALA is excreted in the urine per day

(Haeger, 19 58, Mauzerall and Granick, 19 56, Dean and Barnes, 19 59 and
Malooly and Hightower, 1962). There is no data available for ALA excretion
in bile, but it is believed to be negligible (Scott, 1955, Berlin, et al, 1956,
Berli11 et al, 1956 and Granick and Van der Schrieck, 1955). As has been

r
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described earlier, significant amounts of ALA is excreted in the urine in lead
poisoned humans.
Injection or oral administration of labeled ALA to man and to animals
results in the excretion of a large portion of the unaltered compound in the
urine (Scott, 1955 and Berlin, et al, 1956). Smaller fractions are converted to
PBG, to protoporphyrin, and to stercobilin, the first being excreted in the urine
the latter two in the bile (Scott, 1955; Berlin et al, 1956; Berlin, et al, 1956;
and Granick and Van der Schrieck, 1955). ALA-1, 4_14c gives rise to labeled
co

2

in the breath (Scott, 19 55), a small fraction of the injected ALA is

used for heme biosynthesis in immature rer:J blood cells (Scott, 1955; Berlin
et al, 1956; and Berlin et al, 1956), but in contrast to the observations
in vitro, incorporation of ALA into heme of circulating erythrocytes is several
times less than that found with equivalent amounts of labeled glycine (Berlin,
et al, 19 56). This may be explained in part by the rapid renal excretion of the
injected ALA, either in unchanged form or after its conversion to PBG. In
addition, penetration of ALA into immature red blood cells may be a ratelimiting factor (Berlin, et al, 19 5 6) •
Investigations reported very recently indicate that in man and dogs
injected ALA-4-c 14 is efficiently incorporated into the early-labeled bile
Pigment fraction (Yamamoto et al, 19 65 and Schwartz et al, 19 64). Since
this radioactive precursor also rapidly labels the "easily-split" heme fraction
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where endogenous PBG production is increased it does escape from the cells
and gain access to the urine.

Thus, in acute porphyria of man and in Sedormid

porphyria of animals, large amounts of PBG are derived from the liver and
excreted in the urine (Schmid and Schwartz, 1955; Schmid et al, 1954; and
Goldberg, 1955).
I.

PORPHYRIA
The porphyrias are genetic abnormalities of the regulation of heme

synthesis in which large amounts of heme precursors (ALA and PBG) are
excreted in the urine.

It is now clear that porphyrins are intermediates in

the synthesis of protoporphyrin of heme and are not, as was suspected some
years ago, breakdown products of heme.
There are two major forms of erythropoietic porphyria which is characterized by the porphyrins being elevated in the bone marrow.

These are three

main forms of hepatic porphyria which is characterized by having elevated
porphyrins in the liver.
To refresh ones memory, porphyrins are pigments that possess a
basic structure of four pyrrole rings linked by methene (=C-) bridges. The
individual porphyrins differ from each other according to the nature of the
eight possible side chains.

Porphyrinogens are colorless compounds (reduced

porphyrins) with a basic structure of four pyrrole rings linked by methylene
(-CH -) bridges.
2
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The most important of the naturally occurring porphyrins are uroporphyrin
(isomer types I anri III), coproporphyrin (types I and III), and protoporphyrin
(type III) •
Protoporphyrin III is present in hemoglobin and is, therefore, the most
important of the porphyrins from the physiological standpoint. It is not found
in the urine.
Coproporphyrin is the predominant porphyrin in urine and feces under
normal circumstances.

The compound occurs in urine in a variety of clinical

conditions, such as has been mentioned previously in lead poisoning,
poliomyelitis, liver disease, acute alcoholism, hemolytic anemia, and
Hodgkin's disease. Abnormally high fecal coproporphyrin values are found
in patients with hemolytic anemia and low values occur in patients with liver
disease.
Uroporphyrin is normally excreted in urine in only trace amounts.
The urinary excretion of this porphyrin is moderately increased in lead poisoning and is greatly increased in patients with certain types of porphyria.

1.

Erythropoietic porphyrias
a.

Uroporphyria

This is a very rare disorder inherited probably as a recessive Mendelian characteristic.

The disease is characterized by the excessive deposition

of porphyrin in the tissues, leading to pronounced photosensitization. This
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problem only occurs with skin exposed to light.
It is because of the demonstration of large quantities of uroprophyrin

and coproporphyrin in the normoblasts in the bone marrow that it has been
suggested that in this type of porphyria the excessive quantities of uroporphy-

rin are formed in the marrow.
Goldberg and Rimington (1962) have determined that the excretion of
uroporphyrin and coproporphyrin is predominantly of the unphysiological
series I type.

The biochemical abnormality appears to be caused by the lack

of the enzyme uroporphyrinogen isomerase in red blood cells.
b.

Protoporphyria

Erythropoietic protoporphyria is the most common form of erythropoie tic
porphyria.

It was first reported by Ma gnu~ et al in 19 61.

transmitted as an autosomal dominant characteristic.

The disease is

Uroporphyria and

protoporphyria are manifest in childhood and like uroporphyria protoporphyria
is characterized clinically by skin photosensitivity but to a lesser degree
than uroporphyria.
Biochemically, the disorder is characterized by an increase in the
protoporphyrin content of the normoblasts and erythrocytes, an increased
level of plasma protoporphyrin, and an increased excretion of protoporphyrin

in the feces.

The urinary excretion of Af.A, PBG, coproporphyrin, and uro-

porphyrin is not increased.

...
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2.

Hepa tic porphyria s

a.

Acute intermittent porphyria

This is the most important member of the group of porphyria diseases
and is characterized clinically by (l) periodic attacks of intense abdominal
colic, usually accompanied by nausea and vomiting; (2) obstinate constipation;
(3) neurotic or even psychotic behavior; and (4) neuromuscular disturbances.
The mortality rate for this disease is very high.

In the acute and latent

phases of this disease and often in states of remission, patients excrete
in urine an excessive quantity of PBG and ALA (Haeger, 1958).

In contrast to

the erythropoietic porphyrias acute intermittent porphyria (AIP) has an absence
of skin photosensitivity because the prophyrin precursors are excreted in the
urine.
Freshly voided urine collected from patients with AIP is frequently
normal in color and on standing in the sunlight turns to a Burgundy wine color
or even black.

This color change can be hastened by adding a small amount

of acid to the urine and boiling for 3 0 min.

The explanation for these color

changes is that PBG (colorless) and not uroporphyrin (red) is excreted in the
urine.

Heating of PBG in an acid medium results in the nonenzymatic formation

of uroporphyrin, together with a dark-brown or reddish-brown nonporphyrin
pigment.
In AIP during relapse the presence of PBG is a constant feature.
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Therefore, it is essential that an accurate, rapid method be available to detect
PBG. The Watson-Schwartz modification of the Ehrlich reaction is no longer,
in my opinion, a valuable screening procedure.

I believe the quantitative

determination of PBG using the method described in this dissertation will
serve as an excellent screening procedure.
1.

Causes of porphx:ria

Acute attacks of porphyria in people who have the trait can be caused by
drugs, and these attacks are sometimes fatal.
are involved (Eales and Lender, 1962).

Most frequently the barbiturates

Drugs that cause this idiosyncratic

reaction belong to different chemical classes, but the ally! group is common
to many of them.

Diallylbarbiturate, allylisopropylbarbiturate, and allyl-

methylbutylbarbiturate all provoke great increases in porphyrin excretion;
and allylisopropylacetylurea (Sedormid) was one of the earliest known offenders
Estrogens, certain 5-{J-H steroid metabolites, griseofulvin, some anticonvulsants, chloroquine, sulfonamides, aminopyrine, hexachlorobenzene,
and other drugs without the ally! group have also been implicated (Granick,
19 65).

For obvious reasons it is important to know which drugs do not induce

attacks of porphyria; known to meet this criterion are ether, morphine,
chloral hydrate, and penicillin. A catalog of "safe" drugs would be useful,
not only for pa ti en ts with porphyria, but for all who have genetic defects
in which drug idiosyncrasy is prone to occur.
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2.

Biochemical basis of porphyria

The biochemical basis is evidently an uncontrolled overproduction of
porphyrins, principally PBG, the first pyrrole on the pathway of heme biosynthesis.

In the normal patient there is normally a control or inhibitor of

ALA synthesis in the liver, but this control breaks down in the diseased
subject.
The enzyme responsible for the condensation of glycine and succinylCoA is ALA synthetase.

The step mediated by AI.A synthetase is rate limiting

for the whole pathway.

Thus, an increased activity of this enzyme would

lead to an increased rate of biosynthesis of the heme precursors (Granick
and Mauzerall, 19 58).
Several agents that produce acute porphyria in vivo have been shown to
cause a large increase in the level of ALA synthetase in the liver of experimental animals (

Granick and Ura ta, 19 63).

Studies with embryonic

chick liver cells in vitro have been especially interesting (Granick, 1963).
Addition of drugs such as mentioned above led to the production of porphyrins
detectable by fluorescence microscopy.
if ALA was added.

Porphyrins were also readily formed

Actinomycin D, added to the cultures, blocked the drug-

induced porphyrin formation but not that caused by ALA.

Since the effect of

actinomycin is to prevent DNA-dependent RNA synthesis, it would appear
that the direct effect of the drugs was to induce the synthesis of ALA synthetase

------------~~--------_,.-,,~~--~---------
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and thereby to cause an increase in porphyrin production.
Further elegant studies with the same system of chick-embryo liver
cells have considerably strengthened this interpretation (Granick, 1966).
The induction of ALA synthetase was shown to occur only in liver cells and
to be reversible on withdrawal of the inducing agents.

During induction of

this enzyme there was no general increase in protein synthesis, i.e., the
inducing effect was a specific one.

Moreover, the inducing agents did not

prevent the normal breakdown of MA synthetase, the half-life of which was
4 to 6 hours in the presence or absence of inducers. It is postulated that
heme synthesis is normally controlled by a regulatory mechanism that represses
the synthesis of ALA synthetase and thereby maintains a low rate of synthesis
of heme.

Heme itself is supposed to be the repres sor, combining specifically

with an aporepressor protein to shut down the function of the operator, so
that the operon coding for MA synthetase will not be transcribed, or will
be transcribed at a very low rate (Jacob and Monod, 19 61). According to this
model, the inducing drugs might be expected to displace heme from the aporepres sor and thereby increase the rate of transcription. It would be predicted,
therefore, that heme itself should be able to overcome the effects of inducers;
this has been demonstrated in vitro in the liver cell system (Granick, 1966).
There are noteworthy differences between hep a tic porphyria and most
other genetic diseases of man, perhaps again suggesting that an unusual
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genetic mechanism is at work.

The disease is determined by a dominant gene,

i.e., the normal allele does not confer protection, as it usually would against
a defective protein.

The disease may not become apparent until adult life

(according to Goldberg and Rimington, 19 62) the most frequent age of onset
was the third decade for females and the fourth for males.

The youngest

patient found by these authors was a girl eleven years old, whereas many
genetic defects are manifest at birth.

Finally, porphyria is characterized by

increased activity of an enzyme, whereas most genetic diseases are due to
absence or reduced activity of an enzyme or other functional protein.
b.

Porphyria variega ta

This porphyria is common among persons of European ancestry in South
Africa (Dean, 1963) and is apparently inherited as Mendelian dominant
character. Acute attacks similar to those of acute intermittent porphyria occur
most commonly in affected females, while photosensitivity is found in male
members of the same family.

The photosensitivity present in porphyria

variegata is due to the accumulation in the body of photodynamically active
porphyrins.
c.

Porphyria cutanea tarda

This disease is characterized clinically by cutaneous lesions or
acute attacks of abdominal colic and not infrequently by both.
is inherited as a non-sex-linked mendelian dominant.

The disease

The onset of symptoms

---------------------~~~~·-·--~----------
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is usually between the ages of ten and thirty years.

The outstanding biochem-

ical feature of the disorder is the increased excretion of coproporphyrin and
uroporphyrin in the acute phase of the disease.
During the latent phase of the disease the patients are entirely asymptomatic.

The porphyrin precursors, ALA and PBG, are not excreted.

During the acute phase the excretion of coproporphyrin and uroporphyrin
in the urine increases.
in the urine.

Both ALA and PBG are excreted in increased amounts

Usually when ALA & PBG appear in the urine all manifestations

f acute intermittent porphyria may develop (acute phase).
A summary of the various forms of erythropoietic and he pa tic porphyrias
and a comparison to lead poisoning is shown in Table 39.

J.

CONTROL OF RED CELL PRODUCTION - ERYTHROPOIETIN
In the short span of 20 years, the process by which red cell production

is regulated has, to a large degree, been elucidated.
Although a humoral stimulator of erythropoiesis was described in 1906
by Carnot and Deflandre, it was the classical experiment of Reissmann in

1950 which established the existence of a plasma erythropoietic factor.
Reissmann reported erythroid hyperplasia in the marrow of both rodents joined
in parabiosis when one of them breathed gas of reduced oxygen content.

The

most likely explanation - a humoral stimulator produced in the hypoxic animal
and transferred across the union - undoubtedly is the correct one.

Erslev

(19 53) demonstrated convincingly a factor in the plasma of anemic rabbits

-----------------------·-~------------...
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which produced a reticulocytosis in normal animals, and after many investigators developed bioassays based upon sound physiological principles,
brilliant insights, and the use of radioiron (Plzak, et al, 1955; Fried, et al,
1956; Fried, et al, 1957; and Jacobson, et al, 1957), the stage was set for a
host of investigators to ask questions and seek the answers which constitute
the material reviewed here.
In addition to its inherent interest and value, the study of erythropoiesis takes on wider biological importance because it may serve as a model
for the control of tis sue development in general.

Erythropoiesis represents

the continuous formation and replacement of a well-differentiated tissue that
is readily accessible in many of the most highly developed biological species.
The study of erythropoiesis, therefore, may produce a valuable model for the
basic study of differentiation of mammalian cells.
1.

The chemistry of erythropoietin

The major problem encountered by the chemist attempting to define
the chemical nature of erythropoietin is the difficulty associated with obtaining
adequate amounts of purified material.

As little as 0.4 units of erythropoietin

probably approximates the normal daily production in the mouse (Alexanian,
1969). Since small samples with more than 7, 000 units of activity per milligram
of protein have been produced (Goldwasser and Kung, 19 68). it is apparent
that man, like a mouse, might be sustained by one or two hundred micrograms
of active material per day.
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When in plasma, erythropoietin is resistant to short periods of boiling
(Borsook, et al, 1954).

The conditions were for 15 minutes at pH 5. 5.

purified preparations are destroyed by trypsin (Borsook, 1959), chymotrypsin
(Borsook, 1959), pepin ( Slaunwhite et al., 1957), and neuraminidase
(Winkert and Gordon, 1960). These results indicate the active material is
probably a sialic acid containing protein (Goldwasser, et al, 1962). Limited
studies to date have indicated the biochemical properties of erythropoietically
active concentrates obtained from renal tumors,, renal cystic fluid, or cerebellar cyst fluid of patients with secondary polycythemia are quite similar
to the properties of erythropoietin obtained from plasma and urine of anemic
mammals.
Other interesting properties of erythropoietin include treatment with
alpha and beta amylase, beta glucosidase, cellula se (Lowy and Borsook, 19 62)
and ribonuclea se, lysozyme and carboxypeptida se (Winkert and Gordon, 19 60).
All of these agents did not inactivate the hormone.

Fluorescein isothiocyanate,

which substitutes on free amino groups and phenolic hydroxyls, caused complete inactivation indicating that these groups may be important for biological
activity (Goldwasser and Kung, 1968). Anhydrous formic acid did not inactivate
the hormone, suggesting that serine and threonine hydroxyl groups, where
formate esters are formed, are not important for the hormone's activity
(Goldwasser and Kung, 1968).

P-chloromercuribenzoate did not destroy the
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biological activity, indicating that sulfhydryl groups may not be necessary
for this function (Goldwas ser and Kung, 19 68).

The application of Koshland' s

reagent (2-hydroxy-5-nitrobenzylbromide), which reacts with tryptophan, to
an erythropoietin preparation, resulted in a complete loss of biological
activity (Lowy and Keighley, 1968).

This suggests that tryptophan is

exposed in the erythropoietin molecule and is important for biological activity
(Lowy and Keighley, 1968). Goldwasser and Kung (1968) have postulated that
the sialic acid residue of erythropoietin may play a role in binding the hormone
to a carrier and thus act to preserve the hormone's stability or retard its
excretion in vivo.
It is therefore not clear which of the characteristics attributed to

erythropoietin, including molecular weight estimates varying between 27, 000
(Rosse, et al, 1963) and 70, 000 (Goldwasser and Kung, 1968), might in reality
be properties of one or more carrier proteins or other extraneous substances.
Clearly much work remains before the chemical characteristics of erythropoietin can be defined with assurance.
2.

Erythropoietin metabolism and marrow utilization

Erythropoietin disappears rapidly from the blood stream of animals
and man.

Disappearance curves of exogenous erythropoietin are biphasic

in the rat, presumably because substantial amounts of the hormone must
dilute the extrava scular space before equilibrium is established (Reis smann,
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et al., 19 65).

z. 5 hours

The half-life of endogenously produced erythropoietin is about

(Stahlman and Brecher, 1959 and Reissmann et al., 1965).

The fate of erythropoietin is not well understood.

Urinary excretion

appears to parallel plasma concentrations at both low and high levels
(Novassaghi et al., 1967 and Weintraub et al., 1964). When plasma titers
are high, excretion may be highly dependent on urinary pH (Marver and Gurney,
1968). The level of erythropoietin has been found to fall substantially following perfusion through the liver (Keighley, 1962), but the degree to which
hepatic metabolism participates in degradation of small amounts of endogenous
ly produced erythropoietin remains to be ascertained.
Utilization, destruction, or inactivation of erythropoietin by an
erythroid marrow is a matter of some debate.

Plasma levels have been found

to decline more slowly in irradiated rodents (Stahlman and Brecher, 1959), but
the disappearance of injected erythropoietin does not appear to be influenced
by the administration of 700 R (Naets and Witteck, 1965).

It has been suggest-

ed that the decline of plasma titer from peak levels reached 12-18 hours after
continuous severe hypoxia reflects utilization by an erythropoietically active
marrow.

However this decline is probably a reflection of decreased production

of the hormone since a respite at ambient conditions for a few hours is sufficient to restore the animal's ability to again elevate the plasma level (Fried
.§l_tl.' 19 67) .

From these experiments it seems clear that there is insufficient evi-
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dence to be certain that the marrow is the principal site for the inactivation or
degradation of erythropoietin.

Certainly the marrow reacts with a physiological

response to the hormone, but the amount it consumes in relation to the daily
production has not been clearly measured.

A decline in the injected plasma

erythropoietin level itself may not represent actual consumption since the
volume of distribution also is an important factor (Alpen, 1962).

Furthermore,

a fall in plasma erythropoietin level after erythropoiesis is increased need not
represent consumption since production of the hormone may also vary (Fried
et al., 19 67), and the animal may partially adjust or acclimatize to the hypoxic
situation in diverse ways (Siri et al., 1966).

The difficulty in these experi-

ments, as I see it, has been the lack of direct methods for measuring actual
marrow metabolism of the hormone, and the inability to be certain that other
variables, such as hormone production, shifts within compartments of distribution, and renal excretion, remained constant while declining plasma levels
were measured.
3.

Tissues, neoplasma and fluids having erythropoietin

A plasma factor acting to increase erythropoiesis under hypoxic conditions has been documented in rats (Erslev and Lavietes, 1954, Fried .§.t ~·,
1956; Plzak

et~.•

1955 and Prentice and Mirand, 1957).

An erythropoiesis - stimulating factor has been identified in the following body fluids following hypoxia: urine (Adamson, 19 6 6, Piliero et al., 19 56

--

and Winkert

et~••

1957), lymph (Keighley, 1962), amniotic fluid and fetal

---------~~--"__.,,__

__________
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blood (Finne, 19 64, Finne, 19 6 6 and Halvorsen and Finne, 19 65), and breast
milk (Grant, 1955). Renal cyst fluid (Donatig, et §l., 1963, Penington, 1962
and Waldmann, 1964) and cerebellar hemangioblastoma fluid
19 6 7, Race

~

(Hennessy~

§l.,

.§.!._., 19 64 and Waldmann, 19 61) have been shown to contain an

erythropoiesis - stimulating factor with many chemical - physical properties
similar to serum or urinary erythropoietin (Rosse and Waldmann, 1963).
An erythropoiesis - stimulating factor has been extracted from various
neoplasma such as renal cell carcinoma, hepatic cell carcinoma and undifferentiated carcinoma of the lung (Donati
(Schonfeld

~al.,

~§l.,

1963).

Primary hepatoma

1961), cerebellar hemangioblastoma (Brody and Rodriquez,

1961, Waldman and Levir, 1960), Wilms' tumor in children (Shalet

et&~.

1967),

polycystic kidney disease and renal malignancy (Gurney, 1960), and primary
hepatocellular carcinoma (Nakao et .§1., 1966 and Kan et .§1., 1961) have also
been documented to have an erythropoie sis - stimulating factor.
There are no reports of any studies on animals bearing the Walker 256
Carcinosarcoma.
Thomson and Marson (1953) reported on the stimulating factor produced
by fibroids of the uterus as well as did Horwitz and McKelway (1955) report
on polycythemia associated with uterine myomas.

Both of these conditions

are considered to be benign.
The major site controlling the production of erythropoietin is the
kidney.

This was proven by Jacobson et.§1._in 1957.

He was the first to demon
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s tra te that bilaterally nephrectomized rats or rabbits no longer responded to
bleeding or cobalt administration with markedly increased levels of plasma
erythropoietin (Jacobson et&., 1957, Jacobson..§.!&., 1957, and Jacobson
et ..fil_., 19 60) and that the increased erythropoietin levels which followed
phlebotomy of rabbits fall to near normal soon after nephrectomy (Jacobson
et ..fil_., 1957).

Controls for these experiments consisted of ureter-ligated rats

which developed similar blood urea nitrogen levels, but retained their capacity
to respond to cobalt or phlebotomy.

Further experiments showed that neph-

rectomized rats responded slightly to hypoxic hypoxia with a small increase
in erythropoiesis (Goldwa sser et&., 19 58), and nephrectomized mice exhibited
a very slight response to a phenylhydrazine - induced anemia (Jacobson..§.!&.,
1959).

From these experiments it was estimated that 10 percent of erythropoie-

tin production was controlled by extrarenal sources (Jacobson, 19 62, and
Jacobson..§1.tl_., 1959).
4.

Site and mechanism of action of erythropoietin

Erythropoiesis can be divided into two stages: the development of the
erythron (i.e., the red cells and the erythrobla sts in the marrow or spleen) and
the development of the stern cells (i.e., those cells which reproduce themselves and give rise to the erythron) (Laj tha, 19 6 6). It was suggested that a
stimulus for increased red cell production might act on the stem cells, since
in human beings there is an interval of five days between such stimulation
and the appearance of an increased blood reticulocyte count, and five days is
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the length of time required for '11a tura tion of erythroblas ts from the earliest cell
to the reticulocyte (Yoffey, 1957).
Since the initial work on the polycythemic mouse (Jacobson et al.,
1957) several investigators have studied the morphological sequence of events
which followed the administration of erythropoietin to such an animal
(Filmanowicz and Gurney, 1961,

Ito~~••

1964,

Nakao~

al., 1966, and

Reissmann, 1966). Within ll to 18 hours an increased number of large cells
with fine chromatin and an intensely basophilic cytoplasm appeared (Gurney
et al., 19 65 and Nakao et al., 19 66).
similar to large lymphocytes

These cells have been described as

(Gurney~&.,

19 65) or reticular cells (Nakao

et&,, 19 66). A timed sequence of erythroid maturation followed, beginning
with the appearance of proerythroblasts by 24 hours
Filmanowicz and Gurney, 19 61).

(Nakao~&••

1966 and

This was followed by successive increases in

basophilic, polychromatophilic, and orthochromatic erythroblasts over 51 to
75 hours as the proerythroblasts declined, and a blood reticulocyte peak at
72 to 96 hours while the late erythroblasts declined (Filmanowicz and Gurney,
19 61) .
The response of primitive marrow cells to erythropoietin depends not
only upon the dose of the hormone but also upon the duration of stimulation.
A given amount of erythropoietin yields a progressively greater response as it
is fractionated progressively into a larger number of doses (Schooley, 1965 and
Fogh, 19 6 8) •
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if anti-erythropoietin antibody is given to polycythemic mice one day
after the hormone, the wave of erythropoiesis advancing through the hematopoietic system and culminating in a reticulocytosis continues unabated (Schooley and Garcia, 19 62). Hence continued maturation of erythroblasts is not
dependent upon the continued presence of erythropoietin in the plasma. It has
been proposed, however, that erythropoietin accelerates maturation of developing erythroblasts, since its administration leads to an increase in reticulocytes, often demonstrable within a day (Gallagher and Lange, 1962; Eskuche
and Hodgson, 19 66; and Stahlman et al, 19 63).
The limited information available at this time on the mechanism of
action of erythropoietin comes, to a large degree, from marrow culture studies.
Perhaps the earliest observable effect is enhanced

14

C-uridine incorporation

by RNA of marrow cells after the hormone is added to cultures (Krantz and
Goldwasser, 19 65). Actinomycin D, which blocks DNA - dependent RNA formation, inhibits this early effect.

Formation of several different species of

RNA appear to be enhanced by erythropoietin (Gross and Goldwasser, 1968),
and although the importance of these various RNAs remain to be elucidated it
is reasonable to suspect at least one of them may be a messenger for hemoglobin formation.
Delta-aminolevulinic acid synthetase increases in the spleens of
animals with distention of its blood vessels due to extra blood. ALA synthetase is increased within 8 hours after erythropoietin is injected (Nakao et al.,
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1964) ALA synthetase may be de-repressed by erythropoietin, and in this
manner the first of a whole series of inter-related events might be initiated
(Goldwasser, 1966).
As yet, however, no single primary effect of erythropoietin has clearly
delineated, and no unifying hypothesis accounting for all the recognized biochemical effects of the hormone has been proposed.
K.

RETICULOCYTES
Reticulocytes were first observed by Ehrlich early in his career.
The reticulum of reticulocytes cannot be seen, even by darkground

illumination or by phase contrast microscopy unless stained. However, examination by ultraviolet light with the wavelength that is absorbed by nucleic
acids and observation of the effect of ribonuclease on the basophilic material
(Dustin, 1943) indicated that the reticulum is composed of ribonucleoproteins.
The precipitation of ribosomes by cresyl blue or by New Methylene Blue N
produces the reticular network visible by light microscopy.
In reticulocytes the reticulum may appear as a narrow band traversing
the cell, it may be evenly distributed throughout the cell or it may be so
densely packed as to give the appearance of a nucleus.
Reticulocytes are larger than fully matured red corpuscles, perhaps
20 percent greater in volume (Killmann, 1964). It was assumed at one time
that red corpuscles decrease in size when they mature beyond the reticulocyte
stage.

However, there is good reason to believe that the large reticulocytes
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which appear in the blood as the result of erythropoietic stimulation are the
outcome of skipped divisions and have a short life-span (Brecher and Stohlman,
1962).

This idea is consistent with the rapid rise and fall of the reticulocyte

count following specific therapy of anemias and the subsequent rise of hemoglobin which is only gradual.
Reticulocytes are more adhesive than adult corpuscles and move
about in currents at a much slower rate than mature cells (Davidson, 1930).
This adhesive property, like that described for more primitive cells (Isaacs,
1937), may account for their tendency to remain within the bone marrow under
normal conditions.

It has been reported that there is a coating of globoulin

(Sutherland et&., 1963), at least part of which is transferrin (Jensen et&.,
1965). Their specific gravity is lower than that of adult corpuscles (Key, 1921)
and they tend to collect in the upper portions of suspensions of corpu_scles.
Reticulocytes do vary in their resistance to hypotonic solutions (Daland and
Zetzel, 19 3 6) •
The time required for development from the proerythroblast stage to
the last normoblast division may be 2 to 5 days.

The marrow reticulocyte

time may be about 36 to 44 hours, or less, while the time for maturation of
reticulocytes in the circulation is about 24 to 29 hours (Finch, 19 59). After
hemorrhage, the reticulocyte response begins by the third or fourth day.

It

seems likely that the increased rate of erythropoieosis in response to various
stimuli is not mediated by shortening the generation time of the pronormoblast
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but more probably is the result of a rapid increase in the rate of differentiation
of the multipotential stern cell (Al pen and Cranmore, 19 59).
1.

The orderly reticulocyte response

In response to an appropriate stimulus the percentage of reticulocytes
rises, usually within 2 to 10 days and, increasing rapidly, their number
reaches a maximum within a period of 3 to 10 days.

This rise is a steady and

progressive one and is followed by a slower and some what less regular decline.

The first reticulocytes which appear are

11

young,

11

with large amounts

of reticulum, while later the cells contain less and less reticulum - presumabl
older forms.

Up to the peak of the reticulocyte curve, the increase in the

total red cell count is only such as can be accounted for by the increment of
reticulocytes.

The decline of the reticulocyte curve to normal values is

followed by a rise in the quantity of mature corpuscles.

Thus all the morpho-

logic changes which occur are in the direction of the restoration of normal
conditions with mature red corpuscles replacing the young and probably less
efficient forms.
2.

Factors governing the reticulocyte level in the blood

These include the rate of production of red cells, the stage of their
release from the marrow, the rate of intrava scular reticulocyte maturation,
the rates of reticulocyte as compared with older red cell destruction by external causes and the possible role of the spleen in reducing the number of circulating reticulocytes (Cline and Berlin, 19 63).
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The classic reticulocyte response, on the other hand, appears to be
governed mainly by three factors; namely, the size of the stimulus, the quantit
of blood-building material available and the reactive state of the bone marrow.
3.

Summary

The factors which goven reticulocyte level in the blood may be tabulated
as follows:
Increase in reticulocytes:
Physiologic:
At birth
Menstruation
Pregnancy
In Disease:
Erythropoietic response following treatment of anemias
with Fe, vitamine B12 , folic acid
Blood intQxication
Erythroblas tic anemias
Hemolytic anemias
Following hemorrhage
Severe lead poisoning
Leukemia
Malaria
Pernicious anemia and sprue following folic acid therapy
(as a response to treatment)
Polycythemia vera
Sickle cell anemia
Splenic tumor
In typhoid fever - occasionally
Many parasitic infestations
Low or absent:
Idiopathic aplastic anemia
Acute benzol poisoning
In anaplastic crises of hemolytic anemias
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L.

EARLY HISTORY OF THE WALKER TUMOR STRAIN
The tumor was first found by Dr. George Walker of Baltimore, Maryland,

in 1928, and was carried on by successive subinoculation into rats.

The

following description of the tumor discovery was told to Earle (1935) by Walker:
"On February 12, 1928, a mass about the size of a large pecan nut was
found on the lower left side of the abdomen of a well grown female rat apparent
ly about ten months of

~ge.

The animal was pregnant and soon after the tumor

was discovered delivered a litter of eight males.

During the period of lacta-

tion the mass regressed to a point where it had almost disappeared, but after
weaning it began to grow again and increased in size with great rapidity.

The

animal was mated with a male but failed to become pregnant. She was killed
March 23, 1928, and the mass was removed. It was the size of a small egg,
firm in the upper portion but soft and almost fluctuating in the lower half.
apparent! y originated from a breast.

It

It was enuclea ted with some difficulty,

since in places it had broken through the capsule and had infiltrated the surrounding tissues.
"On section the lower portion of the tumor was found to be hemorrhagic
and necrotic and to contain some free bloody fluid; the upper half was firmer,
granular, grayish red, with small necrotic foci here and there. Some of the
tissue was fixed in formalin and sectioned.

Portions of the remaining tissue

were implanted into 16 young rats of both sexes of about 40 grams each.
plantation was by trocar in the left breast."

Im-
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A histologic section of the original tumor was submitted by Dr. Walker
to Dr. W. G. McCallum of Johns Hopkins University and was diagnosed by
him as a carcinoma.
The tumor was transplanted approximately every two weeks, by trocar,
in Dr. Walker's laboratory until the laboratory was closed in 193 2.

The Doure

Doure strain of rats was generally used for this implantation, other strains
were also tried. With all strains tried the tumor growth was nearly 100 per
cent successful.

The tumor was quite virulent and usually killed the animal

in 4 to 5 weeks.

During all of the transfers in his laboratory from 1928 to 1932,

Dr. Walker found only 4 instances of regression of the tumor.
The 8 sons of the rat which showed the original tumor were mated
with females of the same general strain.

In the third generation which resulted

from these matings a tumor was discovered in the breast of a female thirteen
months of age.

Microscopic examination showed it to be identical with the

original tumor.

In the fifth generation a second tumor was discovered in the

breast of a female nine months old. A third was found in a female of nine
months in the seventh generation.

This too was like the original tumor.

These

tumors were implanted into other rats and grew."
M.

BLOOD ENZYMES IN CANCER AND OTHER DISEASES
Warburg (19 09) observed that the oxygen consumption of erythrocytes

was associated chiefly with the presence of reticulocytes.

Harrop (1919) was

the first to correlate oxygen consumption of human blood with the concentration
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of reticulocytes.

By defibrinating the blood he greatly reduced the number of

leucocytes and platelets, thus eliminating the effect of these fixed elements
on oxygen consumption. In several patients with anemia but with low reticulocyte counts, 0. 5 to 1. 0%, the oxygen consumption was about l to 3% of the
oxygen content of the saturated blood. When the reticulocyte count rose to
about 3%, the oxygen consumption rose to about 10% of the available oxygen,
and at reticulocyte levels of 12 to 13%, the oxygen consumption was 30% of
the oxygen content of the saturated blood. A more precise quantitative relation
ship was elicited by Wright (1930) in rabbits rendered anemic by the injection
of phenylhydrazine. In one experiment the reticulocyte count rose from 1. 5 to
3 3% and then receded; the oxygen consumption rose and fell proportionately,
amounting to about 60 cu. mm. per 10 9 reticulocytes per hour.

1.

The enzymes of the reticulocyte

The marked respiratory activity of the reticulocyte in contrast to that
of the erythrocyte indicates the presence of the enzymes of the citric acid
cycle in the reticulocyte.

Sherwood Jones et al. (1953) found that fluoracetate

decreased oxygen uptake and favored the accumulation of citrate. The reticulocyte possesses other metabolic sequences such as that of the incorporation of
amino acid into protein (Borsook et al., 19 52) which are lacking in the mature
erythrocyte.
Succinic dehydrogenase, cytochrome oxidase, and NADase were found
predominantly in the particulate fraction, where as glucose-6-phosphate de-
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hydrogenase, fumarase, hexokina se, and pyrophosphata se vvere present chiefly
in the stroma-free hemolysa te.

Calculation of the ratio of enzyme activities

in reticulocytes to that in normocytes showed that NADase, lactic dehydrogenase, glucose-6-phosphate dehydrogenase, and isocitric dehydrogenase
were of approximately the same activity in the reticulocyte as in the mature
erythrocyte.

In contra st, some enzymes were present in much greater con-

centrations in the reticulocytes.

The ratios were as follov's for these enzymes:

malic dehydrogenase, 2.. 7; fumarase, 13. 2; hexokina se, 13. 7; and pyrophospha tase, 19. 3.

Succinic dehydrogenase, aconita se, and cytochrome oxidase

were not measurably present in the mature erythrocyte.
The presence of certain enzymes being characteristic of reticulocytes
was further demonstrated by Rubinstein et al. (1956) in in vitro experiments.
The incubation of reticulocytes at 37 C with glucose and penicillin for 12 hours
resulted in a substantial fall of reticulocytes as a result of conversion into
mature erythrocytes.

It was observed that the decreases in activity in NADase,

malic dehydrogena se, and lactic dehydrogenase were only about 0 to 2.0%,
whereas the decreases in reticulocyte characteristic enzymes such as pyrophosphatase, succinic dehydrogenase, aconitase, and cytochrome oxidase
were substantially greater.
2.

Reticulocyte enzymes in disease

When the hematopoietic system is stimulated, the number of reticulocytes in the circulation rises, reaches a maximum, and may then decline.

The
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first reticulocytes which appear are "young" and contain large amounts of
reticulum, while later the cells contain less and less reticulum and are presumably "older" cells.

The reticulocyte may be considered as a stage in the

development from the primitive nucleated cell in the marrow to the mature
erythrocyte, and several studies in the literature show that a progressive
diminution of metabolic activities accompanies this maturation.
Bernstein (1959) employed centrifugation procedures to separate the
young human erythrocytes, including reticulocytes, from the older cells; the
former aggregated in the top layers of a packed red cell column, and the older
cells stratified at successively lower levels.

The reticulocyte count decreas-

ed with the depth of the layer, and this decrease paralleled decreases in the
utilization of glucose, the formation of lactic acid, and the activities of phosphohexose isomera se and aldolase.
It would appear quite likely, therefore, that changes in the enzyme

activities of reticulocytes in many diseases, including cancer, ·1rould merely
reflect the presence and degree of hematopoietic stimulation and, in turn, the
age distribution of the circulating reticulocytes and erythrocytes.
To the best of my knowledge, no investigator has studied the enzyme
ALA dehydrase in relation to cancer and no one has studied this hematopoietic
enzyme in the animal bearing the Walker 2 5 6 carcinosarcoma.
N.

DEFINITION AND SOME CHARACTERISTICS OF TUMORS
Tumors may be defined as growths of cells which are largely or wholly
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independent of the organism which supplies their nutrition, which frequently
possess an atypical structure, and which reach no definite limit to growth •

.

These aberrations of tissue growth are common to all living multicellular
forms, both animals and plants.
Tumors arise from the cells of the host by a transform a ti on at present
unknown, and once this transformation has occured it is apparently not reversible.

Most adult mammalian tissues cultured in vitro fail to grov· except

during a brief early period, '\Nhereas most cancerous tissues under the same
conditions exhibit continuous gro\l'rth over many years.

To all indications, the

capacity for growth of the tumor lies largely within itself and although it may
superfically resemble the grovvth and regenerative capacities of normal tissues,
has certain qualities peculiar to itself.
Normal tissue growth occurs in an orderly, generally logarithmic,
fashion without injury to surrounding tissues.

Cancerous tissue growth, al-

though progressive, may occur at different rates throughout its course.

Normal

tissues do not affect neighboring tissues whereas cancerous tissues often invade, destroy, and replace neighboring normal tissues.

Normal tissues trans-

planted to other sites in the organism may grow or be maintained briefly for a
while, but they ultimately necross and completely regress.

Such a transplan-

tation is incompatible with the harmonious balance of the organism.

In cancer,

any extension of the original, primary tumor is called a metastasis. According to Erving (1940), there is often a gradual loss in structural differentiation
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in metastatic tumors.

They become more a nap las tic, i.e., they resemble to a

decreasing degree the normal tissues of origin, so that metastatic grov.1 ths
from primary tumors of different kinds of normal tissues are sometimes indistinguishable.

The presence of these transplanted cells is also incompatible

with the harmonious balance of the organism, but the latter apparently displays little successful protective reaction against the destructive growth.
Cancerous growth capacity is independent of the organism, and, hence,
the growth capacity of the tumor is a nearly unique property of the tumor itself.

This property of autonomous growth is the most striking characteristic of

tumors as a class, and within the factors responsible for this property lies the
secret of control of this growth.
1.

Classification of animal tumors

Tumors arise in certain tis sues through the agency of certain factors,
some known, some suspected, and many of them unknm. . rn.

Tumors may, there-

fore, be classed according to either (a) their known etiology or (b) the normal
tissue from which they arise or most resemble.

The classification of tumors

was originally designed to be applied to human tissues but, V'rith minor modifications known to the experienced judgment of the histologist, may also be
applied to tumors arising in the lower animals.
The term carcinoma may be applied to tumors which arise from epithelia
tissue, whether pavement or glandular.
The term sarcoma may be applied to tumors arising from connective
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and muscle tissues.
Tumors characterized by the terms carcinoma and sarcoma are frequently
anaplastic and often bear relatively little resemblance in histological structure
to the normal tissues of their origin.

The suffixes carcinoma and sarcoma are

generally applied to what may be called malignant growths.

Malignant gro·1rths

are frequently invasive in character, destructive to neighboring normal tissues,
and prone to give rise to metastatic lesions elsewhere in the host.
2.

Growth and vascular reactions of tumors

Most microscopic studies of tumor growth are performed on fixed,
sectioned, and stained material.

Such studies are limited to discontinuous

stages in the growth of cells obtained from different animals killed at various
intervals.

The disadvantages inherent in this procedure are obvious.

Newer techniques have been developed which permit the cultivation
and direct microscopic observation of tumor cells within the living animal,
thereby making it possible to carry on continuous or intermittent examination
of the same group of cells over a prolonged period of time.

Lucke' and

Schlumberger (1939) used a method based on slit-lamp microscopy on anterior
charrber implants of a carcinoma of the frog.

A transparent-chamber technique

was developed for the rabbit ear by Sandison (1928), Clark et al. (1930), Ebert
et al. (1939), and Williams (1934), and was adapted to the mouse by Algire
(1943).

The application of this technique to tumors has been made by Ide et al.

(1939), who observed the vascularization of the Brown-Pearce rabbit epitheliom ,
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and by Algire (1943) and Algire and Chalkley (1945), who studied the vascular
reactions of transplanted tumors in the mouse.

The basis of the method, as

adapted to the mouse, rests upon the insertion of a transparent chamber into
a skin flap in the animal.

Under the experimental conditions used, the tumor

cells are maintained under normal environmental conditions of groirth and
nutrition.
The results of these investigations indicated (a) that the rapid growth
of tumor transplants is dependent upon the development of a rich vascular
supply, and (b) that an outstanding characteristic of the tumor cell is its
capacity to elicit continuously the gro"'rth of new capillary endothelium from
the host.

The s timula ti on of vascular proliferation is fundamentally a property

shared by traumatized tissues and by transplants of normal tissues as well as
by tumors.

This stimulation is only temporary in normal tissues whereas it is

continuous in tumors.

Cancer cells thus seem to be able to provoke a contin-

ued vascular proliferation from the surrounding host tissue, and this property
may be, in part at least, responsible for their autonomous nature (Lindgren,
1945).

The identity of the provoking substance elaborated by the tumor has

been termed

11

tumor angiogenesis factor (TAF) 11

•

It is postulated, today, that

if TAF could be inhibited the tumor would die due to the lack of nutrition and
the means to elemina te waste products. It is obvious this is a very fertile
area for sound research.
0,

GENERAL CONCEPTS - CHEMISTRY OF TUMORS
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Every normal tissue carries on a specific and unique function.
effect this function, the particular tissue is metabolically (as

\11 1 ell

To

as mor-

phologically) differentiated and possesses a chemical structure and pattern of
enzymatic catalysis peculiar to itself.

Life thus represents the harmonious

integration of a number of individual metabolic mosaics.
The metabolic pattern is as distinguishing a feature of each tissue as
is the gross or microscopic morphology and constitutes a functional characterization of the tissue.

Each of the enzymes behaves qualitatively in much the

same way in all tissues.

Quantitatively, however, the distribution of the

enzymes varies in each of the tissues, and it is this quantitative distribution
which constitutes the individual mosaic of each tissue. Although the pattern
itself is based on a quantitative distribution of each of the enzymes, the net
biological result of the various catalytic systems in each intact tissue is
actually a qualitative one, for these systems are not independent but interrelated, and the particular direction which the individual metabolism of each
tissue will take may be dependent upon, among other factors, the relative
proportion of rate-determining sys terns.
Tumors, like the normal tissues from which they arise, possess chemical substances, enzymes, etc., and their existence, too, must be at least
partially explicable in terms of a chemical and metabolic pattern. A comparison of the pattern of a tumor with that of the normal tissue from which it arose
may be expected to reveal the metabolic and chemical changes

~Nhich

are the
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consequence of neoplasia.

Such a comparison has its limitations, for, among

other things, the normal tis sue under scrutiny is, unlike the tumor, a res ting
non-growing tis sue.

To make the comparison more valid, a normal, grovdng

tissue, such as fetal or regenerating tissue, must be included. It is impossible to assume,

~priori,

that the neoplastic transformation of one type of

tissue is the same for every other type of tissue, and, therefore, such comparative studies should include all available sets of homologous tissues in
as many species as are available, such as, liver and hepatoma, skin and
epidermal carcinoma, lymph nodes and lymphoma, etc.

Furthermore, it is

equally unwise to assume that each enzyme or chemical component alters
during the neoplastic trandormation in exactly the same way, and, therefore,
as many such systems must be investigated as is possible.
The lack of cellular homogeneity, whether in normal or in tumor tis sues,
is hardly a deterrent to investigation, but its recognition is necessary.

Such

inhomogeneity is uniform among normal tissues of the same kind and almost
invariably uniform among tumors in late generation transplants.

The chemical

study of such tissues presents few difficulties from this angle.

On the other

hand, the tumor arising directly from the normal tissue, or in relatively early
generation transplants when alterations may sometimes occur, requires microscopic criteria as controls for both a qualitative description of the tumor itself and for a basis of knowledge of the principal contribution factors (proportion of active cells) to the chemical properties of the tissues.
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Cancer is a problem of abnormal growth, and it might be expected that
study of the energetics of the cati\lytic systems concerned with intracellular
synthetic reactions would be highly revealing.
still be considered a problem for the future.

To date, however, this would

Research on the phenomena of the

cancer cell can progress little faster than comparable research on normal cell
mechanisms.

Thus far, the analytical chemist has only the task of uninspired

digging 'itdthin the cancer cell, of mapping the chemical spectrum of the cancer
cell, and, to further mix the metaphor, of running, among other things, the
enzyme gamut from A for aconitase to Z for zymase.
a "cancer enzyme" has emerged.

To date, no evidence for

There may be a "cancer pattern" of several

enzymes within cancerous tissues.

Little by little the outline of the pattern

has slowly come into view, and the interesting regularity and uniformity of
this pattern has perhaps been even more than might have been expected.
P.

EN2YMATIC PROPERTIES OF CANCEROUS TISSUES
Numerous investigations by biochemists have supplied a considerable

amount of information on the enzymatic activity of different types of tumors.
Epidermis of the mouse is unusual in that some of the enzymes have a very low
activity.

For example, the activities of succinic dehydrogenase (Carruthers

and Suntzeff, 194 7) and of apyrase are very lovr in epidermis but very high in
the squamous-cell carcinomas (Roberts and Carruthers, 1948). A study of
cytochrome C content in epidermis and carcinomas by a polarographic procedure
(Carruthers, 1947) revealed that its content was lower in carcinomas than in
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epidermis (Carruthers and Suntzeff, 1948).

In an anaplastic squamous-cell

carcinoma the arginase activity was 6 times greater than normal and in a highly
differentiated tumor of this type the arginase activity was 18 times greater
than that of normal epidermis (Roberts, 1948; Roberts and Frankel, 1949).

The

activity of cytochrome oxidase of normal epidermis is less than that of squamous-cell carcinomas (Carruthers and Suntzeff, 1947). Although the activity of
the enzymes listed above is higher in the carcinomas than in epidermis, the
values found for these tumors and in general agreement with those for other
kinds of tumors •
The activity of some enzymes, such as alkaline phosphatase and desoxyribonucleodes-aminase, are greatest in transplantable rat he pa tom as and
show decreasing activity in the primary tumor and least activity in the liver.
Other examples could be cited, but it is quite apparent that the activity of a
particular enzyme will depend upon its function v'.'ith respect to the place of
origin of the new growth in a normal tissue and the events follovring this function as tumors arise.

No enzyme has been discovered yet which is character-

istic for only growing tissues - embroyonic and neoplastic.
In general, the study of the enzymology of tumors has led to no striking discoveries, but has indicated for most tumors a much lower activity of
many enzymes than that possessed by the tissue of origin of the tumors; complete or near disappearance of some enzymes probably associated with morphological alterations; and an increase in enzyme activity associated with say,
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more rapid cell division, etc.

Greenstein (194 7) has ably summarized the re-

sults of the many investigations on enzymology in tumors, and his general
conclusions are given below:
(1) Each normal tissue is characterized by the possession of an individual pattern of enzymatic activity which may be characteristic for that tissue.
(2) Qualitatively tumors have the same enzymes as do normal tissues
except where a particular enzyme is native to some tis sue component which
may be lost, resulting in a lack of the enzyme, as for instance, cysteine
disulfura se in the liver.
(3) The range of activity of each enzyme and the content of various
components as vitamins {Greenstein, 194 7 and Pollack et al., 1942) and free
amino acids (Roberts and Frankel, 1949) is much narrower among tumors than
among normal tissues.

These considerations appear to be independent of the

host, site, method of induction or species in which the tumor grov·s.
(4) Enzymatically tumors have much in common biochemically.
Investigations have also demonstrated that qualitatively tumors have
many of the same enzymes as do normal tissues.

For example, Wenner et al.,

(1952) have demonstrated in a series of transplanted mouse and rat tumors that
enzymes of the citric acid cycle and related enzymes were present.

Lactic,

malic and isocitric dehydrogenu.ses, fumarase, oxalacetic carboxylase and the
condensing enzyme were present in tumors in amounts similar to those found in
some normal tis sues.

The activity of aconita se and d.-ketoglutara te dehy-

62

drogenase were lower in the tumors than in the normal tissues examined.
Weinhouse

~

i!.l. (1951)

have also shown that transplanted tumors of various

types are able to oxidize isotopically labeled glucose, lactic acid and palmitic acid at a rate comparable to a representative group of normal tissues.
Finally Le Page, Meyerhof and others have shown that the rapid conversion of
glucose to lactic acid in tumors occurs by way of the phosphorylated intermediates of the Embden-Meyerhof scheme (U. R. Potter, 19 51).
Q.

BLOOD FLOW TO TUMORS
The vascular morphology of spontaneous and transplanted tumors has

been of interest for at least 80 years.

Different concepts have been accepted

from time to time. Algire and Chalkley (1945) shovred that transplanted solid
tumors had a blood supply that was superior to that of the surrounding normal
tis sue.
Aligire (1947) considered that "an outstanding characteristic of the
rapidly growing tumor is its capacity continuously to elicit the production of
new capillary endothelium from the

host"~

that it might in fact "be the real

underlying factor responsible for the autonomous growth inherent within the
tumor cells." Algire (19 54) offered a complete picture of the reactions that
occur by using a transparent chamber.

Coincident with establishment of a

blood supply, the isograft became increasingly translucent, capillaries took
on an irregular pattern, sinusoids developed, little differentiation into arterioles and venules occurred and within 5-8 days, the blood vessels had reach-
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ed a constant 40-50 percent of the total tumor volume.
Goldacre and Sylven (19 59 and 19 62) and Owen (1960) used lissamine
green to map regions of tumors not supplied by blood.

These regions suddenly

appeared in tumors at a critical age, which in the transplanted mouse tumors
studied (mammary carcinoma, sarcoma 37) was about 12 days, and in the rat
Walker 2 5 6 carcinosarcoma about 5-10 days, depending upon the type of host.
The uncolored zones, which remained after dye injection to vessels supplying
the tumor area, contained living cells as shown by vital staining, tissue
culture, and particularly by transplantation into new hosts.
1.

The rate of blood flovr to tumors

Bierman and co-workers (1951and1952) demonstrated that when fluorescein was given intraarterially, this appeared most rapidly in primary skin
tumors and remained longer and in higher concentration than in the adj a cent
normal tissue.

This increased vascularity was most prominent at the periphery

or advancing edge of the neoplastic lesions.

Gullino and Grantham (19 61)

were the first to publish results of measurements of the magnitude of blood
flow in tumors.

The first method they used was a direct one in v·hich the

effluent blood flow from the tumor was measured.

The second or indirect met-

hod was based on the fractional distribution of two indicators, potassium-42
and rubidium-86.

By these methods, they found that in rat tumors the blood

flow followed a uniform pattern independent of the histologic type, site of
implantation and size of the tumor.

They showed that contrary to what Bierman
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et al. (1951and1952) concluded, the blood flow to tumors v as unusually low.
1

A hepatoma had a blood supply roughly one-twentieth that of the host liver.
2.

Tumor perfusion and tumor size

Cataland et al (1962) showed that in transplanted tumors, by using the
indirect method of Sapirstein (1958) with rubidium-86, there exists an inverse
relationship between tumor perfusion and tumor size; the smaller the tumor,
the greater the perfusion.
R.

ANEMIA IN CANCER
1.

Introduction

The etiology of anemia in cancer patients has been a challenging problem to investigators for many years.

Callens and Rose (1948) agreed with

Forkner (193 8) that defective blood formation, blood loss, and increased blood
destruction may each play a part in the mechanism of anemia in cancer.
Anemia is most accurately defined as a reduction in the circulating red
blood cell mass. Anemia is defined in terms of concentrations per unit volume
of blood.

In these terms, anemia is a reduction below normal in the volume of

packed red blood cells per 100 ml, the blood hemoglobin concentration per
100 ml, and/or the red blood cell count per cubic millimeter.

Under most

clinical circumstances, these measurements accurately reflect changes in the
red blood cell mass because the total blood volume tends to be kept within
relatively narrow limits by a variety of physiologic mechanisms.
The anemia that one observes in the Walker 256 Carcinosarcoma tumor
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bearing animal has been judged, by me, to be a hemolytic anemia.

I have

used the excellent work of Haut and Wintrobe (1970) as the basis for this
classification.
They define hemolytic anemia as (1) reticulocytosis sustained for weeks
without relief of the anemia; (2) persistent reticulocytosis with minimal anemia;
and (3) rapid aggravation of the anemia with accompanying reticulocytosis.

It

will be shown that the experimental animals used for the data of this dissertation do, in fact, follow the above 3 points.
It is obvious in all the situations just named, both overt and covert

blood loss must be excluded before hemolysis can be said to be present. Whe
reticulocytosis persists, it may be deduced that abnormal blood destruction
(or blood loss) is occurring only if the expected result of accelerated production, i.e., a rise in the volume of packed red blood cells, does not occur
(Haut and Wintrobe, 1970).
Low hemoglobin concentration and hematocrit values are common findings in patients with malignancy.

Shen and Hom burger (19 51) reported that 65%

of 193 pa ti en ts with advanced carcinoma had a hemoglobin concentration of les
than 80% of the normal value of 15. 6 g/100 ml. (g%).

Of their 116 cases with

low hemoglobin, 52 cases (44. 8%) had a hemoglobin concentration between
70-80% of normal, 42 cases (36.2%) were 55-69% of normal, and 22 (19%)
were below 55% of normal.

Samuels and Bierman (1956) reported that in a

group of 158 patients with various malignant neoplasms, a hemoglobin concen-
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tration below 80% of the normal value of 12. 9% v..ras found in the following
frequency: carcinoma 55%, lymphoma, 7 7%; chronic lymphocytic leukemia, 7 5%
chronic granulocytic leukemia, 95%; and acute leukemia, 97%.
These figures can only give a general estimate as to the prevalence of
the decreased hemoglobin concentration in patients with various types of neoplasms. It is obvious that details as to the stage of the disease and the general condition of the individual patient greatly influence the percentage of
patients with low hemoglobin concentration in any given group.
In studies on tumor-bearing animals, decreased hemoglobin concentration, red cell count, and hematocrit values have been correlated with the
growth of both induced and transplanted tumors in the rat (Dunning and Reich,
1943), the mouse (Taylor and Pollack, 1942), and the embryonic chick (Taylor
et al., 1943).
A hematological picture similar to that of leukoerythroblastosis v·as
found in animals bearing far-advanced transplanted tumors (Sterling et al.,
1958). It was found that animals bearing rat hepatoma 3683 and lymphosarcoma
R2788 had large numbers of immature and nucleated red cells in the circulating
blood, \Nhich had been formed in response to a severe process of red cell destruction in the tumor-bearing animal.

In some of the rats bearing these tumors

reticulocytes and immature cells accounted for over 90% of the red cells.

The

hematological picture in these animals was not associated with any evidence
of physical interference with the bone marrow. Although the marrow was ex-
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truded from the femurs intact and fixed as a tissue, there were no tumor cells
found, and the bone marrow was hyperplastic with a predominance of immature
cells of the erythroid series.
The evidence indicates that a majority of patients with cancer, although
possessing the ability to synthesize cells at a normal rate, do not compensate
for the increased destruction of red cells by a greatly stimulated red cell production.

Only in the exceptional case does the turnover rate double that of the

normal individual.
2.

Role increased erythrocyte destruction

Evidence for increased blood destruction in patients vrith solid tumors
and leukemia has been accumulated slowly over a period of half a century.
Hirschfeld in 19 06 observed a marked increase in hemosiderin in a leukemic
patient with severe anemia and considered the possibility of an increased rate
of blood destruction.

Paschkis (19/.7) observed that the very dark stools in

myeloid leukemia were suggestive of increased red cell destruction.

Many

others reported the existence of hemolytic anemia in cancer (Berlin, 19 51 and
Dacie, 1954) and from these works I was better able to understand the anemia
of the Walker 256 tumor bearing animal.
With the exception of G. M. Erown (1950), all of the earlier red cell
survival studies were limited to patients with leukemias and lymphomas. A
number of more recent investigations have extended these studies to patients
with carcinomas.
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G. M. Brown (1950) in his first report described the Ashby radiochromate
curves of 5 patients with carcinoma of the lung, parotid, prostate, breast, and
uterus.

He found their 50% survival values to be 39, 33, 53, 33, and 16 days,

respectively, as compared to a normal value of 60 days.
In 1954, Hyman presented the first of several comprehensive studies
which demonstrated that a shortened red cell survival was commonly found in
patients with a wide variety of neoplasms.
In 1954 and 1955, Renfer published two reports relating the anemia of
cancer patients to the rate of .increased blood destruction and to the spread of
the neoplasm.

Their investigations were based on studies in 19 patients with

a wide variety of malignant tumors.

The patients presented with bronchogenic

cancer, mammary cancer, Ewing's sarcoma, lymphatic leukemia, cancer of
the tongue, cancer of unknown origin, a round-cell sarcoma, a lymphosarcoma,
a reticulosarcoma and a treated x-ray-sensitive tumor of unstated origin.
Others presented with multiple myeloma, a :xonchogenic cancer, a tumor of the
brain stem, an astrocytoblastoma, a chronic lymphatic leukemia, a lymphoidcell reticulosarcoma, a mammary cancer under treatment, and a treated metastatic x-ray-sensitive tumor of unknown histology.

Renfer concluded from

these studies that the close relationship between the degree of the anemia, the
spread of the tumor, and the patient's red cell survival time pointed to the dom
inating cause of the "tumor-anemia" as being the result of increased erythocyte destruction.

·------~----------------·

·----·----------...
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Sohier et al. (1957) have reported a detailed investigation in which
serial red cell survival studies were performed on 4 patients with metastatic
carcinoma of the breast. Although the initial life span studies were nearly
normal, signs of increased destruction appeared in later studies which became
very marked in the month before death.

The initial life span of 120 days fell

to 105 days and then to 50 days just before death. When 30% of the labeled
red cells disappeared within a 2 week period the hemoglobin concentration fell
by 17% followed by an elevation of the reticulocyte count to about 8%. It
would seem that this sequence of events might represent the transient appearance of the destructive process which became so pronounced toward the end
of the study. At death, one of the patients had a hemoglobin of about 7 grams
% and a markedly elevated reticulocyte count of over 5 0%.
It would seem that this excellent and detailed study should provide a

pattern for future investigations in that by continuously following the rate of
disappearance of tagged cells during serial studies it is possible to more
accurately locate and measure fluctuations in the rate of the destructive process and to correlate these fluctuations with the clinical status of the patient.
3.

Nature of the destructive process

There are four main pathways by which red cells may l::le destroyed within
the body in pathological conditions:
(1) Lysis.

They may be lysed within the blood stream.

The hemoglobin

released binds to the haptoglobin in the plasma (Jayle and Boussier, 1955),
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which leaves the blood stream slowly and is presumably removed by the
reticulo-endothelial sys tern in the liver.

Hemoglobin in excess of the hapto-

globin-binding capacity of the plasma is excreted by the kidneys, causing
hemoglobinuria (Laurel! and Nyman, 1957).
(2) Phagocytosis.

They may be phagocytized directly from the circulatin

blood by components of the reticulo-endothelial system in the spleen, liver,
bone marrow, and lymph nodes.
(3) Hemorrhageo They may escape from the blood stream through breaks
in the vascular wall and be either lysed, phagocytized, or lost from the body
by external hemorrhage.

(4) Thrombosis. When a defect occurs in the vascular wall, a thrombus
is formed.

Entrapped red cells are lysed or phagocytized within the thrombus.

Although the destruction here occurs within the vascular tree, it is not within
the circulating blood.
Regardless of the pathway involved most of all of the hemoglobin not
lost through the urine appears eventually in cells of the reticulo-endothelial
system, where it is degradedo
converted to bilirubin.

The ring of the porphyrin moiety is opened and

The bilirubin passes to the liver where the glucuronide

is formed (Schmid, 1956) and excreted through the bile into the intestines,
where it is converted by bacteria into a complex group of compounds labeled
"urobilinogen."
4.

Evidence for tumor toxins and hemolysins
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One of the main pathways pursued by early investigators on anemia in
cancer was the possibility that tumors produced toxins which had a destructive
action against red cells.

Much of this history has been reviewed by Weil

(1907). At the turn of the century, Metchnikoff had been studying the hemolyti
action of extracts of various normal tissues. In describing the approach of
these early investigators to the problem, Weil reports "It had always been
common knowledge that a characteristic of malignant tumors was to produce
cachexia and secondary anemia in their victims." Marchand (1902) interpreted
the necroses, thromboses, hemorrhages, and round cell infiltrations as
evidence of a toxic influence.

He went even further; he suggested that the

disturbance of tissue equilibrium, to which Weigert had attributed the rapid
advance of tumor cells, was due to the destructive influence of this toxic substance on the surrounding tissues.

11

.

It has frequently been suggested that the

anemia of tumors is probably due to the action of some toxin elaborated by the
tumor and diffused into the circulating blood." Panzacchi (1902) was the first
to demonstrate the lysis of erythrocytes by tumor extracts.

This was

followed by reports of Micheli and Donati (1903) and Kullmann (1904).

Kull-

mann prepared extracts of tumors of the breast and uterus, and on testing
them against washed red cells of man, rabbit, sheep, and dog obtained he molysis in every case, indicating that the toxin of tumors was a general rather
than specific hemolysis.

In his own paper, Weil

(1907) demonstrated that

extracts of normal organs (liver and kidney) thoroughly freed from blood was
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very low in. hemolytic activity and in some cases was entirely absent.

In

studies on tumors, Weil found that necrotic were much more hemolytic
than non-necrotic ones.

He concluded that the anemias of malignant tumors

are probably due in part to the hemolytic and toxic action of such products of
necrosis.
Little of further significance happened in this field for 40 years.
194 7, Gross reported experiments suggesting

11

In

a direct destructive action of

a filterable substance contained in the tumor cells, on the erythrocytes of the
host.

11

His detailed studies were summarized in a later paper (Gross, 1948).
My reading leads me to conclude that evidence that substances from

neoplastic tissues play a significant role in vivo in the destruction of
circulating erythrocytes is still circumstantial. It is obvious that more work
is required to firmly establish a place for them in the etiology of anemia in
cancer.
S.

TUMOR - HOST RELATIONSHIPS - PATHOGENESIS OF CACHEXIA IN
CANCER
Weight loss is a very frequent clinical finding in patients or animals

with cancer; it may be one of the presenting symptoms or it may occur with
advancing disease.
Several factors are responsible and contributory to the tissue wasting
and the eventual cachexia.

Such factors are anorexia, nausea, dysphagia or

mechanical obstruction of the gastrointestinal tract, malabsorption, hemorrhage
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necrosis, ulcerations, proteinuria and gastrointestinal loss of albumin,
impairment of function or destruction of vital tissues and organs, therapeutic
removal of effusions and bacterial, viral, or fungal infections.
It is accepted by some that the described factors account for the path-

ogenesis of all cases of cancer cachexia (Ewing, 1941 and Willis, 19 60).
There are, however, several instances where weight loss is one of the earliest
manifestations of malignancy inducing the patient to seek medical advice, or
other cases where the weight loss is observed with advancing cancer with more
than adequate food intake and in the absence of other contributory factors
(Donovan, 1954 and Nebenzahl, 1932). In the latter cases, the cachexia has
been attributed to systemic effects produced by the tumor on the tumor-free
tis sues of the host.
The growth of the tumor alters markedly the metabolism and induces
measurable biochemical changes in various tissues and organs of the host
(Busch, 1962; Greenstein, 1954; and Theologides, 1967). The clinical
features of cachexia characterized by anorexia, marked asthenia, significant
loss of body fat, protein, and other components, anemia, water and electrolyte abnormalities, and increased basal metabolic rate and energy expenditure
despite the reduced dietary intake are the most obvious manifestations of a
profound systemic derangement of the host metabolism.

1.

Observations in Animals

A short period after inoculation with a tumor the total weight of the
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animal (animal plus tumor) starts increasing (Medigreceanu, 1910 and Murray,
1908). This continues up to a few days before death when the total weight
starts decreasing (McEven and Thomsom, 1933). The weight of the carcass
(animal minus tumor) might remain stable or even increase for a very short
initial period but then decreases progressively (Medigreceanu, 1910 and
Murray, 1908).

The tissues and organs that lose nitrogen and weight during

starvations are the ones that lose nitrogen during the tumor growth (Sherman
et al., 1950).

The alimentary canal weight maintains the normal ratio to

total body weight (Medigreceanu, 1910).

The heart shows hypertrophy in most

animals and the liver in all (Babson, 1954; Theologides, 1970; and Yeakel,
1948). It remains unexplained why in cancer the liver gains weight while all
other tissues lose weight in contrast to starvation where the liver too loses
weight.
The initial increase of the carcass weight is the result of an increase
in the water content of the body of tumor-bearing animal (Rechcgl et al., 1961).
The carcass of the tumor-bearing animal contains less nitrogen and less fat
but has an increased content of phospholipids and cholesterol (Bloor and
Haven, 1955; Boyd et al., 1953; Costa and Holland, 1962; Haven et al., 1949;
Mider et al., 1949; and Mider et al., 1948).
These animals retain a positive nitrogen balance for the initial period
of tumor growth (Cramer and Pringle, 1910), and they exhibit a higher retention
of water and sodium than the controls (Rechcgl et al., 19 61). With further
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growth of the tumor, the animals go into a negative nitrogen balance.

The

creatine and uric acid excretion in the urine is higher in rats bearing Jensen
sarcoma, but the creatinine excretion is lower (Ordway and Morris, 1913).
Terminally, the urea excretion is also significantly increased in tumorbearing animals (Sherman et al., 1950).
Because the tumor continues to grow despite the carcass weight loss,
it was suggested that the neoplasm obtains "foodstuffs" or building
materials from normal tissues (Moldave, 1956).

Mider et al. (1948) showed

that the amount of nitrogen in large tumors exceeded the total dietary nitrogen
stored during the period of growth of the neoplastic tis sue.

The balance of

the tumor nitrogen was provided by the animal carcass, and the tumor's need
took priority over the requirements of normal carcass.

The nitrogen in the

tumor becomes "trapped" and does not become available to a significant
extent to normal tissue (Mider et al., 1948), although the tumor contributes
a small quantity of amino acids to the host metabolic pool (Babson and Winnick,
1954). However, within the tumor cell, a dynamic equilibrium exists between
proteins and amino acids (Moldave, 1957).
The retention of nitrogen during force feeding is short-lived and transient, with a tendency for the nitrogen balance to approach equilibrium
rapidly and then to move to a negative phase (Terepka and Waterhouse, 1956).
2.

Comments

To explain the increased energy expenditure and the inability to
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adjust the metabolic rate in the phase of malnutrition Fenninger et al. (1953)
and Fenninger and Mider (1954) considered two possibilities. First, the
growth of malignant tissue proceeds continuously throughout the entire day,
in contrast to the diurnal periodicity in the metabolic activity of normal
tissues and their periodic reduction of caloric expenditure.

Therefore, the

metabolism of the growing tumor imposes greater energy expenditure than the
normal tissues.

Second, a selective removal of nutrients by the tumor results

in alterations in the pathways of the intermediary metabolism of the host
and forces the host to use more expensive pathways in terms of energy and
nitrogen metabolism.

Mider (19 5 5) further suggested that some biochemical

reactions previously available to the host might be denied to him because the
metabolites involved have been utilized by the tumor.
T.

PURPOSE OF THE DISSERTATION
There were three basic objectives in conducting the research on delta-

aminolevulinic acid (ALA) in lead poisoned and tumor bearing animals that
led to this dissertation.
FIRST: To modify the Davis Urinary ALA test described by Abrahams (1970)
for the early detection of increased lead absorption in children.
In parallel with these modification studies, a research plan was
devised to isolate and quantitate urinary porphobilinogen (PBG) utilizing the
unique combination of disposable ion-exchange column chromatography and
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and the easily prepared ALA standard calibration curve.

The objective was to

develop a rapid, accurate, quantitative screening test for adults suspected
of having the disease acute intermittent porphyria.
The present studies indicated that urinary urea was being washed free
of the dual piggyback column in the adult screening procedure for exposure
to lead poisoning.
in a pure state.

This afforded us the opportunity to isolate urinary urea

The present studies were designed to quantitate urinary urea

for early detection of renal disease states.
The objective of this first section was to be able to take one 0. 50
ml. aliquot of a random urine sample and quantitate one, two, or three urinary
constituents, namely ALA, PBG, and urea.
Second,

The present studies were designed to study the effect of

lead poisoning on rabbits especially in regards to accumulation of ALA in the
tissues.

The objective of this section was to isolate tissue ALA by using

disposable ion-exchange column chromatography, and then to quantitate these
levels.

The novel finding of an accumulation of tissue levels of ALA as a

direct result of a specific inhibitor of heme synthesis hopefully would supply
the forensic pathologist with a means to make a post-mortem diagnosis of
lead poisoning.
Third,

In the present studies a unique finding of a tumor-host inter-

ction involving greatly elevated levels of delta-aminolevulinic acid dehydrase
(ALAD) with a concomitant increase in reticulocyte production led us to
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investigate the effect of the Walker 256 carcinosarcoma on the host.

The

objectives of these studies were 1) to devise a method to detect ALAD in the
tumor host, 2) to determine if there was any relationship to the ALAD
enzyme activity and the appearance of reticulocytes, and 3) to determine
what occurs hematologically in these tumor bearing animals from the initial
day of transplantation to the time of the death of the animal (usually 20 days).
The present studies were expanded to study cell-free water extracts
of the Walker 256 Carcinosarcoma on normal animals.

The objective of these

studies was to determine if there would be any change in ALAD activity,
production of reticulocytes, or change in the basic hematological base line
of the animal.

For control purposes cell-free water extracts of normal liver

wa~

injected into litter mates of the tumor extract animals.
It therefore became of great interest to study this one aspect of the

phenomen of cancer and tumor growth to try to arrive at a small answer to the
question of what occurs in the tumor host in response to tumor growth.

CHAPTER II

MATERIALS AND METHODS
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CHAPTER II
MATERIALS AND METHODS
A.

ANIMALS

l.

Ra ts

Male, Sprague-Dawley rats, 80-100 days old at the time of the experiments, obtained from Abrams Small Stock Breeders, Chicago, Illinois.

Fed

ad libitum Rockland Rat Diet.
2.

Rabbits

Male, New Zealand, white rabbits weighing 3. 3 - 4 .1 Kg at the time
of the experiments, were obtained from Abrams Small Stock Breeders, Chicago,
Illinois and fed ad libitum Wayne Rabbit Ration.
In animal experiments in general, and particularly in chronic toxicity
tests, as was done in the lead and tumor studies, the variability of individual
parameters and hence the evaluation and reproducibility of the results depend
to a large extent on the quality and care of the animals used.

Reduced

variability not only increases the accuracy of the results but decreases
the number of animals needed, which is an important consideration.
In order to maintain the highest health and environmental standards,
and to reduce the variability associated with animal studies, the following
methods were employed •
•
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B.

PHYSIOLOGICAL STATUS OF ANIMALS
The physiological status was always constant.

The rats were always

male, Sprague-Dawley derived and 80-100 days old at the time of the experiments.

The rabbits were male, New Zealand whites weighing 3. 3 - 4.1 Kg.

Both species of animals were supplied by the same animal breeder and both
were housed in our laboratory·' s animal facilities.
C.

ENVIRONMENT
The environment of the animal quarters was generally controlled by the

environmental control station within the Loyola University Medical Center.
The temperature was a constant 73-75 F (22.6 - 24.8 C) and the humidity
averaged, on a daily basis, 40 percent.

The air conditioning operated

evenly giving a good air circulation but without giving any air turbulence.
The light intensity was moderate as supplied by the overhead fluorescent
bulbs.

Daylight cycles were maintained seven days a week to suit the cycles

of the rats and rabbits.
off at 6:00 P. M.

The lights were turned on at 9:00 A. M. and turned

The actual experiments were always performed during a

specific block of time and were never performed at random times.

1.

Diet constituents

The RocklandR Complete Mouse/Rat Diet (Teklad Incorporated, Monmouth, Illinois, 61462) had a guaranteed minimum percent analysis of crude
protein, 24%, crude fat, 4%, and crude fiber of 6% maximum.

The whole,

solid pellets contain soybean meal, ground yellow corn, fish meal, pulverized
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barley, wheat middlings, ground wheat, dehydrated alfalfa meal, pulverized
oats, feeding oat meal, dried skimmed milk, 1% animal fat (preserved with
propylene glycol, BHT, citric acid), vitamin A palmitate, irradiated dried
yeast, niacin, calcium pantothenate, riboflavin supplement, menadione,
vitamin B-12 supplement, 1% calcium carbonate, 0. 5% dicalcium phosphate,
1% salt, and traces of manganese oxide, copper oxide, cobalt carbonate,
iron carbonate, zinc oxide, and calcium iodate.
The Wayne Rabbit Ration (Allied Mills, Incorporated, Chicago, Illinois,
60606) had a guaranteed minimum percent analysis of crude protein 17%, crude
fat, 2. 0%, and crude fiber of 15% maximum. The small, green pellets contain
ground yellow corn, ground oats, soybean meal, wheat middlings, dried
whey, dehydrated alfalfa meal preserved with ethoxyquin, cane molasses,
vitamin A palmitate, irradiated dried yeast, vitamin B-12 supplement, vitamin
E supplement, menadione sodium bisulfite, riboflavin supplement, niacin,
calcium pantothenate, choline chloride, folic acid, ground limestone,
dicalcium phosphate, salt, manganous oxide, copper sulfate, iron sulfate,
potassium iodate, cobalt carbonate, and zinc oxide.
2.

Diet quantity

Adult rats will eat 12 to 15 grams of rat diet per day.

Therefore, the

feeders in the rat cages were designed to hold at least three days supply
of feed at one time.
Adult rabbits will require a daily food allowance of ll3 - 142 grams of
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rabbit ration.

The feeders in the rabbit cages were also designed to hold

at least a three day supply of rabbit food at one time.
3.

Mode of application of diet

The animals food was placed into feeders that would all ow the animals
to feed ad libitum.

The food was never in contact with the bedding or floor

of the respective cages thus their never was any contamination from urine
or feces.
4.

Water

The water supplied to the animals was administered in clean 8 ounce
glass bottles (2 per cage) for the rats and 16 ounce glass bottles (2 per
cage) for the rabbits. The source of the water was from the treated drinking
water of the Hines Veterans Administration Hospital, Hines, Illinois which
supplies all the water to the Medical Center.
The bottles were filled with fresh, cold tap water each day and were
completely replaced with new, sterile bottles once a week from the time the
animals arrived in shipment from the breeders through the time of the completion of the experiment.
5.

Caging

The caging for housing both rats and rabbits was made of stainless
steel.

The hanging type double width rodent cages measured 18"w x ll"d

x 8 11 h.

The cage sides and back were made of solid metal while the front

and floor were formed from a single continuous panel of smooth welded

...
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rod grid with a 2 x 2 mesh size.

Each of these rodent cages had two remov-

able spring steel water bottle holders and one removable feeder.

The water-

tight excreta service pans were positioned under the cages and were at least
l inch below the floor of the cage.
The spacious stainless steel hanging type rabbit cage measured 18"w
x 24" d x 14"h.
for the rabbit.
mesh.

The slotted back and sides provided excellent ventilation

The floor was made from smooth welded rod grid of 2 x 2

The rabbit cage was equiped with 2 water bottle holders and a remov-

able feeder.

The stainless steel watertight excreta service pans were slipped

under the cages and were at least 2 inches below the floor of the cage.
The rectangle-shaped cages were mounted on a mobile galvanized
steel rack.

The rat cage rack had 6 tiers with 3 cages per tier.

The rabbit

rack had 4 tiers with 3 cages per tier.
6.

Bedding

Soft wood sawdust and wood shavings were used as the source of the
bedding material.

Hardwood products were never used due to the high

tannic acid concentration.

The bedding was changed once a week and

completely replaced with fresh sawdust.
7.

Cleaning of facilities

The excreta service trays, the individual animal cages, and the mobile
cage racks were steam sterilized once a month.
The animal room floor was swept as required and washed with a
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solution of hot water and detergent once a week.
D.

PRELIMINARIES FOR THE EXPERIMENT
The animals were transfered from their shipping cartons to the clean

animal cages supplied with fresh water and food.

The rabbits were housed

individually while the rats were housed in groups of 5 per cage.
The animals, both rabbits and rats, were allowed to adapt to the environmental conditions for a period of 10 to 14 days before any experiment
was begun.
The adaptation period is short because the animal housing facilities
and laboratory are under the same roof and on the same floor of the Medical
Center.

This eliminates disturbances of the animals due to transportation,

and it keeps changes in the environment to a minimum.
E.

PREPARATION OF REAGENTS
l.

Sodium acetate, l. 0 M.

68g of NaCzH302-3HzO (J. T. Baker Chemical Co., Phillipsburg, N. J.,
catalog no. 3460) is dissolved and diluted with distilled water to 500 ml.
0.8% boric acid (Baker, catalog no. 0084) is added as a preservative.
2.

Acetic acid, l. 0 N.

172 ml. of glacial acetic acid (E.I. duPont de Nemours and Company,
Wilmington, Delaware) is added to one liter of distilled water.
a 3N solution.

This makes

Make al to 3 dilution of this stock for lN acetic acid.
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3.

Acetylacetone

Purchased under the chemical name of 2, 4-pentanedione (Eastman
Organic Chemicals, Rochester, New York, catalog no. 1088) and used
undiluted.
4.

Reagents required for the isolation of porphobilinogen (PBG)
a.

Glacial acetic acid (duPont)

b.

Mercuric acetate 15% w/v and 1% w/v

Add 15 grams of mercuric acetate (Baker, catalog no. 2584) to 100 ml
distilled water. Mix for one hour using a magnetic stirrer.
in a glass stoppered amber bottle.

Store this solution

The 1% solution is made the same way

except 1 gm of mercuric acetate is added to 100 ml.of distilled water.

Store

this solution in an amber glass stoppered bottle.
c.

H 2 S gas

Generated by adding 6N hydrochloric acid (duPont) dropwise to 20 gms
of stick ferrous sulfide (Baker, catalog no. 17 7 4) •
d.

Lead acetate 10% w/v and 1% w/v

Add 10 grams of the granular lead acetate (Baker, catalog no. 2271)
to 100 ml. of freshly boiled distilled water that has been allowed to cool to
room temperature.
bottle.

Store this lead acetate solution in a glass stoppered amber

Prepare the 1% solution in the same manner except only add 1 gram

of lead acetate to the boiled distilled water.
stoppered amber bottle.

Store this solution in glass

----------------------··-.......
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Silver nitrate 20% w/v and 1% w/v

Add 20 grams of the crystalline silver nitrate (Baker, catalog no. 3426)
to 100 ml of distilled water.
bottle.

Store this solution in an amber glass stoppered

Prepare the 1% solution by adding l gram of the silver nitrate reagent

to 100 ml. of distilled water.

Store this solution in an amber glass stoppered

bottle.
f.

Ammonium hydroxide 3M.

Pour 200 ml. of 28% ammonium hydroxide (Baker, catalog no. 9721)
into one liter of water, mix well.
g.

Acetone

Purchased as reagent acetone (Baker, catalog no. 9006) and used undiluted.
5.

Ehrlich's reagent for determining isolated PBG

Two grams of para-dimethylaminobenzaldehyde (Matheson, Coleman
and Bell, Norwood, Ohio, catalog no. 1606) is dissolved in 100 ml. of 6N
HCl.
6.

Modified Ehrlich's reagent for determining delta-aminolevulinic

acid (ALA), PBG, and amino acetone (AA)
10 grams of para-dimethylaminobenzaldehyde (Matheson, Coleman and
Bell, catalog no. 1606) is dissolved in 420 ml. of glacial acetic acid
(duPont) and 80 ml. of 70% perchloric acid (G. Frederick Smith Chemical
Company, Columbus, Ohio) •
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7.

Ehrlich's reagent for ALA dehydrase assay

One gram of para-dimethylaminobenzaldehyde (Ma the son, Coleman
and Bell, catalog no. 1606) is dissolved in 34 ml. of glacial acetic acid
(duPont) and 16 ml. of 70% perchloric acid (Smith Chemicals).
8.

Urea stock solution

Five mg of pure urea standard (Mann Research Laboratories, New York,
N.Y., catalog no. 9200) is dissolved in 7.0 ml. distilled water.
9.

Reagents for preserving a random urine sample for ALA test
a.

Glacial acetic acid

Use undiluted glacial acetic acid (duPont).
b.

Tartaric acid

Dis solve 90. 05 grams of tartaric acid powder (Mallinkrodt Chemical
Works, St. Louis, Mo., catalog no. 2314) in 200 ml. distilled water to make
a 3M solution.
c.

Oxalic acid

Dissolve 78 grams of oxalic acid (Baker, catalog no. 0230) in 200 ml.
distilled water to make a 3M solution.
d.

Citric acid

Dissolve 114 grams of anhydrous citric acid (Fischer Scientific Company,
Fair Lawn, N .J ., catalog no. A-940) in 200 ml. distilled water to make a 3M
solution.
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Boric acid

Dissolve 37. 2 grams of boric acid crystals (Baker, catalog no. 0084)
in 200 ml. distilled water to make a 3M solution.
10.

0. 0 OlN acetic acid

To 500 ml. of distilled water add 0. 03 ml. glacial acetic acid (duPont).
11.

Trichloroacetic acid - 5%

Dissolve 5 grams of fresh trichloroacetic acid crystals (Baker, catalog
no. 0414) in 100 ml. distilled water.
12.

Biuret reagent

Dissolve 1.50 grams cupric sulfate (Baker, catalog no. 1843) and 6.0
grams of sodium potassium tartrate (Baker, catalog no. 3930) in 500 ml.
distilled water.

Carefully add 300 ml. of a 10% sodium hydroxide solution

(Baker, catalog no. 3722) and stir well.

Dilute to one liter with distilled

water.
13.

Lead acetate solutions - 5, 10, and 30%.

Carefully dissolve 30 grams of granular lead acetate (Baker, catalog
no. 2271) in 100 ml. of freshly boiled distilled water that has been allowed
to cool to room temperature.

For the 5 and 10 percent solutions use 5 and 10

grams of lead acetate per 100 ml. dis tilled water.
14.

n-Butanol containing 0. OlM ammonium hydroxide

0.1 ml. of lM ammonium hydroxide (Baker, catalog no. 9076) is added
to 9. 9 ml. of n-butanol (Baker, catalog no. 9 054) and mixed well.

The final
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concentration of the NH40H is 0. O!M.
15.

Glacial acetic acid - methanol reagent

50 ml. of glacial acetic acid (duPont) is carefully added to 100 ml.
reagent grade methanol (Baker, catalog no. 9076) to make a 1:2 mixture.
16.

Disodium ethylenediaminetetraacetate (EDTA), 5%

Dissolve 5 grams of disodium EDTA (Baker, catalog no. 8993) in 100 ml.
of dis tilled water.
17.

Tyrodes buffer without Ca++ ions

Into one liter of distilled water dissolve 8 grams NaCl (Baker, catalog
no. 3624) and l gram anhydrous, granular D+ glucose (Baker, catalog no.
1916), shake well.

To this solution add 2. 4 ml. of a 25% MgC1 2 solution

(107 gm MgC1 2 -6H 20/200 ml H 20 - Baker, catalog no. 2444), 4. 8 ml. of a
25% KC! solution (SO gm KCl/200 ml. H 2 o·- Baker, catalog no. 3040), and
l. 0 ml. of a 10% NaH 2 P04 solu.tion (23 gm NaH 2P04/200 ml H 2o - Baker,
catalog no. 3506).

Mix this buffer solution well and use within a period of

six hours.
18.

Cupric sulfate - 10% trichloroacetic acid

Capric sulfate crystals (Baker, catalog no. 1843) are added to 100 ml.
distilled water with stirring until a saturated solution is obtained.

10 grams

of fresh trichloroacetic acid (Baker, catalog no. 0414) is added to 100 ml. of
distilled water to make a 10% solution.

O. 05 ml. of the saturated Cuso 4

solution is added to l. 0 ml. of the 10% TCA solution.

..
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19.

Reticulocyte stain - new methylene blue N

Purchased from Harleco Chemicals, Phila., Pa., catalog no. 697
and used undiluted.

The dye is made according to the Brecher formula - 0. 5%

solution of the dye containing l. 6% dissolved potassium oxalate.
20.

IsotonR diluent for blood cell counting

Purchased from Coulter Diagnostics, Inc., Hialeah, Florida. Used
undiluted.
21.

Zap-IsotonR lysing agent

Purchased from Coulter Diagnostics, Inc., Hialeah, Florida.

Used

undiluted.
22.

Stable cyanmethemoglobin reagent

Purchased from Hycel, New York, catalog no. 116C and used undiluted.
23.

Sterile saline for tumor transplants

Sodium chloride, injection, U.S. P., 0. 85% sterile, contains no
bacteriostat.

Purchased from Elkins - Sinn, Inc.

ampules and used undiluted.

Cherry Hill, NoJ., in 5 ml.
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F.

PREPARATION OF ALA STANDARD

l. Crystalline delta-aminolevulinic acid hydrochloride. Obtained
from Sigma Chemical Company, St. Louis, Mo., catalog no. A-8879.
2. Acetate buffer, pH 4. 6 5. 7 ml of glacial acetic acid and 13. 6
grams of NaC H o . 3H 0 are diluted with water to 100 ml.
2
2 3 2
3. A stock solution of ALA is prepared by dissolving 12. 5 mg of ALA
hydrochloride with acetate buffer, pH 4. 6 to a 100 ml mark.

Each ml of

stock solution contains 125 µg of ALA.HCl which is equivalent to 100 µg of
pure ALA.
G.

PREPARATION OF AN ALA STANDARD CALIBRATION CURVE

l. Six aliquots of the ALA. HCl stock solution (O. 01 ml, 0. 05 ml, 0 .10 ml,
0.20 ml, 0.30 ml and 0.50 ml) are pipetted into test tubes and are used as
working standards.
Volume of standard
stock solution
0. 01
0. 05
0 .10
0. 20
0. 30
0. 50

ml
ml
ml
ml
ml
ml

µg of ALA per total
reaction volume
1 µg
5 µg
10 µg
20 µg
30 µg
50 µg

2. Dilute each of the working standards to 7. 0 ml with 1. 0 M sodium
acetate.
3. Pipet 7. 0 ml of l. 0 M sodium acetate into an empty test tube to be
used as a reagent blank.
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4. Add 0. 2 ml of acetylacetone to each test tube and mix.
5. Place the test tubes in a boiling water bath for 10 minutes, remove,
and cool to room temperature.
6. Add 7 .O ml of modified Ehrlich's reagent to each test tube, mix and
let stand for 15 minutes for complete color development.
7. Read the optical density of the standards corrected for the blank, at
553 mµ in a spectrophotometer. The optical path of the cuvette is 1.0 cm.
8. Prepare a standard curve by plotting the concentrations of the
standards against their optical densities.
H.

ISOLATION OF PBG FROM HUMAN URINE
The urine was collected from a 22 year old Negro female who had been

diagnosed as having acute intermittent porphyria after taking a combination
birth control pill for two months.

She had been a patient at Cook County

Hospital, Chicago, Illinois for a period of 30 days before the present PBG
isolation experiments were begun. The method,

with modifications, is that

of Cookson and Rimington (1954).
The collected urine (2 50 ml) containing porphobilinogen was adjusted
to a pH 4-4. 5 with lN acetic acid.

The acid was added dropwise under

conditions of continuous stirring by means of a magnetic stirrer.
monitored with a Sargent pH meter, model L. S.

The pH was

Mercuric acetate (15%, W /V)

solution was added dropwise until all the PBG was precipitated (negative
Ehrlich reaction of the supernatant).

The precipitate was kept in suspension

·------~----~-----,------~Ail''~-·-~----------.
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by using the magnetic stirrer until it was poured into 1 x 3 inch cellulose

nitrate centrifuge tubes (Beckman, catalog no. 078).

The suspended

precipitate was centrifuged at 600 x g, at room temperature, for 10 minutes in
an International Centrifuge - model V.

This centrifugation step and others

modifies the Cookson and Rimington method by not using a Bilchner funnel.
The precipitate pellet was worked three times with mercuric acetate (1%, W/V)
and then suspended in water and decomposed by H S gas.
2

The H S gas was
2

generated by the addition of 6N HCl to sticks of ferrous sulfide.

The gas,

as well as all other additions, was added with constant stirring by means of
the magnetic stirrer. The gas was pumped into the stirring solution for a
period of 18 minutes.

The resulting black sulfide precipitate was centrifuged

at 600 x g for 10 minutes.
ed air - for 10 minutes.

The supernatant was aired - by means of compress-

Excess lead acetate (10%, W /V) was added until no

further precipitate would form in the supernatant fraction.

The deeply

pigmented precipitate was removed by centrifugation and washed repeatedly
with 1% (W/V) lead acetate solution. A.11 supernatants from these washings
were saved and combined. AgN0

3

(20%, W/V) solution was added to the

combined supernatants and washings until precipitation was complete.

The

mixture was centrifuged at 600 x g for 10 minutes and the precipitate was
washed three times with 1% (W/V) AgN) . All the supernatants were combined
3
and were treated, without prior removal of Pb and Ag ions, with a slight
excess of 15% (W/V) mercuric acetate solution.

This mercury precipitate was

95
almost white. It was collected by centrifuging at 600 x g for 10 minutes at
room temperature.

The precipitate was decomposed by passing H 2S gas into

the pellet without the addition of further fluid.

HgS was easily removed by

centrifuging from the pale yellow supernatant, which was freed from H 2S gas
by aeration.

The supernatant was then adjusted to pH 3. 7 with 6N NH 4 0H and

then to pH 4 with 3N NH 4 0H. A very small amount of porphobilinogen
crystallized immediately in almost colorless, well formed, crystals .. After
chilling to 4°c, the solution was filtered and the crystals were washed with
cold water (4°C) containing a little acetic acid, and then with acetone.

The

yield was approximately 5-8 mg.
It was very obvious that this small amount of crystalline PBG would

13
not be enough for further experiments. The E
was determined (Rimington,
1cm
Krol, and Tooth, 1956) as being equal to 1.13 6 x 103. This is the absorption
of a 1% solution of PBG in a l cm light path at a concentration of 1 mg/ml in
acetic acid (1 N) before adding Ehrlich's reagent.
Using this information, and previous published studies of the isolation
of PBG on anion exchange resins (Westall, 1952 and Mauzerall and Granick,
1956) it was decided to utilize the supernatant solution that was supposed to
give PBG crystals. After the supernatant was adjusted to pH 4.0 with NH 4 0H
a current of air was passed over the beaker, which was shielded from light
by being covered with a large cardboard box, for a period of 8 hours.
concentrated 12. 50 ml volume was called the "PBG-syrup".

This
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0. 50 ml of the PBG-syrup was applied to an AG-1-XB resin column
(2 cm high and l. 6 cm in diameter) and was eluted with 10 ml of l N acetic
acid.

0.1 ml of the eluted PBG was diluted with 1.9 ml l N acetic acid to

give a dilution of 1:20. This 1:20 solution was added to 2 ml of Ehrlich's
reagent made by dissolving 2 grams p-dimethylaminobenzaldehyde in 25 ml
concentrated HCl and 75 ml glacial acetic acid (Moore and Labbe, 1964).
The reaction was allowed to proceed for 8 minutes for full color development
before the optical density was determined at 555 and 525 mµ against a reagent
blank. If pure PBG is present in a sample a ratio of A525/A555 will be
approximately 0.83.

For this sample the ratio was 0.80.

The eluted PBG was

called "Column Chromatographed PBG".
The mg of PBG in the PBG-syrup was determined by using the following
formula:
mg PBG

=

As55x10 x 12.5

x

2

x

20

!13. 6
Where As55

=

Optical density of the final reaction
color of PBG and Ehrlich's reagent
read against a reagent blank, and

113. 6

=

absorption of PBG at a concentration
of l mg/ml in the acetic acid eluate
before adding Ehrlich's reagent, and

10

=

dilution of the PBG-syrup aliqust
with acetic acid, and

12. 5

=
=

volume of the PBG syrup, and

2

factor to correct for the 0. 5 ml aliquot
of the PBG syrup added to the
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AG-1-XS column, and
20

=

the 1: 20 dilution factor

A standard curve was prepared, using the human PBG, in the following
manner:

l. Three aliquots of the column chromatographed PBG (0.10 ml, 0.20 ml,
and 0.40 ml) are pipetted into test tubes and are used as working standards.
Volume of standard
stock solution

µg of PBG per total
reaction volume

0.10 ml
0. 2 0 ml
O. 40 ml

4. 91 µg
9. 82 µg
19. 64 µg

.

2. Dilute each of the working standards to 7. 0 ml with l N acetic acid.
3. Pipet 7. 0 ml of l N acetic acid into an empty test tube to be used as

a reagent blank.
4. Add 7. 0 ml of modified Ehrlich's reagent to each test tube, mix well
and let stand for 15 minutes for complete color development.
5. Read the optical density of the standards, corrected for the reagent
blank, at 555 mµ in a spectrophotometer.

The optical path of the cuvette is

1. 0 cm.
6. Draw a standard curve by plotting the concentrations of the standards
against their optical densities.
I.

PREPARATION OF SYNTHETIC PBG STANDARD

l. Porphobilinogen - synthetic, obtained from Bio-Rad Laboratories,
Richmond, California .
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2. One normal acetic acid.
3. A stock solution of PBG is prepared by dissolving 10 mg of synthetic
PBG in 100 ml of distilled water, pH 7 .5.

Each ml of stock PBG solution

contains 100 µg of pure PBG.

J.

PREPARATION OF PBG STANDARD CALIBRATION CURVE

l. Four aliquots of the PBG stock solution (0.01 ml, 0.05 ml, 0.10 ml,
and O. 20 ml) are pipetted into test tubes and are used as working standards.
Volume of standard
stock solution
0. 01
0.05
0.10
0.20

µg of PBG per total
reaction volume
l
5
10
20

ml
ml
ml
ml

µg
µg
µg
µg

2. Dilute each of the working standards to 10. 0 ml with l. 0 N acetic
acid.
3. Pipet 10 ml of 1. 0 N acetic acid into an empty test tube to be used as
a reagent blank.
4. Add 10 ml of modified Ehrlich's reagent to each tube, mix, and let
stand for 15 minutes for complete color development.
5. Read the optical density of the standards, corrected for the blank, at
5 55 mµ in a spectrophotometer.

The optical pa th of the cuvette is l. 0 cm.

6. Draw a standard curve by plotting the concentration of the standards
against their optical densities.

----------~---------~-~~--. --~----------
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K.

PREPARATION OF DISPOSABLE CHROMATOGRAPHY COLUMNS PREPACKED

WITH AN ION-EXCHANGE RESIN
1.

Two-column ALA and PBG analysis

In order to isolate ALA and PBG from urine, the urine sample mµst be
passed through an anionic exchange resin which permits the ALA and urea to
pass through while retaining porphobilinogen.

The effluent passing through

the anionic resin must then be passed through a cationic exchange resin
which retains ALA while allowing urea to pass through.

The anionic resin

employed in the following experiments was AG-l-X8, 100 to 200 mesh, acetate
ionic form.

The cationic exchange resin was AG 50W-X4, 100-200 mesh,

hydrogen ionic form.
A slurry of either AG-l-X8 resin or AG 50W-X4 resin was made in
distilled water using 3 grams of the respective resin and 7 ml of water for
each column to be prepared. A 10 ml aliquot of the slurry was then pipetted
into the appropriate disposable plastic chromatography column (Bio-Rad
Laboratories).

The resin was held in the column by a glass wool plug placed

in the bottom cap of the column. A second glass wool plug was placed on top
of the resin in order to prevent distortion of the resin bed.

Using this method

produced a column 2 cm in height and 1. 6 cm in diameter.
2. The one column ALA analysis
It is now known that children do not excrete porphobilinogen (PBG) in

their urine. Therefore, the principle of using an AG-l-X8 anion res ion to
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retain and remove PBG, as an interfering substance to the ALA test, was no
longer valid for determining lead exposure in children.
A slurry of AG 50W-X4 resin, 100-200 mesh, hydrogen ionic form was
made in distilled water using 5 grams of the resin and 7 ml of water for each
batch of columns. A 1 ml aliquot of the slurry was pipetted into the disposable
plastic chromatography column (Bio-Rad Laboratories) using a 5 ml Cornwall
continuous syringe (Becton-Dickenson). The resin was held in the column
by a small glass wool plug placed in the lower cap of the column.
wool plugs were used on top of the resin bed.

No glass

This method produced a

column 2 cm in height and 0. 6 cm in diameter.
L.

STABILITY OF THE COLOR DEVELOPED WITH MODIFIED EHRLICH'S

REAGENT FOR DETERMINATION OF URINARY ALA
Six aliquots of the ALA hydrochloride stock solution (O. 01, 0. 05, 0 .10,
0.20, 0.30, and 0.50 ml) were placed in test tubes and after appropriate
steps, color development was attained with modified Ehrlich's reagent.

The

optical density of each tube corrected for the blank was determined 15 minutes
and 2 hours after the addition of the modified Ehrlich 1 s reagent.
M.

STABILITY OF THE COLOR DEVELOPED WITH EHRLICH'S REAGENT FOR

DETERMINATION OF URINARY PBG
Two random urine samples from a patient diagnosed as having acute
intermittent porphyria were carefully pipetted to two separate AG-l-X8
columns (2. 5 cm in height, 1. 6 cm in diameter). These urine samples were

----------~--------·--™---·-,-·---~·----------

101
washed with 30 ml of water and eluted with 7. 0 ml of 1 N acetic acid.
1.

Standard Ehrlich's Reagent

7. 0 ml of standard Ehrlich's reagent (2 grams DMAB dissolved in 100 ml
of 6N HCl) was carefully added to the 7. 0 ml eluate.

The optical density was

determined at 5, 15, 30, 45, 60, 75, and 90 minutes at 555 mµ using a
spectrophotometer.

The sample was corrected for the reagent blank at each

time reading.
2.

Modified Ehrlich's Reagent

7. 0 ml of modified Ehrlich's reagent (2 grams DMAB dissolved in 84 ml
acetic acid and 16 ml PCA) was carefully added to the 7. 0 ml eluate.

The

optical density of the sample corrected for the blank was determined at 5, 15,
30, 45, 60, 75, and 90 minutes at 555 mµ using a spectrophotometer.
N.

PROCEDURE FOR THE DETERMINATION OF URINARY ALA BY MEANS OF

TaE TWO COLUMN METHOD
The procedure for the determination of urinary ALA is illustrated in
Figure 4 and is as follows:

1. Insert a dual disposable chromatographic column setup in the support
rack with the column containing the anionic AG-1-XS resin on top and the
column containing the cationic AG 50W-X4 resin on the bottom.
2. Wash the top column with 10 ml of water and allow to drain through
both columns into the drain tray.
3. Apply 0. 5 ml of a random urine sample to the top column after having
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determined that the pH of the urine is 6 or below.
4. Wash the top column three times with 10 ml of water and allow the
water to drain through both columns.
5. Discard the top disposable column.
6. Place the bottom column in a test tube (20 x 150 mm). Add 7. 0 ml of
l. O M sodium acetate to the column and collect the eluted ALA.
7. Discard the bottom disposable column and add O. 2 ml of acetylacetone
to the tube and mix.
8. Place the test tube in a boiling water bath for 10 minutes.
9. Add 7. 0 ml of modified Ehrlich's reagent to the cooled test tube.
10. Read the optical density, corrected for the reagent blank, after 15
minutes at 553 mµ in a spectrophotometer and determine the concentration of
ALA in the urine sample from the standard calibration curve.

Normal values

of urinary ALA produce a faint yellow color, while cibnormally elevated
values produce a distinct red color.
O.

PROCEDURE FOR THE DETERMINATION OF URINARY ALA BY MEANS OF

THE ONE COLUMN METHOD
1.

Remove numbered pip et guide from top of the support rack.

Remove

both the cap and tip cover from each column and place columns in the
support rack. Apply 7 ml of distilled water to each column and allow to drain
into the tray.
2. Take a random urine sample having a pH of 6 or below, gently shake
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and apply 0. 5 ml of urine to each column by inserting a pipet through the
correctly numbered hole in the pipet guide.
3. Remove numbered pipet guide. Apply 7 ml of dis tilled water to each
column and allow to completely drain into the drain tray.

Repeat four more

times for a total water wash of 35 ml.
4. Remove completely drained columns from the support rack and place
in empty numbered 20 x 150 mm pyrex test tube rack. Add 7. 0 ml of 1. 0 M
sodium acetate to each column and collect the eluate in the test tubes.
5. Remove and discard the disposable column from the test tube. Add
0. 2 ml of acetylacetone to the contents of the test tube and mix.
6. Place the test tube rack containing the eluted ALA samples into a
boiling water bath (90 C or greater) for 10 minutes, after which the rack should
be removed from the bath and the test tubes allowed to cool to room temperature
7. Add 7. 0 ml of fresh Ehrlich's reagent to the test tubes and mix.
Allow to stand for 15 minutes for completion of color development.
8. Read the optical density, corrected for the reagent blank, at 553
mµ in a spectrophotometer and determine the concentration of ALA in the urine
sample from the standard calibration curve.

Normal values of urinary ALA

produce a faint yellow color, while abnormally elevated values produce a
distinct red color. It is therefore possible in a large screening program to
immediately eliminate all non-red colors by visual inspection. A very accurate
quantitation of the mg% ALA in the red sample can then be obtained by plotting
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the optical density of the red samples against known concentrations of pure
ALA standard carried through the identical procedure.
P.

PROCEDURE FOR THE DETERMINATION OF URINARY PBG

1. Insert a dual disposable chromatographic column setup on the
support rack with the column containing AG-1-XS resin on top and the column
containing the cationic AG 50W-X4 resin on the bottom.

The dual column

setup is suggested only if one wishes to determine both urinary PBG and ALA..
If one wishes only to determine PBG, then the top column containing AG-1-XS

resin should be used.
2. Wash the column with 10 ml. of distilled water and allow to drain
through both columns into a drain tray.
3. Apply 0. 5 ml. of a random urine sample to the AG-1-XS column.
The pH of this sample must be below 6.
4. Wash the AG-1-XS column, or the total chromatographic column
setup, with 30 ml. of distilled water, in 10 ml. batches, and allow the water
to drain into the drain tray below.
5.

Separate the top AG-1-XS column from the column setup and place

into an empty numbered 2 2 x 17 5 mm test tube held in a standard test tube rack
If one has not elected to use the dual column setup then one just has to

place the AG-1-XS column into the numbered test tube.
6.

Add 10 ml. of 1. 0 N acetic acid to each column and collect the

eluted PBG in the numbered test tube.

It is suggested that this procedure be
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done in reduced light to prevent any photo reactions with the PBG.
7.

Remove and discard the AG-l-X8 column from the test tube.

Add

10 ml. of fresh Ehrlich's reagent to each test tube and mix. Allow the tube
to stand for 15 minutes for completion of the color development.
8.

Read the optical density of the final reaction mixture, corrected

for the reagent blank, at 555 mµ in a standard laboratory colorimeter.
Q.

DETERMINATION OF THE CORRECT VOLUME OF WATER TO WASH THE_

UREA OUT OF THE SINGLE COLUMN ALA TEST
5 mg of pure, crystalline urea standard was added to 7 ml. of a normal,
random urine sample. AO. 5 ml. aliquot of this urine solution was added to
the single, disposable column for determining urinary ALA.
washed with 7. 0 ml. of distilled water five times.
was collected in separate test tubes.

The column was

Each 7. 0 ml. eluate

2.0 ml. of modified Ehrlich's reagent

was added to each tube and the color was allowed to develop for a period
of 15 minutes after which the optical density was determined, corrected for
a reagent blank, at 415 mµ.
R.

PROCEDURE FOR PRESERVING RANDOM HUMAN URINE SAMPLES FOR

THE ALA AND PBG ANALYSES
60 ml. of fresh, normal urine, taken from a random urine sample was
adjusted to pH 9 0 with lN NaOH.
0

PBG for purposes of recovery.

To this- urine sample was added ALA and

0. 2 ml. of 3M solutions of tartaric acid,

oxalic acid, citric acid, and boric acid was added to the empty 15 ml.
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glass screw capped bottles.

The bottles were dried in a 7 5 C oven for one

hour or until dry. After the bottles were cooled to room temperature 10 ml.
of urine with the added ALA and PBG was added to each of the bottles and
shaken well to dissolve the dried preservative.

For control purposes one

bottle had 0 .1 ml. of glacial acetic acid added as the only source of a urine
preservative.

The resulting pH of this urine sample (preserved as directed

in the direction sheet from Bio-Rad Laboratories for the urinary ALA Test)
was compared to the results using the dried preservatives.
The pH of the urine sample, µg ALA, µg PBG, and percent recovery of
these heme precursors as compared to day zero was determined throughout a
28 day storage period at 4 C in the dark.

The dual, disposable chromato-

graphic column setup was used in these studies.
S.

ANIMAL EXPERIMENTS

1.

Procedure for determining tissue levels of ALA in the lead-

poisoned rabbit
Nine rabbits, three of which were controls, were used in this study.
Each animal was given a single s. c. injection of a 5 percent solution of lead
acetate in water (w/v) in the nape of the neck.

The dose for each animal

was 200 mg of lead acetate per Kg of body weight.

Control animals were

administered an equal volume of normal saline by the subcutaneous route in
the nape of the neck.
The following 21 control and lead poisoned tissues were removed and
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analyzed for ALA: bone marrow, kidney, spleen, lung, cauda and caput
epididymis, urinary bladder, seminal vesicles, heart, small and large
intestines, testes, stomach, cerebrum and cerebellum, liver, lymph nodes,
thymus, diaphragm, psoa sis muscle and adipose tis sue.
Approximately one gram of tissue was removed (kidney, liver, bone
marrow, etc.) at standard laboratory conditions of light and temperature and
placed into 9 ml. of cold O. 001 N acetic acid.

The well minced tissue (by ,.

using a scissors) was homogenized in 9 ml. of 0. OOlN acetic acid in a
Corning tissue homogenizer that was 19 x 150 mm in size.

The ground glass

tube and pestle insured adequate abrasive qualities yet produced a fine
homologous sample. A Power-StirR stirrer (Eberback Corpora ti on, Ann Arbor,
Michigan) with a controlled speed of 1000 RPM with a 1/10 H.P. motor supplied
the power for the homogenization procedures.
16 in/lb through a 20 to l worm gear drive.

The torque that developed was

The glass homogenizer was

washed with O. OOlN acetic acid and the total homogenate and washing were
combined, mixed well after the addition of 0 .10 ml. of 5% TCA

and allowed

to stand at room temperature for 10 minutes. The homogenate was centrifuged
at 600 xg for 20 minutes at room temperature.
To prevent excessive vibration during centrifuging every effort was
made to distribute the weight evenly in all the tubes.

This was done by

pairing and numbering the shields and other rotating accessories in such a
manner that opposing pieces were in balance. The centrifuge tubes that were
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chosen had approximately the same weight and shape and chipped glassware
was never used.
The supernatant was saved and combined with 0. 001 N acetic acid
used to wash the pellet from the centrifugation step.

The pH of the combined

supernatants was adjusted to pH 5 with solid Na2C03 and was immediately
frozen at (-) 7°C, in the dark, overnight.

The frozen superna tan ts were

defrosted in a 45C water bath and mixed well before being heated for 5 minutes
in the 45C water bath. After removal from the water bath and cooling to
room temperature the supernatants were centrifuged at 600 xg for 20 minutes.
The supernatant was saved and combined with the 2 ml. of distilled water
used in washing the pellet.
The combined supernatants from the heating step was poured onto the
top AG-1-XS column of a dual, disposable column chromatography unit.
The columns were allowed to completely drain and then were washed three
times with 10 ml. of dis tilled water.
After the washing was completed the column chromatography unit
was separated and ALA and PBG were eluted off the columns and quantitatively
determined as previously described.
2.

Procedure for the isolation and determination of tissue amino-

acetone in the lead poisoned rabbit
Ten adult rabbits, two of which were controls, were used in this study.
Two of the animals received a single subcutaneous injection of a 30 percent

109
solution of lead acetate in water (w/v) in the nape of the neck.

The dose

for one animal was 400 mg of lead acetate per Kg of body weight and the
other rabbit received a single subcutaneous dose of 800 mg/Kg body weight.
A control rabbit was used for comparison.

The six remaining rabbits were

injected with a single subcutaneous injection of a 10 percent solution of
lead acetate in water (w/v) in the nape of the neck.

The dose for these

animals was 200 mg of lead acetate per Kg of body weight.

The controls

in both series (2 rabbits) received an equal volume of normal saline administered by the subcutaneous route in the nape of the neck.
The following four tissues were isolated from each animal and analyzed
for tissue levels of ALA, as described previously, and aminoacetone:
bone marrow, kidney, liver, and spleen and whenever possible random
urine.
The bone marrow was removed from the right femur and was used for
the determination of tissue levels of ALA.

The bone marrow from the right

and left tibia was used for the determination of aminoacetone (AA).

The

bone marrow from the left femur was fractionated for determining whether
or not ALA was concentrated in the centrifuged pellet, in the supernatant, or
in the floating adipose tissue.
The fractionation was performed using approximately 1 to 1. 3 grams
of bone marrow from the left femur.

The bone marrow was carefully

suspended in cold (4 C) Tyrode' s buffer that was made without calcium
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ions (Goodman, 19 60).

0 .10 ml. of 5 percent EDTA was added to prevent

deleterious effects to the suspended cells (Anderson, 19 65, and Harris, 19 66).
The cells were gently mixed using a glass rod with a rubber policeman.
The cell suspension was centrifuged at 10, 000 xg for 20 minutes at 4°c.
The top adipose tissue was removed and treated as a separate tissue as
was the supernatant and the centrifuged pellet.

Each of these fractions was

homogenized, washed, centrifuged and poured onto the top column of
the dual column setup as previously described.
The tissue ALA and AA (both are retained on the cation resin column)
were eluted from the bottom AG-50W-X4 resin column with lM sodium
acetate.

0. 2 ml. of acetylacetone was added to the 7 ml. eluate and mixed

well. This solution was heated in a boiling water bath to form a pyrrole
of ALA and M by a Knorr-type condensation (Mauzerall and Granick, 1956).
After cooling to room temperature, the solution containing the ALA
and AA pyrroles was poured onto an AG-1-XS column (same resin and size of
column as used for the isolation of PBG). The aminoacetone pyrrole is
then eluted with 10 ml of n-butanol containing 0. 01 m ammonium hydroxide.
The eluate containing the AA pyrrole is carefully mixed with an equal volume
of modified Ehrlich's reagent.

The optical density of the color reaction is

read, corrected for a reagent blank, at 55 6 mµ after exactly 10 minutes
(Marver, Tschudy, Perlroth, Collins, and Hunter, 1966).
The formula to determine aminoacetone mathematically is as follows:
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A556

=

E x C x length (cm) of cuvette

where A556

=

Optical density of the reaction
mixture read at 55 6 mµ after exactly
10 minutes of reaction time, and

E

=

molecular extinction coefficient of an
equal volume of AA pyrrole mixed with
modified Ehrlich's reagent, under these
conditions, using a l cm cuvette, the
E of the color complex is equal to 7. 6
x 104, and

c

=

concentration expressed as moles/
liter, and

l

=

length of the light pa th through the
cuvette, in these experiments, l was
always equal to l cm.

Therefore the concentration (C) can be solved by dividing the optical
density by the extinction coefficient to get moles/liter.

c

=

b.5.5.6.

c

=

moles/liter

7. 6 x 104

The grams of aminoacetone per liter is determined by multiplying the
molecular weight of AA (73. 03) by moles/liter.
grams/liter

=

(73. 03) (moles/liter)

The grams of AA per liter is converted to milligrams per liter by
multiplying grams by 1000.
mg/liter

=

grams x 1000

The milligrams of AA per liter is converted to micrograms per liter by
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multiplying milligrams by 1000.
µg/liter

=

milligrams x 1000

The total reaction volume for determining the aminoacetone level of
the tissue is 20 ml. (10 ml. eluate+ 10 ml. modified Ehrlich's).

To convert

µg AA/liter to µg AA/2 0 ml. reaction volume, the following ratio is utilized:

µgM

1000 ml

=

(x) µg M

20 ml

One therefore solves for the unknown quantity of µg M that is in the
20 ml reaction volume.
3.

Procedure for Transplanting the Walker 256 Carcinosarcoma Tumor

A 60 day old male, Sprague-Dawley rat bearing a 7 day old tumor was
sacrificed by decapitation.

The area of the surface of the abdomen (in the

region of the external oblique muscles, either to the left or right of the
anterior midline in the left or right lateral region) bearing the tumor was
cleaned with 70 percent ethanol and pat dried with absorbant cotton.
The subcutaneous tumor weighing approximately l. 5 - 2. 5 grams was
surgically removed under semi-sterile conditions using sterile curved-onflat, 5 1/2 inch, scissors with sharp points.

The tumor was handled with

tissue forceps with 1 x 2 teeth and with forceps without teeth.
The excised tumor was placed in a glass, sterile 100 mm dia, x 15
mm deep petri dish and washed with 5 ml of sterile saline to remove tis sue
debris and stray hairs from the surgical site.
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The cleaned tumor was transferred to a second sterile petri dish and was
carefully cut open and the center necrotic portions of the tumor were separated
and removed. Areas of the tumor containing fatty tissue were also removed
at this time.

The prepared tumor was transferred to a third sterile petri

dish and was weighed.

The usual weight of the clean, prepared tumor was

1.3 to 2.1 grams.
The weighed tumor was then carefully cut into small pieces of tissue
with a sterile curved-on-flat scissors.
repeated cutting with the scissors.

These pieces were finely minced by

The minced tumor mass was carefully

scrapped out of the petri dish and placed in a screw type stainless steel
tissue press (Harvard Apparatus, Millis, Mass.) fitted with a fine sieve with
holes measuring 1 mm in diameter.

The method of Busch (1953) was used to

further assure a clean cellular preparation free from connective tissue.

The

method was to use a 90-mesh stainless steel screen placed over the fine
sieve.
The tumor cells were forced through the screen and fine sieve by the
pressure of the tissue press piston.
diluted with 5 ml of sterile saline.

The tumor cells thus produced were
The sterile beaker was gently swirled to

suspend the tumor cells which were then aspirated into a 2 1/2 cc sterile,
disposable plastic syringe fitted with a 20-gauge sterile, disposable needle
(Becton, Dickinson and Company, Rutherford, New Jersey) and injected into
60 day old male, Sprague-Dawley recipient rats.
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O. 50 ml of the tumor suspension was injected subcutaneously in the
area of the external oblique muscles in the right or left lateral region of the
abdomen.

This total procedure was repeated every seven days.

The Walker 256 Carcinosarcoma tumor used in these experiments has
been propagated .in this laboratory for the past year (5 animals were used in
one series of experiments). After 58 generations an infection of the tumor
occurred necessitating starting a new series of Walker tumor propagations.
The new tumor series had 2 experiments conducted several generations apart
from each other (3 animals in each series).

There was no difference in the

results obtained with the old or the new tumors.

The viability of these

transplanted cells was established by tumor growth following injection.
The growth of the tumor was determined by measuring, with calipers,
the length, width, and height and multiplying these factors together to
express the cubic millimeters of tumor growth.
In order to be able to monitor the type of cells that were being injected,
a sample of the tumor suspension from each transplant was submitted to the
Cytology Laboratory of the Loyola University Hospital for non-gynecological
staining.
The cell suspension was applied to clean glass slides and was allowed
to set up for two minutes before being placed into 9 5 percent ethyl alcohol
for a period of 45 minutes.
After removing the fixed slides from the 95 percent ethyl alcohol, the
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following modified Papanicolaou staining procedure was carried out:

l.

80 percent ethyl alcohol - 30 seconds

2.

70 percent ethyl alcohol - 30 seconds

3.

5 0 percent ethyl alcohol - 3 0 seconds

4.

Dis tilled water - l minute

5.

Harris hematoxylin - l minute

6.

Dis tilled water - 3 0 seconds

7.

Distilled water - 30 seconds

8.

7 0 percent ethyl alcohol/ammonium hydroxide until just blued - 2 0 seconds

4.

9.

80 percent ethyl alcohol - 30 seconds

10 .

95 percent ethyl alcohol - 30 seconds

ll •

9 5 percent e thy 1 alcohol - 3 0 seconds

12 .

OG6 - 60 seconds

13 .

9 5 percent ethyl alcohol - 3 0 seconds

14 •

9 5 percent ethyl alcohol - 3 0 seconds

15 .

EA65 - 60 seconds

16.

95 percent ethyl alcohol - 30 seconds

17 .

9 5 percent ethyl alcohol - 3 0 seconds

18 •

Absolute ethyl alcohol - 30 seconds

19 •

Absolute ethyl alcohol/xylol - 30 seconds

20.

Xylol - 30 seconds

21.

Xylol - 30 seconds

22 .

Xylol - 5 minutes

Procedure for preparing ultracentrifuged, lyophilized tissue

extracts
a.

Walker 2 5 6 Carcinosarcoma tumor extracts
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Three different generations of the Walker tumor were used for these
three separate studies. A 60 - 70 day old male, Sprague-Dawley rat bearing
a 7 day old tumor that grew in at least 4 injection sites was sacrificed by
decapitation.

The site of tumor injection and growth was the same as was

described under the section entitled, "Procedure for Transplanting the Walker
256 Carcinosarcoma".
The semi-sterile removal of the solid, subcutaneous growing Walker
tumor, its washing to free from hairs etc., and its transfer to sterile petri
dishes has been explained in detail under the section entitled, "Procedure
for Transplanting the Walker 2 5 6 Carcinosarcoma".
After proper cleaning, transfer, and removal of the center necrotic
portions, the tumor was weighed. After weighing, the tumor was finely
minced using sterile curved-on-flat scissors.
The minced tumor mass was carefully scrapped out of the petri dish in
approximately l - 2 gram amounts.

This mass of tissue was placed into a

19x150 mm Corning tissue homogenizer that had a ground glass tube and
pestle.

10 ml of cold distilled water (4 C) was added to the tissue homo-

genizer and the tumor mass was carefully homogenized using a Power-StirR
stirrer operating at 1000 RPM.
This homogenization procedure was carried out until all of the tumor
tis sue was homogenized.

For every gram of tis sue homogenized 5 ml of

distilled water was used, thus, a resulting 1:5 (w/v) homogenate resulted.
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The 1:5 (w/v) homogenate was swirled for 30 minutes at 4 C using a
serological rota tor (Scientific Products, model R4140). After 3 0 minutes of
swirling, the homogenate was centrifuged at 10, 000 x g for 30 minutes at
4 C in a International High Speed Refrigerated Centrifuge, model HR-1.
The supernatant from this step was centrifuged at 600 x g for 10 minutes
at room temperature.

The resulting supernatant from this centrifugation was

centrifuged at 105, 000 x g for l hour at 4 Cina Beckman Model L ultracentrifuge.
The 105, 000 x g supernatant was carefully poured into a 600 ml
VirTis freeze-drying glass flask with a filter-seal.

This type of flask was

choosen in order to eliminate using vacuum grease that could contaminate
the lyophilized powder.

The freeze-drying flask was placed into a shell-

free zer 9nd was mechanically rotated in a refrigerated bath with a temperature
of (-) 60 C.

Once the 105, 000 x g supernatant was frozen in the flask, the

flask was attached to a VirTis auto ma tic, refrigerated freeze-dryer model
D7024, outfitted with a Cenco heavy duty vacuum pump that could deliver an
ultimate vacuum of 0.1 micron.
ser temperature of (-) 65 F.
gauge.

The system delivered a maximum low conden-

The vacuum generated was read using a McLeod

The lyophiliza ti on procedure usually took less than 24 hours using

this instrument.
b.

Normal liver extracts

Livers were removed from normal, non-tumor bearing, rats on two
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different dates from different shipments of animals.
The procedure and methods that were described above for preparing the
ultracentrifuged, lyophilized tumor extract was followed for preparing the
liver extracts.
After lyophilization of the 105, 000 x g supernatant (Tumor or Liver)
the lyophilized powder was carefully removed from the flask and placed into
a clean glass vial. The vial was weighed and placed into a freezer at (-) 7 C,
in the dark, until the appropriate experiment was conducted.
The method of injection for the tissue extracts was by the cardiac
puncture route. The lyophilized powder was reconstituted with sterile
distilled water. The animals were lightly etherized and the cardiac punctures
were easily carried out with minimal trauma to the animals.
5.

Effect of pretreatment with Walker tumor extracts on growth of

solid tumors in the rat
Normal, adult, 60 day old, male Sprague-Dawley rats were injected,
by the cardiac puncture route, with Walker tumor extract or with normal

liver extract prepared as described in the preceeding section. The dose was
200 mg of tissue extract (lyophilized powder) per Kg of body weight.
The animals were bled, via the tail vein, approximately 0. 25 - O. 30
ml of whole blood on day 0, 1, 2, 4, 6, 8, 12, 14, 16, 18, and 20. This
amount of blood was required for the enzyme and hematological studies to be
described in a later section.
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On the 20th day, after the blood was drawn from the rats, a solid
Walker tumor was transplanted via the subcutaneous route (one site per animal)
as previously described in the section entitled, "Procedure for Transplanting
the Walker 256 Carcinosarcoma".
The solid, subcutaneous tumor was allowed to grow until it became
palpable at which time its total volume (1 x w x h
a non-biased person.

= mm3) was determined by

The volume of the solid growing tumor was determined

every other day until the solid tumor broke open or until the animal died.
The rate of growth of the solid Walker tumor both in the tumor extract
and normal liver extract pretreated animals was compared to the rate of
growth of the same transplanted Walker tumor in normal, non-pretreated
Sprague-Dawley rats.
6.

Procedure for determining ALA dehydra se levels in the solid tumor

bearing and tissue extract injected rats
The method of Weissberg (1971) was used which was a modification of
the method of Bonsignore (19 65).
in that

who!~

This technic differs most notably from others

blood rather than washed erythrocytes was employed, and only

small volumes were required.
In the experiments described in this dissertation, the tail of the experimental rat was immersed in a 45 C water bath for 2 minutes prior to the
cutting off of the end 2 - 4 mm with a sharp scissors exposing the tail vein.
The first few drops of blood were wiped away using KimwipesR.

150 µL of
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whole blood was drawn, by gravity, into a calibrated, heparinized (ammonium
heparin) Natelson blood collecting pipet (Scientific Products, catalog no
B-3092-2). Any blood that collected on the outside surface of the pipet tip
was carefully wiped away before the blood was expelled into 1. 45 ml of
dis tilled water.

The pipet was flushed in the distilled water - hemolyzed

blood cell mixture to remove any of the blood sample that adhered to the
inner surface.
The hemolysate was warmed to 37 C, and to this was added 1 ml of
freshly prepared 0. 01 M ALA, pH 7. 0, also warmed to 3 7 C.

The reaction

was stopped after one hour of incubation at 37 C, in a constant temperature
water bath, by the addition of 1 ml of 10 percent trichloroacetic acid and 0. 05
ml of saturated copper sulfate solution.

The mixture was centrifuged for five

minutes in an International centrifuge, model V, at 600 x g.

Two milliliters

of the supernatant was added to 2 ml of modified Ehrlich's reagent.

The

optical density, corrected for a reagent blank, was determined in a spectraphotometer at a wavelength of 555 mµ.
A unit of ALAD activity was defined as the amount of enzyme necessary
to convert lµ mole per milliliter per minute of ALA to PBG per milliliter of
red blood cells.

The molar extinction coefficient of PBG is 3. 6 x 10 4

(Mauzerall and Granick, 1956, and Weissberg et al., 1971).
formula was employed to determine ALAD units:
OD6o - ODo x .J..Q_Q_ x 44. 61
ur+

=

Units of ALAD

The following
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where OD 60
ODo

44 61
•

=

Optical density after l hour at 37 C, and

=

Optical density at 0 time (it was measured in samples to which trichloroacetic acid and copper sulfate were
added to the incubation mixture before
the addition of blood; it was consistently found to be O) .

= Incubation

Volume (3. 65ml) x 2 ( . )
Blood Volume (0.15ml)
60 time x

l
x
2
0.036 (PBG ext. coeff)

The following studies were carried out to arrive at the above conditions
for the rat ALAD assay; it should be noted that the whole blood was hemolyzed
in 1.45 ml distilled water for all experiments.
a.

Localization of enzyme activity

Three volumes of fresh whole blood (50 µL, and 200 µL) were hemolyzed and then incubated for one hour at 37 C with 1 ml of 0. OlM ALA (pH 7. O)
as the substrate.

The reaction was stopped with a TCA-Cuso 4 mixture as

previously described and the units of ALAD were determined.
Three volumes of fresh plasma (50µL, lOOµL, and 200µL) were incubated
as described above and the reaction was stopped and the ALAD units were
determined to compare whole blood ALAD activity to that found in plasma.
b.

Effect of substrate pH

Six whole blood samples (100 µL apiece) were added to individual
test tubes and hemolyzed in distilled water.

The six hemolysates were

individually incubated with one of the solutions of 0. OlM ALA (1. 0 ml)
brought to pH 5. 0, 5. 5, 6. 0, 6. 5, 7. 0, or 7. 5.

The reactions were stopped
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by using the TCA-Cuso 4 mixture and the ALAD units were determined.
c.

Effect of temperature

Two samples of 100µ1 of whole blood were hemolyzed in distilled
water and incubated with 0. OlM ALA (pH 7. O) at 3 7 C.

The enzymatic

reaction was stopped using the TCA-CuS04 mixture and ALAD units were
determined as previously described.

Two samples of whole blood (100µ1

each) were hemolyzed and treated as described above but were incubated
at room temperature (approximately 25 C) and the results were compared.
d.

Effect of enzyme concentration

Five samples of whole blood (50µ1, 100µ1, 150µ1, 200µ1, and 250µ1)
were hemolyzed in individual test tubes.

Each of these were incubated with

l. 0 ml of 0. 01 ALA, pH 7. 0, at 37 C for one hour.

The reactions were

stopped and the optical density, corrected for a reagent blank, was determined for each test tube.
e.

Stability of the color developed with modified Ehrlich's

Reagent
In order to achieve an optical density greater than 0 .100 for the final
color developed with the modified' Ehrlich's Reagent, a 400µ1 blood sample,
from a normal rat, was hemolyzed in l. 4 5 ml of distilled water.

The hemo-

lysate was warmed to 37 C and was incubated with 1. 0 ml of 0. OlM ALA,
pH 7. 0, for 60 minutes at 37 Cina constant temperature water bath.

The

reaction was stopped as previously described and the optical density of
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the color developed with modified Ehrlich's, corrected for a reagent blank,
was determined at 2, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, and 60 minutes.
7.

Procedures for performing the hematological studies on control

and experimental rats
a.

General princi];)le of electronic counters

The Coulter counter (Coulter Electronics, Inc., Hialeah, Florida)
model FN was used for counting all red and white cells in these s tu dies.
The Coulter counter counts the individual red blood cells of a measured
volume of diluted blood as it passes through a minute orifice guarded by an
electric current flowing between platinum electrodes. The red blood cells,
which are poor electrical conductors, passing through the orifice displace
an electrically conductive 0. 9 percent saline solution (IsotonR, Coulter) in
which the cells are suspended and thus modulate the electric current.
modulations are amplified and counted.

The

They depend on the number and size

of the cells pas sing through the orifice. The counter works with an accuracy
and reproducibility of about 2 percent.

The electronic counter enumerates

red and white blood cells alike, and an error will be introduced if leukocytosis
of over 3 0, 000 cells/mm3 exists. In this case, the results have to be corrected.
b.

Procedure to count red blood cells using the Coulter counter

2 OµL of whole blood, drawn from the tail of the experimental rat, is
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diluted with IO ml of IsotonR to make a stock dilution of 1: 500.

100µ1 of this

stock 1:500 solution is diluted 1:100 with 10 ml IsotonR using an automatic

.

pipeting machine (Dade Industries, Cleveland, Ohio).

The 1:100 solution is

expelled into AccuvetteR vials (Coulter) by the automatic pipet and the red
blood cells are counted by the Coulter counter when the tip of the orifice and
the external electrode are immersed in the red cell suspension.

To correct

for the coincidence effect one records the first three digits of the count on
the digital counter and applies these to the conversion chart supplied with
the instrument (figure nine ) to obtain the correct red blood cell count.
last two digits are ignored.

The

One adds four zeros to the corrected red cell

count and reports the result as the number of red cells/mm3.
c.

Procedure to count white blood cells using the Coulter

counter
The stock 1:500 solution prepared from whole blood used for the red
blood cell counts was used for the white blood cell counts.

6 drops of Zap-

IsotonR lysing agent is added to lyse all the red cells. Within a period of
20 - 3 0 seconds the red cells are completely lysed leaving a white cell
suspension ready to be oounted.
The white cell count is performed in the same manner as the red cell
count except no correction is made for counts less than 10, 000.
of this count is reported as the number of white cells/mm3.
d.

Procedure to determine the hematocrit

The result
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The hematocrit reading gives the number of millimeters of packed red
cells/100 mm blood, indicating the volume (percent) of packed red cells/100 ml
blood.

Two heparinized capillary tubes (Sherwood Indus tries, St. Louis, Mo.)

were filled about two-thirds full with tail blood by capillary attraction.

The

dry end of the tube was sealed with molding clay (Seal-EaseR, Clay-Adams,
Inc., New York, New York) and the capillary tubes were centrifuged for three
minutes at 12, 000 RPM in an Adams autocrit centrifuge (Clay-Adams, Inc.)
provided with a special head for capillary tubes.
After centrifugation, the volume of packed cells was determined from a
scale on a hematocrit capillary tube reader (Scientific Products, catalog no.
B-4397).

The error of the microhematocrit method is less than 2 percent.
e.

Procedure to determine hemoglobin

Hemoglobin is a conjugated protein (heme + globin).

Heme contains

iron in the ferrous state and can unite in a loose combination with oxygen to
form oxyhemoglobin. About 55 percent of the red blood cell is hemoglobin.
In 1964 the Technical Subcommittee on Haemoglobinometry of the International Committee for Standardization in Haematology (published in 1965)
recommended the cyanmethemoglobin method as the method of choice for
determining hemoglobin.
20µ1 of whole blood, from the tail, was added, by using 20µ1 micro
Pipets (Scientific Products), to 5 ml of Drabkin solution (Van Kampen, 1965)
which cons is ts of potassium ferricyanide, potassium cyanide, potassium
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phosphate and Sterox SER, a polythiol compound added to increase the velocity
of the overall reaction (Hartman-Ledden Co., Phil., Pa.). After 5 minutes the
percent transmission, corrected for a reagent blank, was determined at 540
mµ in a 13 x 100 mm cuvette in a Turner colorimeter.

The grams percent of

hemoglobin is determined by referring to the printed chart as shown in figure

10.
f.

Procedure for staining and counting reticulocytes

Reticulocytes are young red blood cells, some of which appear as
macrocytic polychromatic cells (gray-blue) on smears stained with Wright
stain, and if stained with supra vital dyes, they exhibit a blue-staining
reticulum.
The method used to stain the reticulocytes was to mix one full heparinized micro-hema tocrit tube of peripheral tail vein blood with 3 drops of new
methylene blue N (Harleco) in a 5 ml pyrex beaker.

The reticulocytes were

stained after 10 minutes of incubation at room temperature. After this
staining time, the blood-dye mixture was gently mixed and thin smears were
made on 3 x l inch, 1. 2 mm thick, micro slides.

The slides were allowed to

air dry.
The reticulocyte count was performed using an oil-immersion lens and
a 20x eye piece fitted with a Whipple eyepiece micrometer grid.
magnification was 2000x.

The total

Ten fields of 100 red cells per field were counted

so that the number of reticulated red cells per thousand red cells could be
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expressed in a percentage, i.e., /100 RBC.
It should be noted that all cells that contained a blue-staining

reticulum or even just a fragment or granule of it were counted as reticulocytes.

CHAPTER III

RESULTS

129

CHAPTER III
RESULTS
A.

ONE-COLUMN ANALYSIS FOR URINARY ALA
The inappropriate use of lead has resulted in outbreaks of lead poisoning

in humans from time to time since antiquity.
At the level of cellular metabolism the best known adverse effect of lead
is its inhibition of the activity of enzymes that are dependent on the presence
of free sulfhydryl (SH) groups for their activity.

The clearest manifestation

of the inhibitory effect of lead on the activity of SH-dependent enzymes is
the disturbance it causes in the biosynthesis of heme.
Figure 1 is a presentation of the metabolic fate of ALA via the succinateglycine cycle.

Shemin and Russell (1953) postulated a succinate-glycine

cycle through which ALA can be oxidized to succinic acid and this oxidation
would thus provide a pathway for glycine oxidation.

The first step of this

cycle is the deamination of ALA to a.-ketoglutaraldehyde which then releases
the ALA-carbon derived from glycine to form succina te.

The ALA-carbon

derived from glycine provides the a-carbon atom to ureido groups of purines,
the

B-carbon atom of serine, the methyl group of methionine, and forms

formic acid (Shemin et al., 1955).
Figure 2 presents the mechanism of ALA accumulation in lead-poisoned
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humans of animals using a simple reaction equation.

It is noted that glycine

plus succinyl-CoA with the rate limiting enzyme, ALA synthetase, form ALA.
Normally 2 moles of ALA are condensed together by the enzyme ALA dehydrase
to form one mole of porphobilinogen which is the second product in the heme
biosynthetic pathway.

This pathway then continues on to make the final

product, heme. When lead is introduced into the host the enzyme ALA dehydrase is inhibited.

The end result of this inhibition is an accumulation of ALA

which spills over into the urine of the host.

This urinary ALA is determined

quantitatively in the urinary ALA test as a means to detect early exposure to
lead poisoning.
The increased use of the commercially available ALA kit (Bio-Rad,
Richmond, Ca.) for screening for lead poisoning in children has placed a
financial strain on many budgets of local health departments.

The reason for

this expense has been due to the use of the dual piggyback unit which
selectively removes PBG from the urine via the top

anion AG-l-X8 resin

column and ALA via the bottom cation AG-50 resin column (Abrahams, 1970).
It has now been proven by many sources that children do not excrete

PBG in their urine.

The youngest recorded case of PBG in the urine of a child

was that reported by Goldberg and Rimington (1962) of an ll year old girl.
The ALA test kit, to date, has been primarily used to screen children for
early detection of lead poisoning.
It therefore became of interest to us to redesign the dual piggyback ALA
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test kit into a one-column kit. This reduction in materials and cost of
manufacture would then be passed along to the consumer and theoretically
twice as many tests could be performed for the same price that one test did
previously.
The one-column test kit would be used only for screening a pediatric
population while the original dual piggyback disposable column unit would
remain the test kit for screening for lead exposure in an adult population.
Table 1 presents the effect of varying the mesh size of the cation resin
in the one-column ALA analysis. One column was filled with 100-200 mesh
and another column was filled with 50-100 mesh, both resins were AG-50Wx4, H-ionic form (Bio-Rad). For internal control purposes,

a commercial

dual piggyback column prefilled with 100-200 mesh size resin was used to
compare the optical densities obtained from the eluted ALA of each of the onesolumn experiments.

Normal urines, normal urines with added ALA, as well

as urines from industrial workers exposed to lead intoxication were used to
compare the various mesh sizes of resin to the results of the dual piggyback
column unit. It was found that 50-100 mesh resin gave a very fast flowing
column but had little retention of the ALA. The 100-200 mesh resin gave the
same results as the dual piggyback column unit. lt therefore became possible
to obtain the same results with the one-column unit as was previously
determined with the dual disposable chromatographic column (piggyback unit).
Table 2 presents data comparing a dual piggyback column data to
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that of the one-column. It also presents data on a one column that has had
its bed height reduced from 4. 0 to 2. 0 cm keeping the column diameter
constant.

The bed volume was reduced to speed up the flow without sacrificing

ALA retention of the cation resin bed. It can be noted that the 2. 0 x 0. 6 cm
bed resin column matched the obtained optical densities from the dual piggyback unit while the 4. 0 x 0. 6 cm column consistently produced a reduced
optical density.

It was concluded to use 100-200 mesh size cation resin

(AG-50W-X4, H + ionic form) and to have the bed height no higher than 2. 0 cm.
Table 3 presents the data on the recovery of ALA from aqueous solutions
using the one-column method.

The average percent recovery of ALA using the

one-column method was 94. 25 percent.
Table 4 compares the dual piggyback versus the one-column method for
determination of urinary ALA.
5 to 40 µg.

Normal urine had ALA added to it ranging from

Endogenous ALA was subtracted from the final determined ALA

and it was found throughout the whole range of µg ALA determined, the onecolumn averaged 94. 68 percent recovery while the dual piggyback column
averaged 93. 58 percent.
Table 5 once again compares the dual piggyback to the one-column unit
but also compares the effect of storage for a 2 8 day period upon ALA remaining
constant in tartaric acid preserved urine and its recovery using the onecolumn unit.

It can be observed that the difference between dual piggyback

ALA values and one-column data is insignificant and may be considered to be
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equal throughout the 28 day storage period. It was interesting to note the
greater decrease in ALA values obtained with glacial acetic acid preserved
urine than with tartaric acid preserved urine.

It can be concluded from these

data that: 1) a one-column unit is just as effective as a dual piggyback unit
for urinary ALA analysis and 2) tartaric acid preserved urine does not affect
the stability of urinary ALA or hamper its recovery from a random urine sample
so preserved.
Figure 3 illustrates the commercially available one-column unit for
determination of urinary ALA as a method for screening children for early
detection of lead poisoning.
An interesting problem arose in the methodology related to the onecolumn analysis for urinary ALA and that was washing the column free of
urinary urea.

The piggyback column unit is washed with 3 0 ml of water to

free the columns from urea and other contaminants that do not adhere to
the anion or cation columns.
Table 6 summarizes the data obtained from the experiments involving
washing the column free of urea.

The table shows the effect of increasing the

volume of water to remove the urea from the column. As an internal control,
a dual piggyback unit was used to compare the optical density of the urea
remaining on the cation column to the optical density of the urea that was
on the one-column.

Normal urine with Sµg ALA added to it was added to

the dual piggyback and one-column units and analyzed for ALA in the usual
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manner.

The ALA-pyrrole-Ehrlich' s reaction product was analyzed using a

Beckman DB-G spectrophotometer.

Maximum absorption for urea plus Ehrlich's

occurred at 415 nm and always served as the wavelength to determine urea.
The data shows an optical density at 415 nm of 0. 025 for the dual piggyback
column while an optical density of 0. 017 for the one-column at 3 0 ml of water
wash.

To be assured of complete washing, 35 ml of water has been suggested,

by this laboratory, to be the most effective volume of water to use.

It is

to be noted that the percent recovery of ALA remains constant and comparable
with the dual piggyback unit.
Table 7 presents the data obtained when one prepares the ALA standard
calibration curve according to the directions as described in Materials and
Methods.

The reproducibility of the data assures one of the realiability

of the standard curve .
Table 8 summarizes the data obtained whem one prepares an ALA standard
curve in urine and applies this urine to a one-column unit.

Endogenous ALA

is subtracted from the recovered ALA and the values so obtained are plotted
as a standard curve.
Table 9 presents the data of an ALA standard curve that is prepared in
water before being applied to the one-column unit for elution. Again the
data reproducibility assures one of the realiability of the ALA standard curve
and in particular the ALA test for early detection of lead poisoning.
Chart l is a composite of the three standard curves presented in tables
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7, 8, and 9.

It may be observed that any differences noted from one curve

to the next is insignificant.

One concludes that the ALA standard curve,

prepared as directed in Materials and Methods, is accurate, reproducible,
and easy to prepare.

It is therefore the method of preparing a standard

calibration curve that was followed throughout this dissertation.
B.

PRESERVATION OF RANDOM URINE SAMPLES FOR DETERMINATION OF

URINARY DELTA-AMINOLEVULINIC ACID (ALA)
The simple problem of collecting random urine specimens from clinics,
hospitals, or physicians' offices for urinary ALA determinations, whether done
at the site of collection of the urine specimen or involving transportation of
the specimen to a central laboratory for analysis at a later date, was complicated by the fact that maximum recovery of ALA from the disposable ion exchange
columns required a urine specimen having a pH of 6. 0 of below.
Table 10 presents the effect of urine pH on the recovery of ALA from
disposable ion-exchange columns.

Urine samples having a pH from l. 0 to

10. 0 were applied to piggyback columns (tandem units) and there was found to
be an essentially identical recovery of ALA from these columns which received
urine samples with a pH of 1. 0 to and including 6. 0.

However, when the pH

of the urine specimen was 7. 0 or above, a decrease in the recovery of ALA
was noted.

From these data it is suggested that the pH of all urine samples

applied to the disposable column units be 6. 0 or below (Abrahams, 197 O).
Chart 2 depicts the method of identification of ALA in urine and tissue
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specimens.

The ordinate is percent transmission and the abscissa is wave-

length in nm.

The curve was made in a Beckman spectrophotometer, model

DB-G, from urine and tis sue samples taken from lead intoxicated rabbits.
The color curve was formed on heating pure ALA and ALA suspect samples
with acetylacetone to form a pyrrole and subsequent reaction with DMAB in
acid solution.

The optimum wavelength to measure this color reaction is

553 nm and all ALA determinations completed in this dissertation were measured at this wavelength.
Chart 3 presents the stability of the color developed with modified
Ehrlich's reagent.

The optical densities of the ALA standards when read

15 minutes and 2 hours after the addition of modified Ehrlich 1 s reagent are
similar and thus the color formed with this reagent is stable for at least 2 houn .
Chart 4 presents a typical ALA standard calibration curve obtained by
following the procedure described in Materials and Methods entitled "Preparation of an ALA Standard Calibration Curve".

Urinary ALA concentrations

up to 10 mg/100 ml (10 mg%) can be determined from this curve without
dilution of the final red-colored reaction mixture.
Figure 4 depicts the individual steps of the test procedure for the rapid
analysis of urinary ALA.

It should be noted that prefilled disposable chrom-

atography columns are illustrated and used in piggyback fashion.
Table 11 summarizes the interpretation of urinary ALA values and the
relationship of these values to lead exposure. It should be noted that the
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urinary ALA code is divided into six classifications ranging from normal to
5+.

Similarly, the relationship to lead exposure is graded from none to

overwhelming.

The terms in the column "re la ti on ship to lead exposure"

were arbitrarily selected (Abrahams, 19 70).
It became of paramount importance to determine an alternative method

to preserve random urine specimens. It had been suggested by this laboratory
to add 10 ml of urine to a glass bottle containing 0 .10 ml glacial acetic acid.
The problem arose when nursing personnel would dump out the preservative
because of its offensive smell.

The result was that urine samples were

not adjusted to the proper pH while in transit to the lab.
serious errors in determining urinary ALA.

This resulted in

Thus a new approach to urine

preservation is described below.
Table 12 shows the effect on pH of random urine preserved with 3M
oxalic, boric, citric, and tartaric acid.
9. 0 with solid Na

2

co 3

Normal urine was adjusted to pH

and then added to a 15 ml screw-capped glass bottle

containing one of the above acids.

The four bottles were gently shaken for

5 seconds and the pH of each urine sample was determined.
placed into a cold room at 4 C and stored in the dark.
was determined at 12 and 24 hours.

The urine was

The pH of each sample

It should be noted that citric acid and

tartaric acid gave slightly cloudy and clear solutions, respectively, at 12
hours and that tartaric-acid-preserved urine remained clear at 24 hours.
The objective of having a urine sample preserved at a pH below 5. 0 was met
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with the oxalic, citric, and tartaric acid preserved specimens.

Only the

tartaric acid was chosen to preserve the random urine samples because in
no instance did a precipitate form during the storage time.
Table 13 presents the effect of 3M tartaric acid on the pH of random
urine specimens stored at 4 C, in the dark.
urine was 6.0.

The initial pH of the fresh voided

This pH was adjusted to pH 8.30 with solid Na

2

co

3

.

The

adjusted urine specimen was added to a screw-capped bottle containing either
0.10 ml or 0.20 ml of a 3M tartaric acid solution that had been previously
dried in an oven resulting in a fine even coat of tartaric acid crystals adhering
to the bottle walls.

The pH was determined after the initial mixing as well

as 14 days and 28 days after storage.

One sample of the original, normal

random urine specimen was not adjusted with Na

2

co

3

.

This sample's initial

pH of 6. 0 rose to 7. 01 by the 28th day of storage. As an internal control,
one urine specimen was preserved with glacial acetic acid (O .10 ml/10 ml
urine) as is routinely done in the commercial ALA. test kit.
It is of interest to note and compare the O. 20 ml-dried-down-tartaric-

acid-preserved urine specimen with the glacial acetic acid preserved
specimen.

The pH of the tartaric acid bottle remained stable throughout the

28 day storage period while the acetic-acid-preserved specimen's pH rose
from 4 . 5 0 to 4 . 6 0.
Table 14 demonstrates the effect of various volumes of tartaric acid on
the final pH of mid-afternoon voided urine.

12 ml of urine was adjusted with
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lM Na

co 3

2

solution to a final pH of 9. 0.

Mid-afternoon voided urine was

chosen because it presented an ideal, average test specimen to evaluate the
acidifying property of 3M tartaric acid.

The bottle to which the 0. 2 0 ml of

tartaric acid was added, lowered the pH to 4. 4 which is safe for the proper
preservation of urine specimens for the ALA analysis.

Thus, O. 20 ml of the

3M solution was judged to be the correct volume to use in the preservation
of urine for ALA determinations.
Table 15 presents the effect of storage on the recovery of ALA from
random urine specimens preserved with 3M tartaric acid.

Specimen number

l and 2 had 8. 0 µg and 11. 0 µg ALA per 0. 5 ml urine, respectively, added
before being added to the bottles containing the dried down tartaric acid.
It can be observed that specimen l had a 95 percent recovery while specimen

2 had a 98 percent recovery after a 28 day storage period at 4 C in the dark.
Table 16 compares the pH of stored random urine specimens that have
been preserved with tartaric or glacial acetic acid.
for a period of 28 days.

The storage time was

The pH of the urine specimen was determined every

7 days for both of the preserved specimens. It should be noted that no change
in pH was observed with the tartaric-acid-preserved-specimen throughout
the 28 day storage period.
Chart 5 illustrates the recovery of ALA over a 28 day storage period.
ALA was determined on day 0, 7, 14, 21, and 28 as well as was the urine pH.
It should be noted that essentially no change in urinary ALA values or urine
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pH was observed throughout the 2 8 day period.
C.

PRESERVATION OF RANDOM URINE SAMPLES FOR DETERMINATION OF

URINARY PORPHOBILINOGEN (PBG)
The interesting and complex nature of preserving urine for determining
urinary porphobilinogen (PBG) was thrust upon us when it became of interest
to determine PBG in

uri~e

samples obtained from industrial workers exposed to

inorganic lead.
Later, as further studies progressed, it became necessary to evaluate
whether or not the lead poisoned animal excreted PBG in his urine or accumulated PBG in his body tissues.
Chart 6 illustrates the absorption curve obtained in a Beckman spectrophotometer for PBG and PBG-like substances found in urine from leadintoxicated rabbits.

The maximum absorption occurs at 555 nm after PBG

is condensed with DMAB in acid solution. It should be recalled that PBG
does not undergo pyrrole formation as ALA must, but rather directly reacts
with DMAB in acid solution.
Chart 7 compares the stability of the color developed with modified
Ehrlich 1 s versus traditional Ehrlich 1 s reagent in chemical reaction with PBG.
It can be noted that the color with modified Ehrlich's develops within 15

minutes and remains stable over a period of 9 0 minutes.

The color developed

with unmodified Ehrlich's begins to loose absorbance within 10-15 minutes
and continued on very rapidly until at 90 minutes the absorbance is less
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than 50 percent of the original 0. D. measured at 5 minutes.

It also should

be noted that there is a difference in initial absorption obtained with modified
Ehrlich's reagent over plain Ehrlich's.

The initial increased color of PBG

with modified Ehrlich's plus the stability of the color reaction directed us
to use modified Ehrlich's reagent for all determinations of PBG.
Chart 8 presents a typical standard calibration curve obtained with
PBG and modified Ehrlich's reagent.

The curve was constructed using the

procedure described in Materials and Methods entitled "Preparation of a PBG
Standard Calibration Curve".

Urinary PBG concentrations up to 6 mg/100 ml

(6 mg%) can be determined from this curve.
Table 17 lists the expected results for the test for urinary PBG.
sensitivity of the test indicates its usefulness clinically.

The

The high percent

of recovery from the column indicates its reliability.
Table 18 summarizes the data for interpretation of urinary PBG values
and the relationship of these values to porphyria (acute intermittent).

The

urinary PBG code is divided into 7 classifications ranging from normal to
5 plus and similarly the relationship to porphyria is graded from none to
overwhelming.

The terms in the column "relationship to porphyria" were

arbitrarily selected.
Chart 9 illustrates the stability of the color developed with PBG and
modified Ehrlich's reagent.

The initial graph was plotted after 15 minutes

while the second curve was plotted 90 minutes after the reaction was started.
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The stability of the color assures one of a constant optical density for an
extended period of time.
Chart 10 illustrates the comparison of standard curves obtained from
PBG isolated from human urine versus synthetic PBG.

It is of great satisfaction

to obtain these identical curves because 1) it speaks highly for man's
ability to synthesize organic compounds and 2) it encourages us to continue
on isolating biological compounds.
Table 19 presents the data on the stability of PBG in random urine
preserved with tartaric acid while being stored at 4 C in the dark.

The data

represented is taken over a 7 day storage time and presents an interesting
problem concerning the day by day loss, from control values, of PBG. Within
24 hours of storage time, urinary PBG declined by 4 percent and by the 7th
day of storage the PBG loss was 28 percent.
during this period.

The urine pH remained stable

These data indicate the hazard in preserving urine samples,

intended for PBG analysis, with tartaric acid - or any other acid media.
Table 20 summarizes the effect of urine pH and storage time on stability
of PBG stored at 4 C in the dark.

Five urine samples were adjusted with

acetic acid or sodium bicarbonate to the indicated pH.

PBG was added to

each urine sample and 0. 50 ml of this urine mixture was analyzed for PBG
in the usual manner.

The PBG eluted from the columns was considered to

be equal to 100% on day 0 and served as the point of reference to determine
percent loss.

The experiment lasted for 7 days.

It should be noted that
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the percent loss of PBG from day 0 was considerably less at urine pH above
7. O than that observed with random urine specimens preserved at pH below
7. O. When the pH of the stored urine is 8. 0 the percent loss of PBG over
a 48 hour period is 1. 0 percent. When one compares this 1 percent loss of
PBG in alkaline urine with the ll percent loss of PBG in acid urine over the
same 48 hour period, one appreciates that urine that is to be analyzed for
PBG must be preserved differently than urine being stored for ALA analysis.
Chart ll graphically illustrates the loss of PBG over a 28 day storage
period when a random urine sample is preserved with tartaric acid.

The

random urine sample had PBG added to it before being added to the bottle
containing the preservative.

Urinary PBG was determined on days 0, 7, 14,

21, and 28. It should be noted that PBG loss over a 28 day storage period
approximates 50%.
Table 21 in the form of a direction sheet, summarizes the recommended
procedure for collection and storage of random urine samples for the detection
of urinary ALA or urinary PBG.

For the ALA analysis, one adds a random

urine sample to a pre-packaged 15 ml screw-capped bottle containing a
dried down film of tartaric acid.

It is to be noted that if one refrigerates

the preserved urine, the ALA remains constant up to a period of 4 months.
Frozen urine samples preserved with tartaric acid will have constant values
for ALA for a period up to a year.

It should be noted that urine samples

preserved with tartaric can only be analyzed for PBG within 24 hours of
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collection time.
To preserve a random urine sample for urinary PBG analysis one adjusts
the pH of the random urine sample as summarized in table 21.

By observing

this procedure the refrigerated urinary PBG will remain constant for a period
of 7 2 hours. If one elects to freeze the alkaline urine, the urinary PBG
will remain constant, in the dark, for a period of 8 months.
D.

THE UTILIZATION OF THE ALA STANDARD CALIBRATION CURVE TO DETER-

MINE MILLIGRAM PERCENT URINARY PBG
The great difficulties involved in isolating PBG prohibited its supply
with each ALA-PBG analysis kit.

It therefore became of prime interest to

determine a method that would utilize the existing, readily available ALA
standard to determine urinary PBG.
Chart 12 illustrates a typical standard calibration curve of both ALA
and PBG. It is seen that the ALA curve is approximately linear to 4. 0 mg
percent while the PBG curve remains linear throughout the standard curve.
To convert mg percent ALA to mg percent PBG one has to draw a horizontal line from the optical density reading obtained with the PBG sample to
the ALA standard calibration curve which was previously plotted and extend
a line at right angles to the abscissa of the graph.

This value of mg percent

should then be multiplied by the conversion factor of 3. 53 in order to obtain
the true value of mg percent PBG in the 0. 5 ml aliquot of urine applied to
the column.
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It should be noted that the conversion factor of 3. 53 (mg% PBG

ALA x 3. 53) was obtained with authentic samples of PBG.

= mg%

It is therefore

recommended that ALA hydrochloride be used to plot an ALA standard calibration curve which in conjunction with the conversion factor of 3. 53 can then
be employed to calculate the mg percent concentration of PBG in the 0. 5 ml
aliquot of urine applied to the column.
Table 22 presents data for converting mg percent ALA to mg percent
PBG with known optical densities. ALA and PBG were determined using the
same batch of fresh Ehrlich's reagent.

The two curves were constructed

using the procedures outlines in Materials and Methods under the appropriate
titles of preparing ALA and PBG standard calibration curves.
E.

DETERMINATION OF URINARY UREA
The determination of urinary urea became of interest because it was

a biological compound being passed through the piggyback column unit
with the 30 ml of water used to wash the 0.5 ml of a random urine sample.
The urea is not retained by the column unit but substances that would interfere
with its determination, such as porphobilinogen, are.
urea was

Thus relatively pure

obtained and determined along with the determination for urinary

ALA and PBG.
Table 23 presents, in flow sheet form, the determination of urinary
urea.

Random urine is applied to a piggyback unit and washed with 30 ml

water as previously described in Materials and Methods under the section

146
entitled "procedure for the determination of urinary

Af.A

by means of the two

column method". The entire 30 ml water eluate is collected and to it is
added 4. 0 ml of fresh, modified Ehrlich's reagent. A lemon-yellow color
develops maximally within 15 minutes after the Ehrlich 1 s is added. The
optical density is determined at 415 nm in a standard laboratory colorimeter
against a reagent blank. The mg of urea is determined by referring to a
standard calibration curve. The method is simple and rapid and presents no
complicated obstacle to its utilization.
Chart 13 illustrates a typical urea standard calibration curve obtained
by adding known amounts of urea to 30 ml of water, adding fresh Ehrlich 1 s
reagent and determining the optical density at 415 nm after 15 minutes full
color development. The curve is linear from 1 mg urea/30 ml water. We have
determined up to 40 mg urea and have noted the curve remains linear to
this point.
Chart 14 shows the stability of the urea-Ehrlich's color reaction.
The reaction was carried out over a 45 minute period with no significant loss
of optical density at 415 nm. It may be concluded that the color developed
is stable and will remain so for an extended period of time.
Chart 15 and 16 illustrate the 95 percent confidence limits of human
PBG, ALA and urea, pH respectively. 100 normal medical students donated
mid-afternoon urine specimens to be analyzed for urinary ALA, PBG, Urea,
and pH. The upper limit of normal for urinary ALA is 0. 54 mg percent, for
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urinary PBG is 0. 205 mg percent, for urinary pH is 6. 88, and for urinary urea
is 15.35 mg percent.
F.

POST-MORTEM DETERMINATION OF TISSUE LEVELS OF DELTA-AMINO-

LEVULINIC ACID (ALA) IN LEAD-POISONED RABBITS
Previous results from this laboratory (Davis, 1970) have indicated a
positive correlation, in children, between lead poisoning and an increase in
urinary ALA excretion. It became of interest to attempt to answer the question
of whether an accumulation of ALA might also occur in various tissues of
the animal poisoned with lead.
The unique idea of determining tissue levels of ALA using dual disposable column chromatography units became of great interest because it afforded
an opportunity to easily quantitate ALA in a manner never achieved before.
To those investigators charged with the responsibility of determining the
cause of death of an individual, the advantage of having a means to quantitate
a product of a specific poisoning process presented itself favorably for
medical-legal purposes.
The utilization of tissue specimens was dictated by the fact that the
post-mortem examination of bodies usually begin some four to six hours
after the death of the deceased.

The bladder urine, by this time, contains

bacteria, products of enzymatic ca tabolism, and general waste products
and debris associated with death. All of these have the potential to interfere
with the ALA analysis.
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Chart 17 presents the effect of a single injection of lead acetate on
the excretion of ALA over a period of 58 days.

The random urine samples

were collected from the clean excreta service trays and adjusted with glacial
acetic acid to a pH of 5. 0 (Abrahams, 19 70).

The upper limit of normal

for urinary ALA values, in control rabbits, was found to be 0. 05 mg percent
as indicated by the dashed line. An essentially linear increase in urinary
ALA was observed following the single subcutaneous injection of 200 mg/kg
lead acetate.

The urinary ALA reached a level of approximately 3. 0 mg

percent at 58 days after injection.

These data indicated that the adult rabbit

exposed to a single injection of lead acetate would constitute a useful model
for investigating any changes in tissue levels of ALA that might occur during
the course of lead poisoning.
Table 24 presents, in flow sheet form, the method for determination
of tissue levels of ALA.

The time for analysis of one gram of tissue from the

time the tissue specimen is brought to the lab to the time the supernatant
pH is adjusted to pH 5. 0 and frozen is approximately one hour.

The freezing

step takes about one hour to an indefinite period depending upon the laboratory
concerned and when they wish to analyze for tissue ALA.

It takes another

hour to complete the analysis after the supernatant is defrosted.

It therefore

becomes very easy and rapid to determine levels of ALA in tissues of animals
poisoned with lead.
Table 2 5 presents, in flow sheet form, the method for the determination
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of a tissue blank in the ALA analysis.

The purpose of this tissue blank was

to detect any possible substances present in the tissues that might interfere
with the analysis of ALA by reacting with Ehrlich's reagent alone.

The optical

density of the tissue blank was so small that it was concluded that no interfering substances were coming through the column to hinder or hamper the
ALA analysis.
Table 2 6 shows the recovery of various quantities of added ALA to liver
homogenates.

One gram of tissue was used in each of these experiments

to which ALA was added ranging from 2. 5 to 2 0. 00 µg.

The total experiment

for tissue extraction was carried out and an average of 92 percent of ALA
was recovered indicating an accurate method for recovery was found.
Chart 18 graphically presents the mean control levels of ALA found in
21 tissues of non-treated adult rabbits.

Control levels of tissue ALA ranged

between 0. 02 microgram per gm for adipose tis sue to 0. 53 microgram per
gm for the tail of the epididymis.
Chart 19 illustrates the effect of a single subcutaneous injection of
200 mg per kg of lead acetate on the tissue levels of ALA found in the bone
marrow, kidney, spleen, and liver of the adult rabbit. A marked progressive
increase in the ALA content of both bone marrow and kidney was observed
throughout the time period studied.

In contrast, very little ALA accumulation

was noted in samples of both the spleen and liver.
Because of the extremely large amounts of ALA found in samples of the
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bone marrow and kidney 58 days after injection of lead acetate, an attempt
was made to investigate whether other tissues might not exhibit an increase
in ALA content at a similar time following exposure to lead acetate.
Chart 20 indicates the levels of ALA found in 21 tissues of the adult
rabbit 58 days after the single subcutaneous injection of 200 mg per kg of
lead acetate.

The bone marrow was found to have the highest content of

ALA of all the tissues studied averaging 24. 6 micrograms per gram wet weight
of tissue.

The level of ALA found in the kidney was 10. 9 micrograms per

gram while corresponding values for the spleen, lung, and tail of the epididymis were 1.50, 1.25, and 1.05, respectively.

All of the remaining tissues

studied were found to have an ALA content below O. 7 microgram per gm wet
weight.
Chart 21 presents a comparison of the degree of lead induced ALA
accumulation in tissues 58 days after lead acetate injection.

The height of

each bar represents the ratio of tis sue ALA found in lead-poisoned rabbits over
the control levels of ALA found in non-treated rabbits.

The greatest accumula-

tion of ALA occurred in the bone marrow which approximated a 100 fold increase
in ALA over control values.

The kidney and lung displayed an accumulation

of ALA amounting to a 27 and a 20-fold increase, respectively. ALA accumulation in all the other tissues studied was found to range from an 8-fold increase
to essentially no change.
Tables 27 and 2 8 indicate the effect of a subcutaneous injection of
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lead acetate on the accumulation of ALA or PBG in the bone marrow and kidney
of the adult male rabbit.

It is observed that ALA increases almost 100 fold

over control in the bone marrow while the kidney increases 27 fold over
control, both at 58 days after the single injection of lead acetate.

The bone

marrow PBG increases to 40 fold over control while the kidney increases 85
fold 58 days after the single injection of lead acetate.
Chart 22 demonstrates the effect of increasing the dose of lead acetate
for the single subcutaneous injection. Animals were injected once either with
200, 400, or 800 mg lead acetate/kg body weight and were sacrificed 20
days latter.

The bone marrow, kidney, spleen, and liver were analyzed

for ALA accumulation.

It was observed that the bone marrow consistently

had a higher quantity of ALA accumulating per dose of lead acetate administered followed very closely by the kidney.

The spleen and liver essentially

showed no change in ALA accumulation over the entire dose range of lead
acetate administered. It can be concluded from this chart that 1) ALA
accumulation is dose dependent, 2) the bone marrow accumulates the most
ALA per gram of tis sue, and 3) the kidney serves as an excellent second choice
for a tissue to study that accumulates ALA.
G.

DETERMINATION OF AMINOACETONE IN URINE AND TISSUES OF THE

LEAD-POISONED RABBIT
Aminoacetone (AA) is an aminoketone of physiological significance
produced enzymically by the condensation of glycine and acetyl coenzyme A
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or by the oxidation of threonine.
Since both ALA and AA occur in urine, are produced in mitochondria,
form pyrroles by condensation with acetylacetone, anr:! form a color complex
with Ehrlich's reagent measured at 553 nm (ALA) and 556 nm (AA), respectively,
the measurement of these substances in both urine and tissues requires their
separation. The objective of this separation was to determine whether or
not aminoacetone was being synthesized and, if so, in what quantity in the
lead-poisoned animal.
The question that had to be answered by this study was how much
color does the AA-pyrrole plus Ehrlich's reagent add to the overall optical
density in the ALA analysis.
Table 29 presents, in flow sheet form, the method to fractionate AA
from ALA contained in tissues from a lead poisoned animal.

The procedure

is carefully described in Materials and Methods under the section entitled
"procedure for the isolation and determination of tissue aminoacetone in
the lead-poisoned rabbit". The tissue submitted to the laboratory for
analysis of ALA and AA is processed and homogenized in the same manner as
previously described for the tissue ALA analysis.

The fractionation procedure

begins after the ALA and AA pyrroles have been formed.

The pyrroles are

added to the anion AG-1-XS column and AA pyrrole is eluted from the column
as indicated by the flow sheet. The remaining ALA pyrrole is eluted from the
anion column by first washing the column with acetic acid and then eluting
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the ALA pyrrole.

Thus by this frac tiona ti on procedure, one can readily

separate and identify the two pyrroles. Once the AA and ALA pyrroles have
been separated, they then can be individually reacted with modified Ehrlich's
reagent.

The color complex optical density formed from this reaction is

determined in a laboratory colorimeter and the quantitation of ALA is completed
by referring to an ALA standard calibration curve. Aminoacetone is determined
mathematically as described in Materials and Methods.
Table 30 indicates the data for the total percent of final color due to
aminoacetone in a urine specimen from a lead-poisoned rabbit.

The table

compares the two methods of Marver (19 6 6) and Davis (19 68) for determining
ALA.

Marver uses Ehrlich's reagent that contains l gm DMAB dissolved in

3 O ml glacial acetic acid to which is added 8. 0 ml of 7 0 percent perchloric
acid. After mixing, the solution is diluted to 50 ml with acetic acid.

Davis

uses Ehrlich's reagent that contains 2 gm DMAB dissolved in 84 ml glacial
acetic acid to which is added 16 ml of 70 percent perchloric acid.

The only

difference, in essence, between the two formulas is the method of mixing
the components together.

The proportions are almost identical".

It can be

seen that the total percent of color due to aminoacetone averages 2. 0
percent between the two methods.

It can be concluded from this data that 98

percent of the observed optical density obtained in the urinary ALA analysis
is due to ALA and that the amount of aminoacetone present is there in only
insignificant amounts.
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Table 31 presents the percent of final color due to aminoacetone in
tissue samples from lead-poisoned rabbits. The percent of color developed
from the AA for the kidney, bone marrow, spleen, and liver averaged 0. 39
percent.

The kidney and bone marrow each averaged 0. 01 percent.

These

data indicate that the aminoacetone pyrrole does not add any increased color
to the two tissues we are suggesting for post-mortem analysis for lead
poisoning -- namely the bone marrow and the kidney.

These data also

suggest that ALA was determined accurately in these tissue samples and
that a minoacetone can be ruled out as an interfering biological compound.
H.

DELTA-AMINOLEVULINIC ACID DEHYDRASE (ALAD) LEVELS IN THE

SPRAGUE-DAWLEY RAT BEARING THE WALKER 256 CARCINOSARCOMA
The purpose of this investigation was to study the enzyme deltaaminolevulinic acid dehydrase (ALAD) in rats bearing the Walker tumor. We
investigated this enzyme because its inhibition in the lead-poisoned animal
results in severe anemia. The anemia of cancer was observed in the rats
bearing the Walker tumor and the question arose as to whether or not ALAD
was inhibited, in some manner as in the lead-poisoned animal, by the action
of the growing, malignant tumor.
Chart 23 illustrates the inhibition of ALAD in the lead-poisoned rat.
One observes two important items on this chart: one -- the immediate fall
in ALAD units within one day of the single intraperitoneal injection of lead
acetate, with the slow return to 50 percent of original activity by day 10,
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and two -- the immediate rise in urinary ALA levels to a maximum 1. 86 mg
percent within 24 hours after the initial injection. ALA levels slowly fall
back to control levels by day 18. The inhibition of this enzyme in leadpoisoned humans and animals accounts for the spill-over of its substrate,
ALA, in to the urine •
The concept of studying an hematopoietic enzyme such as ALA dehydrase
appeared to be unique and warranted further investigation.

In preliminary

studies evaluating the anemia observed in these malignant tumor bearing
rats, a survey of peripheral blood smears revealed a marked reticulocytosis.
It therefore became of interest to us to answer the following questions:
1) can ALAD be detected in rats bearing the Walker tumor,

2) is there any

relationship to the ALAD enzyme activity and the appearance of reticulocytes,
3) what occurs hematologically in these tumor bearing animals over the span
of time the tumor is growing, and 4) is this enzyme inhibited when extracts
from the tumor are injected into control animals.
Table 3 2 presents, in flow sheet form, the method for transplanting
the Walker 2 56 Carcinosarcoma. A 60 day old Sprague-Dawley rat bearing
a 7 day old subcutaneous growing tumor was sacrificed and the tumor was
removed. It was washed and trimmed to remove debris and fatty tissue,
while the center necrotic area was carefully cut away and discarded.

The

tumor was finely minced and this minced preparation was added to a tissue
press fitted with a fine sieve covered with a 90-mesh stainless steel screen.
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Under pressure, the tumor cells were forced through the sieve and screen
and were suspended in saline and mixed well.

0. 50 ml of this cell suspension

was injected subcutaneously in the lower abdomen of an untreated, 60 day
old Sprague-Dawley rat.

This procedure was carried out every seven days

to propagate the tumor.

Samples of the suspension were sent to pathology

for staining and for careful microscopic examination.
Table 33 presents, in flow sheet form, the method for determination of
IALAD activity (modification of the method of Weissberg, 1971). Whole blood,
drawn from the tail, is added to distilled water and the resulting hemolysate
has added to it fresh 0. 01 molar ALA. After incubation for 60 minutes, the
enzymatic reaction is stopped, centrifuged, and the supernatant is added to
an equal volume of modified Ehrlich's reagent.

The color is allowed to

develop for 2 minutes after which the absorbance is measured in a standard
laboratory coloimeter at 555 mµ against a reagent blank.

Therefore, within

a period of 80 minutes one could determine ALAD activity in a peripheral
blood specimen.
Table 34 illustrates the formula for determining ALAD activity in peripheral blood.

The formula is optical density at 60 minutes times 100 divided by the

lhematocrit times 44. 61.
!in the table.

The value 44. 61 is derived from the formula as shown

The incubation volume of 3. 65 ml represents the total volume of

the incubation (1. 45 ml distilled water, 0 .150 ml whole blood, 1 ml of ALA,
1 ml 10% TCA, and 0. 05 ml copper sulfate).

The answer is multiplied by 2
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because one ml aliquot of this incubation mixture is mixed with an equal
part of Ehrlich's reagent.

The final answer is multiplied by 2 to represent

the fact that the enzyme activity is defined "as amount of enzyme necessary
to convert lµ mole of ALA to PBG" and that 2µ moles of ALA are utilized to

synthesize one µmole of PBG (Oski, 1973).
Blood was drawn from the tail vein on alternate days, up to and including
day 20 after transplantation of the tumor, and was assayed for ALAD using
whole blood by a modification of the procedure of Weissberg (1971)
Table 35 summarizes the data on the determination of ALAD activity
in whole blood and plasma. It was determined that the activity of the
enzyme was always found in the whole blood rather than the plasma, in fact
the plasma had no enzymatic activity.
Table 3 6 represents the data on the stability of the color reaction
developed in the analysis of ALAD in peripheral blood of the 60 day old rat.
It can be observed that the optical density, measured at 555 nm, begins to

decrease within the first 5 minutes of the reaction by 1. 55 percent, reaching
10 percent by 3 5 minutes. At 60 minutes of reaction time the optical density
decreased by 17. 83 percent indicating a steady decline and loss of optical
density. It was therefore concluded to determine the optical density exactly
at 2. 0 minutes after the color reaction began.
Chart 24 illustrates the effect of the growing Walker tumor on the
reticulocyte count and ALAD activity of the host.

The left ordinate represents
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cubic millimeters tumor volume while the two right ordinates represent ALAD
units and percent reticulocytes respectively, while the abscissa represents
days after transplantation of the tumor. The growing tumor becomes slightly
palpable at 4 days and increases up to a maximum of lll, 000 cubic millimeters
at 16 days, after which the size of the tumor could not be measured accurately.
The upper limit of normal for ALAD uni ts in control rats was found to be 4. 0.
It is to be noted that the increase in ALAD activity begins immediately after

transplantation, and on day 4, the first day of palpable tumor growth, the units
were 16 and on day 16, the day of maximum growth of the solid tumor, the
units were 35 to continue onto a maximum of 47 units on day 20.
The reticulocyte count followed the same pattern as the enzyme
activity.

The upper limit of normal for percent reticulocytes in control rats

was found to be 4. 2. The percentage rose to 13 percent on day 4, to 43
percent on day 16 continuing onto a maximum of 62 percent on day 20.
It is of interest to note two things about this graph:

1) the similarity

and parallelism of the ALAD units curve with the percent reticulocyte curve,
and 2) the immediate and rapid elevation of these two parameters before any
growth of the tumor could be detected as well as their persistence throughout
the time of the growth of the tumor.
Chart 25 demonstrates the percent increase in reticulocyte count and
ALAD activity over control. ALAD activity increased ll7 percent over control
within 24 hours after transplantation and rose to 619 percent by day 4, to
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1440 percent by day 16, rising to two thousand percent over control on day
20.

The reticulocyte count increased 70 percent within 24 hours and rose

to 387 percent by day 4, to 1822 percent by day 16 rising to 2300 percent over
control on day 20 after transplantation.
Chart 26 is a composite chart presenting the e.ffect of a growing
subcutaneous tumor on the host.

The abscissa in all 4 graphs is days after

transplantation while the right and left ordinate change per individual chart.
The top chart summarizes the growth of the tumor as compared to total body
weight.

The next chart summarizes the units of ALAD compared to percent

reticulocytes - again it is important to note the ever increasing and immediate
response both of these parameters have as a result of the growing transplanted
tumor.

The third graph presents data on the red and white blood cell counts

compared to each other.

Both of these counts were done electronically and

it should be noted that the red cell count consistently decreased per unit of
time starting with an initial value of 5. 8 million per cubic millimeter and
ending up with 2 million per cubic millimeter on day 20.

The bottom graph

shows the data obtained when one compares hemoglobin grams percent to
hematocrit percent.

Both curves decrease per unit of time in parallel with

the decreasing red cell count.

Therefore, these data suggest that there is

no accumulation of red cells but rather a severe distruction of them.
Figure 5 is a composite of one of a series of photomicrographs depicting
the reticulocyte response to the growing, subcutaneous Walker tumor.
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The freshly drawn peripheral blood was stained with the vital dye New Methylene Blue - N.

The photograph on the left is a control blood obtained from

a rat before transplantation of the tumor.
in this field.

One reticulocyte can be identified

The photograph on the right shows the response to tumor

growth 16 days after transplantation. In this particular field 40 percent of
the cells are reticulocytes.

The photograph below the above two depicts

the reticulocyte response obtained on day 20 after transplantation.

The pre-

ponderance of reticulocytes -- approximately 65 percent in this field -demonstrates the reticulocytosis that is occuring in response to malignant
tumor growth.
Because of these results indicating a positive correlation in the tumor
host between ALAD activity and reticulocytosis we then turned our attention
to cell-free water extracts of the Walker tumor and compared these data
with that obtained from a normal liver cell-free water extract.
Table 3 7 presents, in flow sheet form, the method of preparing a
lyophilized cell-free water extract of the Walker tumor. A number of 7 day old
tumors from several 60 day old rats were combined together, homogenized,
gently swirled in the cold and centrifuged. The supernatant from this
centrifugation was centrifuged twice, the last being at 105, 000 x g.

The

resulting supernatant was lyophilized for 24 hours producing a lyophilized
cell-free water extract of the Walker tumor.
Chart 27 presents the effect of a single intra-cardiac injection of a
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lyophilized cell-free water soluble tumor extract. It should be noted that
the reticulocyte count reaches the highest percentage at day 2 while ALAD
activity reaches its highest level at day 8.

Both of these parameters return

to normal values by day 20.
Chart 28 is a composite chart showing the effect of a single intracardiac injection of the lyophilized cell-free water soluble tumor extract.
The ordinates and abscissa is the same as previously described.

The body

weight, red and white cell count as well as the hemoglobin and hematocrit
remain relatively stable and constant with a slight depression in the red cell
count.

The increase in ALAD units and reticulocyte percent remain the

only significant parameters affected by the tumor extract.
Figure 6 is a composite summarizing the tumor extract experiments.
The photograph on the left is a control blood smear stained with New Methylene Blue-N.

The photograph on the right is taken from a blood smear two

days after injection of the tumor extract. The reticulocyte count reaches its
highest percentage on this day.

The photograph below the above photographs

depicts the reticulocyte response obtained on day 20 after injection of the
tumor supernatant. It should be observed that the reticulocyte count has
returned to control values -- in marked contrast to the reticulocytosis obtained
when there is a growing malignant tumor.
Table 3 8 presents, in flow sheet form, the method for preparing a
lyophilized cell-free water extract of normal rat liver.

This flow sheet is
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identical to the method used to prepare a water extract of the Walker tumor.
The end product is a lyophilized cell-free liver extract that can be utilized in
the experiments comparing extracts of the tumor to extracts of normal liver.
Chart 29 presents a composite graph showing the data obtained with a
single intra-cardiac injection of a lyophilized cell-free water soluble extract
of normal liver. The ordinates and abscissa are the same as previously
described. It is to be noted that there is no change in any of the parameters
measured during the 2 0 day period.
Figure 7 is a composite summarizing the liver extract experiments.

The

photograph on the -left is a control blood smears tained with New Methylene
Blue-N.

The photograph on the right is taken from a blood smear 2 days after

injection of the liver extract and essentially shows no change over
controls.

The photograph below the above photographs depicts the results

20 days after injection and once again demonstrates the lack of reticulocyte
response characteristic of the liver extract experiments.
Chart 30 presents a comparison of the effect of a single intra-cardiac
injection of the lyophilized cell-free protein from the Walker tumor extract
and from normal liver extract.

The upper 2 curves represents the data

obtained from the tumor extract injection while the lower 2 curves represent
the data obtained from the normal liver extract injection.

Essentially all

the change is noted with the animals given the tumor extract while no change
is observed with the liver extract injected animals.
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It is therefore concluded that the growing Walker tumor produces a

stimulating substance that initiates a great increase in ALAD activity with a
concomitant increase in reticulocytosis.

A water soluble lyophilized cell-

free extract of the tumor will cause similar but smaller increases in ALAD
activity and reticulocytosis for a short period of time while normal liver
extracts will not.
It should once again be pointed out that the immediate and unique

elevation of ALAD activity in parallel with reticulocyte formation before
tumor growth becomes palpable suggests an early tumor-host relationship
that may be unique in the early detection of neoplastic disease.
I.

STUDY OF THE EFFECT OF PRE-TREATMENT WITH EXTRACTS OF THE

WALKER TUMOR ON FACILITATION OF GROWTH OF THE WALKER 2 56 CARCINOSARCOMA IN SPRAGUE-DAWLEY RATS
The fascinating subject of manipulating conditions of tumor growth
have been and will continue to be of prime research interest to investigators.
The purpose of this preliminary study was to determine if pretreatment
of rats with 100 mg/kg body weight of the lyophilized cell-free water soluble
tumor extract would in some way facilitate or inhibit growth of the subcutaneous growing transplated Walker tumor.
The animals were pretreated with one intra-cardiac injection of the
tumor extract.

For control and comparison purposes an injection of a

lyophilized cell-free water soluble extract of normal rat liver was employed.
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The animals were bled, via the tail vein, for 20 days to determine ALAD
activity, reticulocyte counts, and basic hematology studies as previously
described.
On the 20th day each pretreated animal, whether tumor or liver extract,
was inoculated with a O. 5 ml subcutaneous injection of a Walker tumor cell
suspension from a 7 day old growing tumor.

Control, untreated litter mates

of the pretreated group were injected with a 0. 5 ml of the same Walker tumor
cell suspension, as previously described.
Each animal was housed in a separate cage during the pretreatment
period as well as during the growth or the Walker tumor.
The volume of the growing subcutaneous tumor was measured, as
previously described, by an unbiased observer on alternate days until the
tumor could not be accurately measured or until the animal died.
Chart 31 illustrates the percent increase in tumor volume in animals
pretreated with water soluble extracts of the Walker tumor or normal liver.
It is to be noted that the water extracts of the Walker tumor facilitated the

growth of the subcutaneous growing tumor.

On the sixth day after transplant-

ation, the tumor extract pretreated animals had a 200 percent increase in
tumor volume over the control tumor bearing rats.

This percentage increased

to 295 percent by day 12.
In contrast, the liver extract pretreated animals showed very minimal
percent increase in tumor volume over control untreated rats.

The maximum
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percent of increase in tumor volume was observed on day 10 with a 73 percent
increase but this peak in tumor volume was lost by day 12 when the control
tumor volume approached the liver extract pretreated animals.

CHAPTER IV

DISCUSSION
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CHAPTER IV
DISCUSSION
A.

ONE COLUMN ALA ANALYSIS
One of the cardinal manifestations of lead intoxication in man is the

disturbance in the synthesis of heme. Indeed, this biosynthetic pathway is
so sensitive to the toxic effects of lead, that one of its metabolites - deltaaminolevulinic acid - can be consistently demonstrated in great excess in the
urine even in the absence of clinical symptoms.
Porphyrinuria was first demonstrated in human cases of plumbism by
Garrod in 189 2 so its appearance is nothing new to the scientific community.
In a series of papers published chiefly during the past twenty years,
Shemin and his collaborators have shown that prophyrins are formed from
glycine and succinyl-CoA & that ALA and PBG are early intermediates in this
biosynthesis.
When methods for quantitative determination of ALA in urine became
available (Granick and Vanden Schrieck, 19 55; Shuster, 19 5 6; and Mauzerall
and Granick, 1956) a study of the excretory pattern of these metabolites in
various diseases with disturbed porphyrin metabolism was started.
Using the method of Mauzerall and Granick (1956) the concentration of
an ALA-like substance was found to be markedly raised in urine from men
exposed to lead (Haeger, 1957). Later, it could be stated that this substance
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consisted of ALA (Haeger, 1958).
The findings of Haeger-Arons en (19 60) prompted Davis et al (19 67, 19 68)
to modify the method of Mauzerall and Granick (1956) to utilize disposable ionexchange chromatography columns for the determination of urinary ALA levels
in the lead poisoned pediatric population.
Abrahams (1970) completed a Ph.D. dissertation on "Urinary DeltaAminolevulinic Acid (ALA) Levels in Childhood Lead Poisoning", under the direction of Davis, using the disposable dual piggyback ion-exchange columns.
The Ph.D. dissertation was based on utilization of urinary ALA as a possible
indicator for early lead poisoning in children, which until that time had never
been carried out.

The studies had three objectives - first, the modification

and simplification of the method described by Mauzerall and Granick; second,
making the urinary ALA test readily available for use throughout the country;
and third, the initial correlation of the urinary ALA test with the clinical incidence of childhood lead intoxication.

Recently Davis (197 0) published a paper

on the "Reliability of Urinary ALA as a Mass Screening Technic for Childhood
Exposure to Lead" •
This dissertation (Abrahams, 197 O) plus the many excellent papers on
the validity of urinary ALA for determining the degree of lead absorption has
allowed us to move one step further in the pursuit of a means to detect early
exposure to childhood lead poisoning.
We agree with Vincent (1970) and others that there are no known condi-
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tions in children which might cause an accumulation of PBG in the urine.

For

this reason it is not necessary to use a top anionic column for the removal of
PBG as an interfering substance in this age group.
It therefore became of interest to modify the dual piggyback unit to a

simplified, disposable ion-exchange one-column determination of urinary
ALA for children only.

The objective was to obtain identical results with those

obtained by the originally-modified dual piggyback column described by Davis
(1967, 1968).
It should be emphasized that the use of urinary ALA as a mass screen-

ing procedure for the detection of childhood exposure to lead was never intended to replace the determination of blood lead levels.
always recommended that

11

Davis (1970) has

all children found to have elevated urinary ALA

excretion should be followed up with a careful history and physical examination
together with a blood lead determination

11
•

The data of the present experiments indicate that the mesh size of the
cation resin is critical for obtaining exactly similar results with the onecolumn ALA analysis as was obtained with the dual piggyback unit.

It was

found that a coarse mesh would increase the flow rate greatly but the retention
of ALA on the column was lost.

Therefore, the 100-200 mesh of the AG-50W-

X4 analytical grade cation exchange resin in the hydrogen ionic form was
determined to be best suited for our requirements.
An interesting part of the study to obtain optimum conditions for
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retention of ALA on the one-column unit as well as ease of eluting the sample
from the column was the discovery that

~s

one reduced the resin bed height

by 50 percent while keeping the resin bed width the same, one could match,
identically, the results obtained with the dual piggyback unit. Apparently,
with the increased bed height the urinary ALA was being tenaciously retained
and not being completely eluted by the 7. 0 ml of IM sodium acetate.

The

reduced height gave the surface area required for proper retention but also gave
the proper physical conditions resulting in ease of elution of the ALA with the
sodium acetate.
The experiments involving the percent recovery of ALA were most rewarding because, on the average, they resulted in a 94 percent overall recovery
versus a 93 percent recovery from the dual piggyback unit.
The storage of urine that was preserved with tartaric acid presented no
obstacle to the recovery of ALA.

In fact, the data that is presented in Table

17 indicates that tartaric acid preserved random urine safeguarded the total
ALA content better the longer the urine was stored as compared to acetic acid
preserved urine.
The data obtained from the experiments determining the elution of
urinary urea demonstrated that the one-column unit retained less urea than
the dual piggyback unit. It is fortunate that in both cases the absorbance at
415 nm does not interfer, as small as it maybe, with the determination of the
ALA chromophore at 553 nm.
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The present data indicate that the one-column unit is just as effective
as the dual piggyback unit for urinary ALA analysis.

The data also indicates

that the tartaric acid preserved urine does not affect the excellent recovery of
ALA even upon prolonged storage at 4 C, in the dark.

MEDICAL-LEGAL AND CLINICAL IMPLICATIONS OF THE ONE-COLUMN ALA
ANALYSIS
The primary aim of treatment for plumbism in children is the prevention
of injury to the nervous system. In practice today, therapeutic intervention at
the subclinical stage of lead poisoning and close follow-up observation during
the toddler and preschool years can do much to prevent the severe forms of
residual nervous-system injury. At least 25 percent of young children with
acute lead encephalopathy or recurrent but less severe clinical bouts of
plumbism sustain permanent injury to the nervous system (Byers and Lord, 1943;
Perlstein and Attala, 1966; and Smith, 19 64).

Treatment instituted before the

onset of symptoms may be far more effective.

Under this concept, any child

with

> 80µg

of lead per 100 ml of whole blood (2-4 mg% urinary ALA) should

be handled as a pediatric emergency, hospitalized and treated with calcium
disodium edetate, even if he has no symptoms (Silver, 1971). The rationale
for this approach is as follows: children with

> 80µg

of lead per 100 ml of

whole blood (2-4 mg% urinary ALA) generally show marked derangements in
heme synthesis due to lead (National Research Council - National Academy of
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Sciences, 1972) that can be demonstrated by appropriate tests (urinary ALA);
at levels ) 80µg, neither blood lead concentration nor any other clinical
laboratory test is predictive of the onset or severity of symptoms, which may
appear without warning.
Under this concept, children having 40 to 80µg of lead per 100 ml of
whole blood (O. 6-2. 0 mg% urinary ALA) may also require at least brief chelation therapy to reduce soft-tissue lead levels, if they show derangements in
heme synthesis.

This precaution is considered prudent, although there is

as yet no clear evidence whether this lower level of increased lead absorption
is associated with subtle neurologic impairment.

The available evidence in

this area is scanty, but provocative (Lin-Fu, 197 2).
The utilization of the one-column ALA test for screening the pediatric
population for early exposure to lead was summarized by Cramer and Selander
(1966) when they wrote "By far the closest correlation between clinical findings
and a biochemical test for lead poisoning was between the amount of ALA in
the urine and the symptom score".

The one-column urinary ALA test has the

unique value of indicating individual overexposure to lead before symptoms
become obvious.
As stated in the introduction, the ALA test indicates high body burdens
of lead from previous exposures to lead. In such cases, blood lead values
could be found acceptable whereas the accumulated reserves of lead in the
body may be exerting a pathological effect.

This pathological effect could
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go undetected when based on the blood lead level alone.

Thus, a case of

lead poisoning could go undetected when diagnosis is based solely upon the
observed blood lead level.
The utilization of the one-column ALA analysis will shift the focus
from treatment of lead poisoning to prevention through early detection and
termination of undue exposure.
The tragic problem today is that there is an erroneous concept regarding "normal" levels of lead. It is obvious that Davis (1967, 1968, 1970) has
determined correct limits for urinary ALA in its relationship to lead exposure
(table 11).

The upper limit of "normal" blood lead has been variously set at

80, 60, 40, 36 and 20µg per 100 ml of whole blood (Amer. Academy Pediatrics,
1961; Blanksma, et al., 1968; Berman, 1966; Rennert et al., 1970).

The inter-

esting point about these papers is that they imply that values not diagnostic
of lead poisoning are normal.

In fact, most papers written on the subject

equate the lowest blood lead level diagnostic of lead poisoning with the upper
limit of normal. A level not associated with overt clinical evidence of toxicity
is not necessarily normal; however, most children with increased and therefore
"abnormal" blood lead levels are reported as "asymptomatic" (Sachs et al.,
1970; Greengard et al., 1968; Berman, 1966; and Rennert et al., 1970).

But

symptoms from low-level lead intake may have been overlooked because no one
knows what to look for, and children are considered asymptomatic when classic
symptoms and signs of lead poisoning are absent.
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The problem is quite simple - blood lead concentration is the result of
several equilibria and should thus be interpreted with caution.

Thus, a low

blood lead level value does not necessarily exclude a high bone burden of
lead. In fact, there is evidence that different laboratories use different
methods of blood lead determination, and some of these laboratories vary considerably in accuracy (Keppler et al., 1970).
In summary, undue absorption of lead is a health problem of alarming
proportions among young children living in old dilapidated neighborhoods.
Its magnitude is many times that of lead poisoning, an illness already labeled
as "epidemic" in many areas (Rothschild, 1971). At present, it remains uncertain whether or not lead causes permanent damage in humans at a low level of
absorption and in the absence of clinical symptoms.

But there is in vitro

evidence of metabolic disturbance at such low levels, and some reports sugges
that permanent neurologic damage can occur in the absence of overt clinical
symptoms.
One certainty is that if exposure is not terminated in children with
early evidence of undue absorption of lead, many will become poisoned.
Early detection via urinary ALA levels and termination of the exposure at this
stage is therefore an essential step foreward in the prevention of childhood
lead poisoning.
B.

PRESERVATION OF URINE SPECIMENS FOR ALA AND PBG ANALYSIS.

URINARY UREA ANALYSIS COMPLEMENTING ALA AND PBG DETERMINATIONS
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ALA Data.

The question of stability of the porphyrin precursors delta-

aminolevulinic acid (ALA) and porphobilinogen (PBG) in human urine is of
great importance from the standpoint of analysis in the clinical laboratory.
The qualitative Ehrlich reaction for PBG may change from strongly positive to
negative in a few hours if the urine is kept at room temperature.

This may

result either from the formation of an inhibitor of the reaction and/or simple
disappearance of PBG through conversion to porphyrin, or other unidentified
substances. When analysis of the freshly voided urine is not possible it is
important to know the optimum conditions under which the urine can be
preserved.
Previous data from this laboratory have indicated that a small amount
of glacial acetic acid (O .1 ml/10 ml urine) satisfactorily preserves urine specimens for the ALA analysis (Davis, 1970). At the time this method of preserving
urine was introduced no concern was given for PBG determinations.

Subsequent

to these investigations an analysis for urinary PBG has been worked out (reported in Materials and Methods chapter) utilizing disposable ion-exchange
column chromatography.
Thus, the present study was undertaken to provide more definite information about preserving the urine specimen prior to determination of ALA and/or
PBG.
It was found by Abrahams (1970) that ALA recovery from the disposable

ion-exchange columns was found to be essentially identical if the urine
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samples had a pH of 1. 0 to and including 6. 0. However, when the pH of the
urine specimen rose to 7. 0 or above, a decrease in the recovery of ALA was
noted.
A comparison was initiated to study the effect of 3M oxalic, boric,
citric, and tartaric acid upon the recovery of ALA from urine specimens.

Fresh

voided urine was made alkaline (pH 9. O) to ensure that the studied acid would
be capable of lowering the urine pH to below 6. 0 and to maintain this pH
for a reasonable period of storage.

The data indicated in table 12 shows tar-

taric acid lowered the pH of the urine to proper levels, maintained a correct
pH during storage, and at no time did a precipitate form during the storage time.
It was found that if 0. 2 ml of a 3M tartaric acid solution was added

to a 15 ml screw-capped bottle, and heated to 75 C for 60 minutes a clear,
crystalline film would result firmly adhering to the bottom and sides of the
bottle.

This thin film is readily soluble in urine and became the basis for

future preservation of urine.
The data of the present studies indicate greater than 94 percent recovery
of ALA from urine samples preserved with 3M tartaric acid - even if the urine
is stored for a period of 2 8 days at 4 C.
The data also shows that no change in pH of the urine sample was
observed throughout the 28 day storage period.

It was later determined that

ALA will remain constant up to a period of 4 months if the urine is stored at
4 C in the dark.

Frozen urinary ALA samples will remain constant up to a year,
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as long as they are in the dark.
PBG Data: The introduction of disposable ion exchange column chromato
graphy in the analysis of ALA in lead poisoning opened a new area - that of
detection of PBG.

Use of the disposable column facilitated the rapid identifi-

cation and quantitative determination of PBG from a random urine sample.
Up until a few years ago, before the drug culture came into vague,
acute intermittent porphyria (AIP) had its most frequent age of onset in the
late second decade for females and the fourth decade for males.

Today AIP

must be suspected in all age groups over ll years old.
The most serious consequence of the administration of a porphyrogenic
drug is the precipitation of an acute attack in cases of latent porphyria.

It

is difficult to estimate what proportion of the total number of porphyries will
develop attacks after taking barbiturates, steroid oral contraceptives and other
drugs. It is also impossible to predict whether or not an acute infection
(Heroin addict) will precipitate an attack.

Since the attacks can be extremely

dangerous and even fatal and, once they have been precipitated, very little
can be done to improve the outcome, the prevention of this dangerous reaction
is of the greatest importance.
Acute intermittent porphyria has been named "the simulator" because
abdominal pain is frequently the presenting complaint.

The pains are easily

mistaken for manifestations of renal colic, acute appendicitis, cholelithiasis,
or pancrea titis. It is not uncommon for patients with AIP to have multiple
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surgical scars on the abdomen due to misdiagnosed AIP.
A summary of the characteristic features of lead poisoning compared
with several types of porphyrias is presented in table 39.

This table could

serve as a ready reference when the emergency laboratory is called upon to
determine urinary ALA and PBG.
The significant point of these experiments based on urinary PBG lies
in the fact that this is the first report of the utilization of disposable ionexchange columns in conjunction with the ALA standard calibration curve.
This unique combination results in a rapid, accurate, and quantitative determination of urinary PBG that, to date, has been absent from the clinical
laboratories armamentarium.
THEORETICAL CONSIDERATIONS OF AIP: IN REGARDS TO STEROID
HORMONES:

The primary lesion in acute intermittent porphyria has been post-

ulated to reside in an operator gene defect (Watson, 1964) that ultimately finds
expression in the

11

over-production

11

of the mitochondrial enzyme delta-amino-

levulinic acid synthetase (ALAS) (Nakao, 19 66; Tschudy, 19 65).

This enzyme,

as previously discussed in the introduction, controls the rate-limiting step
in porphyrin-heme formation (Granick and Urata, 1963). Hepatic ALAS, however
is inducible experimentally by a variety of drugs and foreign chemicals (De
Matteis, 1967; Granick, 1966; Marver, 1966) and recent studies from the laboratories of Kappas have demonstrated that many 5 13-steroid metabolites
derived from hormones natural to man are also potent inducers of ALAS
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(Granick and Kappas, 1967; Kappas and Granick, 1968; Kappas, 1971). Kappas
postulated that AIP patients might have abnormalities in steroid hormone
biotransformation that lead to the disproportionate formation of 5

S-metabolites

from precursor compounds. The Kappas data indicates that individuals carrying
the genetic lesion of AIP do have an abnormality of steroid hormone metabolism
that results in the disproportionate generation of 5 S-steroid metabolites from
precursor hormones such as all neutral steroid hormones secreted by the
adrenals and the gonads.

These hormones have one common structural feature--

the basic steroid nucleus characteristic of 5 S-H compounds --they are all
derivatives in which the junction of the A & B rings is of the cis, or highly
angulated configuration.

Trans configurations have no porphyrin-inducing

activity (Kappas, 1971).

This abnormality is due to a relative deficiency in

4
activity of the steroid hormone metabolizing enzyme D -5 o:-reductase in such
individuals (Kappas, 1971).
As a result of this deficiency, reductive transformation of endogenous
steroids of appropriate structure is shunted away from the 5 a: toward the 5 S
pathway through which metabolites having potent ability to induce ALAS are
generated.
These findings of Kappas define a new biochemical lesion involving
steroid hormone metabolism in AIP and support the view that there is significant
interplay of endocrine and genetic factors in the pathogenesis of this hereditary
disorder.
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Table 40 is taken from the data of Granick (1966) and lists some of
known inducers of porphyrins that were detected in primary cultures of chick
embryo liver cells.
It is for these reasons that the procedure for the proper determination

of PBG as well as the correct method to preserve its stability in urine was
undertaken.
The data from the present experiments indicated that urine preserved
with tartaric acid enhanced the loss of PBG. Within 24 hours of storage, the
urinary PBG decreased by 4 percent from control and that by the seventh day
the loss was 28 percent.

Further experiments confirmed these results.

The percent loss of PBG from stored urine decreased as the pH of the
urine increased above pH 7. O. It was observed that when the pH of the urine
was 8. 0 the percent loss of PBG over a 48 hour period was 1. 0 percent. The
data indicated that urine to be analyzed for PBG must be preserved differently
than urine being preserved for future ALA analysis.
The experimental evidence presented in this series of experiments
allowed us to conclude that the random urine specimen pH must be adjusted
to approximately 8. 0 and that it must be refrigerated, in the dark, as soon as
pas sible after the collection.
The present studies have indicated to us that refrigerated urinary PBG
will remain constant up to 7 2 hours, while frozen PBG in alkaline urine will
remain constant, in the dark, up to 8 months.
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Previous to the advent of the use of ion-exchange column chromatography the nonspecific nature of the Ehrlich aldehyde reaction made the evaluation of qualitative and quantitative urinary PBG determinations very difficult
and very often meaningless.

In a very fortunate way, PBG is distinguished

in having a strong absorption peak at 555 nm with a weaker peak at 525 nm
(Mauzerall and Granick, 19 5 6), the ratio of the optical densities being 0. 82.
The Ehrlich-positive metabolites which have caused confusing results in the
qualitative tests, are effectively removed by the anion AG-l-X8 resin.
The possibility of obtaining false-positive results in the qualitative
PBG tests have been reported (Ludwig and Epstein, 1961).
have resulted from indole compounds in the urine.

The false results

The passage of the 0. 5 ml

of urine through the anion column effectively eliminated all interference due
to indole and 5-hydroxy-indoleacetic acid (Taddeini, 19 62).
It is with anticipatory optimism that the author wishes to see the PBG

test utilized in the clinical practice of medicine.

The test should be used to

evaluate whether a woman, placed on steroid contraceptives, is indeed a
latent carrier of the gene.

This should be done at the one, six and twelve

month office visits after starting on the "pill". PBG should also be routinely
determined in all patients placed on barbiturates for one medical reason or
another and the results of such determinations should become part of the
patients permanent medical record.
Urinary Urea Data: Urea is the principal end product of protein
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metabolism in the human, it usually represents 80 to 90 percent of the total
urinary nitrogen.
The excretion of urea is decreased in certain liver diseases, such as
cirrhosis, in which the capacity to form urea is decreased. In cases of
severe acidosis the amount of urea excreted maybe considerably reduced because of diversion of amino nitrogen to ammonia formation,

Excretion of

urea also maybe decreased in nephritis when the ability of the kidneys to
excrete it is severely impaired.
As discussed previously, the introduction of disposable, dual piggyback ion-exchange chromatography columns for determining urinary ALA and
PBG allowed us to collect urea free from interfering substances.
The quantitative determination of urinary urea would be practical,
rapid, and inexpensive as well as being very convenient in regards to the
patient (0. 5 ml of urine required) and to the clinical laboratory.
The data of the present experiments is based upon the color reaction
of modified Ehrlich 1 s reagent with urea producing a lemon-yellow color. The
optical density is determined at 415 nm in a standard laboratory colorimeter.
The ease of collecting the 30 ml of water washed through the column
to remove the urinary urea from the 0. 5 0 ml urine sample afforrl ed us the
opportunity to produce a linear calibration curve for urea.
The average adult excretes 12 grams of urinary urea in 24 hours in an
average volume of 2, 000 ml.

For the data on 95 percent confidence limits, the
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present studies indicated a mean of 6. 9 6 mg of urea in a 0. 5 ml urine .sample
while the data showed 15. 3 5 mg of urinary urea as being the upper limit of
normal.

There was no difference noted in the age of the adult nor his sex.
The experiments determining the 95 percent confidence limits of ALA,

PBG, urinary pH, and urinary urea showed the upper limit of normal to be
0.54 and 0.20 mg percent, respectively, for ALA and PBG and 6.88and15.35
for pH and mg urinary urea.
The present studies indicate that disposable ion-exchange chromatographic columns can be employed for the isolation of urea from the urine in a
manner which permits a rapid, accurate, and quantitative test procedure to
be performed.
An advantage of the colorimetric determination is in the visible spectrum with regard to a large-scale screening program dealing with a vast number
of samples.

Normal values of urinary urea produce a light lemon-yellow color

while abnormally high urea produce a definite and distinct bright lemon-yellow
color. It is therefore possible to immediately eliminate all non bright yellow
colors as being of normal urea values.
If kidney disease or urinary obstruction causing decreased amounts

of urinary urea are detected, or if acute nephritis, pyelonephritis, renal tuberculosis, renal cortical necrosis, malignancy or chronic gout are suspected,
then it becomes critical to have an accurate, rapid, quantitative test procedure
to determine urinary urea.

The goal, in this case, is the detection of
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potentially toxic manifestations of kidney disease in asymptomatic individuals.
Another use for quantitating urinary urea would be to reflect the level
of dietary protein intake or to reflect the degree of adherence to a specific
protein-restricted diet.

Another use would be for determining the presence of

unrecognized catabolic stress.
Finally, one must remember the urinary urea value is affected by the
level of renal function and the rate or urine flow.

It is also affected by the

net breakdown of body protein.
C.

DELTA-AMINOLEVULINIC ACID TISSUE LEVELS FOR POST-MORTEM

ANALYSIS
Lead is absorbed into the human organism by respiratory and digestive
routes and is distributed to organs and tissues by the bloodstream. As a
result of growing industrial use and the introduction of alkyl lead compounds
such as gasoline additives, exposure to lead is substantially above the background of absorption from food and drinking water.

Experimental and epidem-

iological data point to a logarithmic correlation between the concentration of
lead in the air and that in the blood of exposed individuals suggesting that,
· in man, lead can accumulate as a result of increasing environmental contamination.

Needless to say that childhood lead poisoning with true ingestion of

lead-containing paints presents an environmental problem that must be constantly searched out and eradicated.
To date, there is no data correlating tissue ALA levels with lead
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ingestion.

This unique finding is missing from the literature because there is

a lack of a rapid and practical laboratory method for quantitative determination
of ALA levels in post-mortem tissue specimens.

One can determine lead levels

in tissue but the analysis is so very cumbersome that for manpower reasons
alone, most laboratories avoid determining lead.
There is no literature on ALA tissue levels as a means to diagnosis lead
poisoning in the post-mortem period. In fact, ALA tissue levels for any diseasE
or toxicology related mishap is non-existent in the literature.
The data of the present experiments shows that urinary ALA increases
with time after a single subcutaneous dose of lead acetate had been administered.

It should be pointed out once again that the urinary ALA increased after

one exposure to lead - and the ALA remained elevated.

If blood lead was

determined it probably would show normal due to the deposition within the bone
The time required to complete the total tis sue analysis, excluding
the freezing time, is under 2 hours. It therefore became, for the first time,
a very easy and rapid determination of ALA.

The urinary ALA standard calibra-

tion curve served as the reference for these tissue ALA level determinations.
The method, as the data indicates, gave over a 92 percent recovery of added
ALA to control tissues, indicating an accurate method.
The control levels of tissue ALA ranged from 0. 02 microgram/gram for
adipose tissue to a maximum of 0. 53 microgram/gram for the tail of the epididymis. After a single subcutaneous injection of 200 mg/kg of lead acetate,
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the bone marrow averaged 24. 6 microgram/gram while the kidney averaged
10. 9 micrograms/gram 58 days after the one-time injection.
The greatest accumulation of ALA occurred in the bone marrow which
approximated a 100 fold increase in ALA over control values.
an average of a 27 fold increase over control.

The kidney showed

In all of the experiments the

bone marrow consistently had a higher quantity of ALA accumulating per dose
of lead acetate administered followed very closely by the kidney -- one must
keep in mind the fact that this data is based upon a single subcutaneous dose
of lead acetate.
It is always of interest to compare the dose of lead that was administer-

ed to the rabbit to that dose a child may be exposed to in a 3 month period
(the average time required for a child, with pica, to demonstrate signs and
symptoms of lead intoxication). As has been discussed in the Introduction,
a chip of paint about the size of an adult's thumbnail can contain between 50
and 100 milligrams of lead. If the child only eats 3 chips of paint per day for
a period of 9 0 days and if the lead content of those paint chips averages 7 5
milligrams (225 mg/day dose) he will ingest 20, 250 milligrams of

lead~

He absorbs 10 percent of this dose or approximately 2000 milligrams of lead.
If the child weights 10 killiograms, he will have given himself a dose of 2 00

mg/kg - the same dose used in the animal experiments -- except the dose is
being administered over a 90 day period.
The accumulation of ALA in the bone marrow and kidney and its physio-
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logical effects have not been studied to date.

This avenue of research appears

to be most needed and most rewarding if we are to understand the full meaning
of lead intoxication.
D.

DELTA-AMINOLEVULINIC ACID DEHYDRASE (ALAD) LEVELS IN THE RAT

BEARING THE WALKER 256 CARCINOSARCOMA
I would like to begin this section with a quote from J.B. Sumner (1950)
who said "One way of defining life is as an orderly functioning of enzymes.
Disease manifests as a disorder, inhibition, or hyperfunction of enzymes".
The unique finding of greatly increased ALAD activity in parallel with reticulocyte formation in the rat bearing the Walker tumor certainly fits the last part
of Sumner's quote - hyperfunction of an enzyme.
The general concept behind most chemical studies of tumors is that
there must be, at the origin of neoplasia, some fundamental change(s) in
cell chemistry. If such change(s) were revealed, therapeutic means could be
attempted, probably with much greater chances of success.

The change is

believed by many to occur in the enzymes which regulate cell metabolism
and cell function.

It is not known whether the cause of cancer resides in

abnormal cell metabolism or, more specifically, in altered enzymatic properties and whether it represents a gain or a loss of a given substance(s).
The bulk of the data accumulated on enzymatic properties of tumors
has been obtained by biochemical analyses of tissue homogenates or tissue
slices.

Such methods, which include a great number of precise quantitative
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procedures, have contributed greatly to a better knowledge of many processes
in living organisms.
Recently biochemists have become progressively aware of the limitations of chemical assays on homogenates or tissue slices.

Their conclusion

was that enzyme activities present in homogenates represent, in a majority
of cases, the mean of the activities of several cell types and that of extracellular elements. In such cases, variations in mean activities may reflect
not only the changes in the enzyme activities of several tissue elements,
but also those resulting from changes in the relative proportions of various
structural elements.
The methods utilized in the present studies assured us of pure Walker
tumor cells in the proportion of
cellular elements.

9 8 percent tumor cells to 2 percent extra-

This data was obtained by careful microscopic examination

of the growing tumor as well as cell suspensions from it.
Previous studies on ALAD have focused on lead-poisoning and the effect
of lead upon the inhibition of the enzyme.

Many authors have discussed ALAD

but always in relation to lead poisoning, some of these authors besides those
mentioned in the Introduction include: Granick and Mauzerall (1958), Lichtman
and Feldman (1963), Bonsignore {1966), de Bruin and Hoolboom (1967), de Bruin
(19 68), Nakao et al (19 68), Chisolm (1970), Hemberg et al (1970), Hernberg and
Nikkanen (1970), Millar et al (1970), Deutsch (1971), Burch and Siegel (1971),
Haeger-Aronsen et al (1971), Esham and Avent (1972), Moore (1972), Padmanaban
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and Malathi (1972), Goldberg (1972), Granick and Sassa (1972), Hernberg et
al (1972), Morgan and Burch (1972), Kao and Forbes (1973), Tola et al (1973),
Mcintire et al (1973), and Oski (1973).
The unique feature of this study, outside of the fact that ALAD has never
been studied as an indicator of the neoplastic process, was that we did not
study slices or homogenates from the Walker tumor.

The experimental data

was based on the hemopoietic effects of the in vivo tumor or homogenates
from it.

The biological effects we studied were two in number: 1) increased

degree of reticulocytosis and 2) elevation of ALAD activity. As has been
discussed in the Results chapter other hemopoietic factors were also studied
but they served only to highlight the unique biological activity of the enzyme.
It is hoped that the control of enzyme levels in normal and pathological tissues

may be a field of enzymology which will flourish in the coming years.
Of great interest to neoplastic studies is the fact that with the growth
of the Walker tumor there is an alteration of the enzyme pattern of cells (reticulocytes) coming from the bone marrow of the tumor host.

This elaboration

of cells into the circulation with concomitant enzyme activity appears to be a
documentation of such an enzyme-tumor interaction that Bodansky began
searching for in 19 60.
Another point of interest to the clinical laboratory is the fact that the
enzyme activity was always found in whole blood and never in the serum or
plasma.
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Chart 24 illustrates the effect of the growing Walker tumor on the
increased degree of reticulocytosis and increased ALAD activity. It is of
interest to note two things about this chart: 1) the similarity and parallelism
of the ALAD activity curve with the percent reticulocyte curve and 2) the
immediate and rapid elevation of these two parameters before any growth of
the tumor could be detected,

as well as their persistence throughout the time

of the growth of the tumor.
ALAD activity increased 117 percent over control within 24 hours after
transplantation of the tumor and rose to 619 percent by day 4, the first day of
palpable tumor growth, rising to 2, 000 percent over control on day 20, the day
of termination of the experiment. The reticulocyte count increased 70 percent
within 24 hours and rose to 3 87 percent by day 4, rising to 2, 3 00 percent
over control on day 20.
The fact that the ALAD activity rose to 619 percent over control by day 4
after transplantation of the tumor makes one want to speculate about the availability of any other enzyme systems that respond so quickly to a beginning
neoplastic process in the host. To date, no literature data can supply this
information with which to compare ALAD activity.
The fact that reticulocytosis was occuring in such magnitude lead us
to believe that the Walker tumor was excreting erythropoietin. We also thought
we may have an excellent model for the control of tissue development within
the tumor with an endogenous indication - ALAD activity.
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We determined erythrocyte counts to evaluate if there was, in fact,
a process of erythropoiesis occurring.

By definition, the process is one of

production of erythrocytes with concomitant increases in red cell count, hemoglobin, and hematocrit. If erythropoietin was being excreted by the Walker
tumor it would take an interval of five days before the appearance of an increased blood reticulocyte count would occur.

Five days is the length of time re-

quired for maturation of erythroblasts from the earliest cell to the reticulocyte
{Yoffey, 1957).
Chart 2 6 is a composite chart showing the effect of a growing subcutaneous tumor on the host. It is of interest to note several items from this
chart: 1) the immediate response of reticulocytosis and increased ALAD activity,
2) the red cell count consistently decreased per unit of time, starting with
an initial value of 5. 8 million per cubic millimeter and finishing with 2 million
per cubic millimeter on day 20, and 3) the hemoglobin and hema tocrit decreased
in parallel with the decreasing red cell count.

The data indicates a severe

destruction of red cells from the moment the Walker tumor is transplanted.
The data indicates there is no process of erythropoiesis occuring
because of the immediate response of reticulocytosis to the transplanting
of the tumor and most important of all, the immediate destruction of red cells
with a parallel decrease in hemoglobin and hematocrit.
To date there is insufficient evidence to be certain that the bone
marrow is the principal site for the inactivation or degradation of erythropoietin
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but one would like to speculate on the induction of factor(s) caused by the
Walker tumor which may be responsible for the apparent shut-down of the bone
marrow in the tumor host.
The data indicates that the primitive bone marrow cells are being inhibited, by the growing Walker tumor, from the day of transplantation to the
day the animal dies. It would be interesting to investigate the effect the
growing tumor has on the development of the erythron (i.e. the red cells and
the erythroblasts in the marrow or spleen) and the development of the stem
cells (i.e. those cells which reproduce themselves and give rise to the erythron).

The question of selectivity of the factor(s) from the tumor would have

to be investigated.
The question arises how does the growing Walker tumor affect the
kidney, the major site controlling the production of erythropoietin. Would
this effect of the tumor affect the basic cellular integrity of the renal tubules
etc? Could one detect these changes using a light microscope?
It would be of interest to determine if the tumor excretes anti-erythro-

poietin antibody.
It should be pointed out that no attempt was made to isolate the factor(s

from the Walker tumor which produced the reticulocytosis and increased ALAD
activity.
The extreme immaturity of the reticulocyte was noted in the peripheral
smears stained with New Methylene Blue-N. It normally takes 24 hours for
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a reticulocyte to mature once in the circulation (Finch, 1959) - that is a loss
of reticulum.

In the preparations from these experiments the reticular network

filled the cells in an evenly distributed pattern indicating very immature
reticulocytes.
The preponderance of reticulocytes in blood smears, studied throughout
the total experiment, demonstrated up to 65 percent of the total cell count
consisted of reticulocytes, indicating the biological response to malignant
tumor growth.
We turned our attention to water soluble cell free extracts of the
Walker tumor when it became clear that the results of these experiments
indicated a positive correlation in the tumor-host between ALAD activity
and reticulocytosis.

The objective of the water extract experiments was to

determine whether or not cell-free homogenates could produce the same effect
on increased ALAD activity and reticulocytosis. The control in these experiments was soluble cell free water extracts of normal rat liver.
Malignant Tumor Extracts:

The concept of studying the effect of tumor

extracts was originated in 1947 with the work of Gross (1947) who reported
that hemolysis occurs when centrifuged or filtered extracts prepared from
spontaneous mouse mammary carcinomas were mixed with mouse erythrocytes.
He found that the hemolysis was specifically directed against mouse red blood
cells and no hemolysis occurred when these extracts were mixed with other
species blood cells including human.
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In 1948 Gross showed that extracts made in a weight to normal saline
ratio of 1:20 could be heated up to 68 C for over 30 minutes without any loss
of hemolysis activity. Heating the extracts over 68 C destroyed the hemolytic
potency.
Experiments were conducted using the transplantable mouse sarcoma
180 extracts. These results matched the original data of the mammary carcinoma.
Gross studied extracts from normal, healthy mouse organs on mouse
erythrocytes in vitro. Extracts were prepared from mammary glands, liver,
kidneys, spleen, and lungs. The technic of these experiments was identical
with that used for the tumor extracts and the results were all negative -neither hemolysis, nor agglutination resulted from these tests (Gross, 1948).
Reynolds and Friedell (1963) studied extracts of hamster sarcomas.
They use separate saline extracts of the necrotic and viable portions of the
tumor for their studies.

The active material in the tumors that caused hemo-

lysis was localized to the viable tumor tissue.
The evidence presented in the paper suggests that the hemolytic agent
is a protein or that it is bound to a protein. It does not pass through a
membrane.

dialyzin<~

The factor is soluble in ether and this implies a lipid-protein

complex.
Sohier et al (19 57) have shown by repeated determinations of red cell
survival how the onset of hemolysis correlates closely with the beginning of
rapid host deterioration.
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Knowledge of what causes a progressive decrease in the viability of
the erythrocytes at the time of rapid clinical deterioration might help us understand how the last barriers of host resistance are destroyed.
In the natural history of neoplastic disease, decreased red cell production has been ascribed to a tumor toxin, to replacement of bone marrow
cells by tumor, to disturbances in protein synthesis including globin, to
inadequate intake or storage of hematinic factors such as vitamin

s12 ,

iron,

or folic acid due to malnutrition or extensive liver metastases (Hyman, 1954).
In the many patients dying of cancer where massive hemorrhage, infection, or destruction of vital organs does not take place, the direct cause
of death still remains unknown, so it still remains a valid research question
to answer.
Normal Liver Extracts: Soergel and Friedel! (19 64) investigated the
concept that chronic, progressive liver disease is perpetuated by production
of autoantibodies.

The extracts were prepared in saline from normal rat livers.

The investigation studied single versus multiple (subcutaneous) injections,
serum e.lectrophoresis, agar double diffusion, and hemagglutina ti on tests to
detect any appearance of antibodies.
The results of this study were that liver extracts did not give rise to
specific liver lesions, serum protein changes, or the appearance of antibodies
to the water soluble components of liver tissue.

Repeated injections and

variations in the age of the experimental animals did not alter these negative
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results.
Soergel and Friedell conclude that the search for an experimental
model for the production of autoantibodies to liver tissue and autoimmune liver
disease has, so far, not met with success. They also proved how innoxious
water soluble liver extracts are on the experimental animal so injected.
The data of experiments indicated that cell-free homogenates of the
Walker tumor did cause an increase in ALAD activity with concomitant increase!
in reticulocytosis. After a single cardiac injection of 100 mg/kg of 105, 000 x g
unheated, lyophilized tumor extract two things were noted: 1) the reticulocyte
count reached the highest percentage at day 2 and 2) ALAD activity reached
its highest activity at day 8. It is of interest to note that both of these
parameters return to normal values by day 20.
Chart 28 illustrates the effect of a single intra-cardiac injection of the
water-soluble tumor extract. The body weight, red and white cell count as
well as the hemoglobin and hematocrit remain relatively stable and constant
with a slight depression in the red cell count.

The increase in ALAD units

and reticulocyte percent remain the only significant parameters affected by
the tumor extract.
These water extract experiments held the potential, in the cell-free
aquoeus solution of the lyophilized tumor, to reveal any erythropoietin or
erythropoietin-like activity that may have been masked by the great destruction
of red blood cells that occurs with the growing tumor in vivo.

It is obvious,
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from the data, that no such activity could be elicited.
It should be observed in Chart 27 that the reticulocyte count has

returned to control levels ---- in marked contrast to the reticulocytosis
obtained when there if an in vivo malignant tumor.
The potential arguement that the simple procedure of injecting an
aqueous protein solution, via the intra-cardiac route, was the cause of the
release of reticulocytes from the bone marrow with concomitant increase in
ALAD activity was rejected by the normal liver extract data. As shown in
Chart 28, there was no change in any of the parameters measured during the
20 day period.
Essentially, all the change is noted with the animals given the tumor
extract while no change is observed with the liver extract injected animals.
As stated in the Results section, the data indicates that the growing
Walker tumor produces a stimulating substance (s) that initiates a great increase
in ALAD activity with a concomitant increase in reticulocytosis.
The immediate and unique elevation of ALAD activity in parallel with
reticulocyte formation before tumor growth becomes detectable suggests an
'

early tumor-host relationship that may be unique in the early detection of
neoplastic disease.
Recently, Emmanuel Farber (1973), the president of the American Association for Cancer Research said in his presidential address that work in his
laboratory has shown the rise in serum a-fetoprotein coincides with the
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early appearance of nodular hyperplasia.
One of Farber's collegues, Dr. Oki ta, has now found that the reappearance of a-fetoprotein often occurs before any recognizable malignant
neoplasia appears.

Farber is very excited about this property of malignant

neopla sia appearing well before cancer can be detected.
The data from the current experiments suggests that the unique elevatio
of ALAD activity, in every experiment, before tumor detection may serve, in
conjunction with the

a-fetoprotein, as a dual means of detecting a neoplastic

cell population at the molecular level.
As data is gained in the field of enzymes in cancer, one hopes that soon
an order in which certain events occur prior to the actual appearance of overt
neoplasia will be discovered.

This discovery will allow the pharmacologist

to turn off the sequence of events leading to neoplasia by pharmacological
inhibition of the rate limiting enzymes.

The key question to be answered in

the future is - when in the cellular evolution of a neoplastic process do the
rate limiting enzymes begin to be expressed.

Then we must answer the obvious

question of what might the mechanisms be for the encouragement of growth
of selected populations of cells that have the enzymes of the neoplastic
process without involving the whole organ or tissue population.
Farber (1973) states "If we are to understand the essential nature of
neoplastic development, we must begin to identify, isolate, and study the
different cell types that seem to be the key precursors from which the malignant
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neoplasm is ultimately derived". We believe the discovery and study of enzymes such as ALAD will contribute to a small part of the understanding process
Farber speaks about.
It is obvious that researchers are attempting to discover the one
mechanism that triggers the neoplastic process to begin. We have studied the
result of a growing neoplastic tumor - but somehow, someway the two processeE
must be related. We realize the severe limitations imposed upon the speculations discussed.
Some other speculations the current studies have generated include
the possibility that many zymogens that are not normally detected in whole
blood are activated at the time of transplantation.

Could there be cleavage

of peptide bonds to open up cyclic peptide structures, or the cleavage of
portions of the enzyme proteins with loss of these portions as peptides resulting in increased ALAD activity?
Could there be an induction of a coenzyme which associated with ALAD
facilitates the enzyme reaction more efficiently and maybe improves the
enzyme activity?
Could such ions as Ca, Fe, K, Mg, Mn, Na, or Zn become activators
of the ALAD as a result of the transplantation process? These ions were
chosen because they are known to be loosely bound to enzymes versus Mo,
Cu and Co which have been found to be non-dissociable (Bray and Harrap,
19 59).
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E.

FACILITATION OF GROWTH OF THE WALKER TUMOR AFTER PRE-TREATMENT

WITH WATER EXTRACTS OF THE TUMOR
The data reported in the current investigation is the result of the exposure
of the author to cancer research.
The original objective of pre-treating a future receipent of a Walker
tumor with water soluble cell-free tumor extracts was to cause rapid rejection
of the transplanted tumor. It was obvious that if facilitation of tumor growth
occurred as a result of such manipulations of the tumor-host then the data so
received would be treated as a bonus.
The data of the present experiments indicates a phenomen occurring
that is similar to the production of antilymphocytic serum (ALS).

The data

also is completely opposite to that which ALS is founded - that is ALS is
raised in one species against the lymphoid tissues of another, e.g. rabbit,
goat or horse anti-mouse.
which it is raised.
goats and horses.

In general ALS is specific to the species against

The most widely used animals for raising sera are rabbits,
Usually the antigen is derived from spleen, lymph nodes

or thymus lymphocytes.

Normally ALS is raised by injecting 10

9

mouse

thymus lymphocytes intravenously into each rabbit; the injection is repeated
14 days later and after a further week the rabbits are bled out.

The serum is

separated, decomplemented, absorbed with mouse erythrocytes to remove
hemeagglutinins and sterilized by filtration; it can be stored indefinitely
at -20 C.
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The present experiments were opposite to ALS in the following manner:
1) No lymphocytes or cells from the tumor host were used: 2) No injections of
any cells were made into the host-to-be or into another species of animal,
and 3) No collection of serum was attempted nor was there any interaction with
rat erythrocytes.
The method of pre-treatment is fully explained in the Materials and
Methods chapter under the section "Effect of pretreatment with Walker tumor
extracts on growth of solid tumors in the rat". It is enough to say that cellfree, lyophilized tumor and normal liver water extracts were used in these
studies.
The results obtained were identical to those one would expect if he had
used ALS - that is a facilitation of growth of the transplanted subcutaneous
growing tumor.

In fact, by the sixth day after transplantation, the tumor

extract pre-treated animals had a 200 percent increase in tumor volume over
the control litter mate tumor bearing rats. This percentage increased to
approximately 3 00 percent by day 12.
To date ALS has proved to be one of the most useful laboratory tools for
elucidating the basic physiology of the immunological processes - such as that
ALS coats the lymphocyte surface, preventing contact with antigens.

It is now

established that ALS acts by eliminating from the circulation that pool of lymphocytes which is long-lived and derived from the thymus (T-cells) (Taub and
Lance, 19 68). ALS was first used by Starzl (19 68) and his colleagues in Denver
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in renal and liver transplantation studies as a powerful immunosuppressant
which worked very effectively.
The current studies do not indicate we have anything approaching an ALS
type of activity. It does, however, allow us the opportunity to speculate
on many subjects using the ALS experiments of Starzl (19 68) as a reference.
Would the pretreatment of the tumor receipent with tumor extracts inhibit
the rat's cellular immune processes?

Could this method be used to prolong

the survival of homografts in the rat? Is this pretreatment applicable to
transplantation research?
An interesting question is does the water extract treatment prevent the
action of host antigens against the growing tumor.

The data comparing the

growth of the tumor in pretreated rats to their brother ~itter mates indicates
the treated animals offered little resistance to tumor growth.

For example,

on day 6, after transplantation, the control, untreated rats, had a tumor volume
of l, 650 cubic centimeters while the treated animals had a tumor volume of
4, 9 28. On day 12, the data became even more impressive: control tumor
volume equaled 18, 682 while the pre-treated group measured 73, 360 cubic
centimeters. We could ask if the host's immunological memory had been
erased.
Another interesting question would be based on the use of several doses
of the cell-free tumor extract.

First what would happen to the host -- would

tumors be established that normally the body rejects?
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Finally, one would like to think there may be a very small possibility
that cell-free water extracts of the tumor could be used as a test to give a
rapid indication of tumorigenic potential of experimental protocols in rat
tissue culture cells.

Today the use of newborn hamsters with inoculation into

cheek pouches are the biological tool of research.
to several months.

This process could take up

CHAPTER V

SUMMARY

I

)

205

CHAPTER V
SUMMARY
1.

The method for the isolation of urinary ALA from random urine specimens
has been modified utilizing a one-column disposable chromatographic
unit prefilled with resin that can be conveniently held in a support rack
over a drain tray.

2. The screening for lead poisoning is divided into two routes utilizing the
one-column or the dual piggyback column unit. It is suggested that the
pediatric population be screened utilizing the one-column unit because
PBG is not excreted in this age group while the dual piggyback column
unit is to be used for screening an adult population.
3. It was determined that the cation resin bed height of the one-column unit
had to be reduced to half of its expected bed height -- from 4 cm to 2 cm
keeping the diameter constant at O. 6 cm -- for maximum elution of ALA.
4.

The recovery of ALA in the range of 5 to 40 µg when added to normal random
urine averaged 94. 68 percent for the one-column unit as compared with a
93. 58 percent recovery from the dual piggyback unit.

5. The recovery of ALA using the one-column method was not affected in
urines preserved with tartaric acid, even if the urine was stored in the
dark at 4 C for a period of 28 days or longer.
6. The amount of urinary urea remaining on the one-column unit after washing
the column with distilled water was determined by eluting the urinary
ALA and urea with lM sodium acetate, forming an ALA pyrrole with acetylacetone and then adding modified Ehrlich's reagent. After 15 minutes
reaction time, the color absorbance of urinary urea was determined at
an optical density of 415 nm. Theoretically, urea should be completely
wa.shed through the cation resin column but in reality a minute amount
may adhere to the column (less than 0. 50%). It was determined that
35 ml of distilled water would give an O.D. of 0.013 at 415 nm in comparison to an O.D. of 0.025 obtained from the dual piggyback commercial
column unit, washed with 30 ml of water as directed in the ALA test kit.
7. The ALA standard calibration curve can be accurately produced in sodium
acetate, normal urine, or in distilled water with essentially similar
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results. The method utilizing lM sodium acetate is rapid, accurate,
and reproducible and is utilized throughout this dissertation.
8. Recovery of ALA from random urine is critically dependent upon the pH
of the urine sample. It was found that recovery of ALA was reduced
when the pH of the urine specimen was 7. 0 or above. It is suggested
that the pH of all urine samples applied to the one and dual piggyback
column uni ts be 6. 0 or below.
9. The color formed with the ALA-pyrrole and modified Ehrlich's reagent produces a maximum absorption at 553 nm. A Beckman spectrophotometer,
model DB-G, was utilized throughout this study to determine the
absorption spectra of the urine or tissue sample being studied.
10.

3M tartaric acid was found to be an excellent preservative for urine
being analyzed for ALA. It was found that 0. 20 ml of a 3M solution of
tartaric acid, in water, would lower the urine pH to 4-5 and that this
pH would remain constant, even upon storage of the urine sample for
28 days at 4 C in the dark. It was also determined that tartaric acid did
not affect the recovery of urinary ALA from one or dual piggyback column
units. The recovery of urinary ALA, from one-column units, after being
preserved for a period of 28 days at 4 C in the dark averaged 95 percent.

11. The maximum absorption of PBG when condensed with DMAB in acid
solution occurs at 555 nm with a shoulder at 525 nm. If pure PBG is
present in a sample, a ratio of A525/ASSS will be approximately O. 83.
In all studies carried out in this dissertation the determined PBG always
had a ratio of 0.80-0.83.
12. Pure crystalline PBG was isolated from the urine of a 21 year old female
patient with acute intermittent porphyria. The standard quantitative
curve obtained with the human PBG matched identically the standard
calibration curve obtained with synthetic PBG supplied through the
cooperation of Bio-Rad Laboratories, Richmond, California.
13. The color reaction that develops with PBG and modified Ehrlich's reagent
is stable for a period beyond one hour while the color developed with
unmodified Ehrlich's begins to fade within the first 15 minutes of the
reaction. The reaction with modified Ehrlich's assures one of a constant
optical density for an extended period of time.
14. Guidelines for the quantitative interpretation of urinary PBG values were
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establsihed. The urinary PBG code is divided into 7 classifications
ranging from normal to 5 plus. The similarity to porphyria is graded
from none to overwhelming.
15. The data on preserving urine with tartaric acid for later PBG analysis
indicated that urinary PBG decreased 4 percent within 24 hours of storage
and by the 7th day the PBG loss was over 25 percent. The data indicates
the hazard in preserving urine samples, intended for PBG analysis,
with tartaric acid -- or any other acid media.
16. It was found that the urine intended for PBG analysis must be adjusted
to pH 8. 0 with sodium carbonate. If the urine is so adjusted then the
PBG loss in 48 hours of storage is approximately l. 0 percent. By
observing this procedure, refrigerated urinary PBG will remain constant
for a period of 72 hours. If one elects to freeze the alkaline urine, the
PBG will remain constant, in the dark, for a period of 8 months.
17. A method was devised to convert mg percent ALA to mg percent PBG
utilizing the ALA standard calibration curve. One plots the ALA curve
and determines the optical density of the PBG sample in modified Ehrlich's.
By drawing a horizontal line from the 0 . D. ordinate to the ALA curve
and then drawing a line at a right angle to the abscissa will give one the
mg% ALA. The value of mg% ALA is then multiplied by the conversion
factor of 3. 53 in order to obtain the mg% PBG in O. 5 ml aliquot bf urine.
Therefore, mg% PBG = mg% ALA x 3 . 53. It should be noted that this is
a rapid, quantitative method to determine urinary PBG.
18. The utilization of the dual piggyback column unit to remove all interfering
substances from a 0. 50 ml urine sample allowed pure urinary urea to be
washed from the unit with distilled water. Modified Ehrlich's reagent
was added to the urea-water solution and the resulting lemon-yellow
color absorption was determined at 415 nm against a reagent blank. The
color developed is stable and will remain so for an extended period of
time.
19. The 9 5 percent confidence limits were determined for human urinary ALA,
PBG, pH, and urea. The upper limit of normal for urinary ALA and PBG
is O. 54 and 0. 205 mg percent, respectively. For urinary pH the value
is 6.88 and for urinary urea it is 15.35 mg percent.
20. Post-mortem determination of tissue levels of ALA in lead-poisoned
rabbits utilized the unique idea of using dual piggyback disposable
column chromatography units. This method afforded an opportunity to
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easily quantitate ALA in a manner never achieved before.
21. A single subcutaneous injection of lead acetate steadily increased the
excretion of ALA in the lead-poisoned rabbit over a period of 58 days.
The upper limit of normal for urinary ALA in rabbits was found to be 0. 05
mg percent. After the single injection of 200 mg/kg of lead acetate the
urinary ALA reached a level of approximately 3. 0 mg percent at 58 days
post injection.
2 2. One gram of tissue was considered to be sufficient for the analysis of
tissue ALA levels.
23. The time required for complete analysis for tissue ALA, excluding the
freezing step, was approximately two hours.
24. The recovery of ALA added to normal liver homogenates from one gram of
tissue averaged 92 percent. The amount of ALA added ranged from 2. 5
to 20 µg per gram of tissue being analyzed.
25. Control levels of tissue ALA in 21 tis.sues of non-treated adult rabbits
ranged bet~. 02 microgram per gram for adipose tissue to 0. 53
microgram per gram for the tail of the epididymis.
26. It was observed that after a single subcutaneous injection of lead acetat~,
a marked progressive increase in the levels of ALA was noted in the bone
marrow and kidney of the lead-poisoned rabbit.
27. 21 tissues of the lead-poisoned rabbit were studied for accumulation of
ALA and it was found that the bone marrow had the highest content of ALA
of all the tissues studied averaging 24. 6 micrograms per gram wet weight
of tissue. The level of ALA found in the kidney was 10.9 micrograms per
gram, while corresponding values for the spleen, lung, and tail of the
epididymis were 1. 50, 1. 25, and 1. 05, respectively. All of the remaining
tissues studied were found to have an MA content below 0. 7 microgram
per gram wet weight.
28. The greatest accumulation of ALA occurred in the bone marrow which
approximated a 100 fold increase in ALA over control. The kidney displayec
an accumulation of ALA amounting to a 27 fold increase over control.
29. Studies were completed showing that ALA accumulation in the bone marrow
and kidney were dose dependent on the lead acetate injected.
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30. It was concluded that the bone marrow and kidney served as excellent
tissues to determine ALA levels in the post-mortem diagnosis of lead
poisoning.

£)

31. Aminoacetone
was determined because there was a doubt whether or
not AA was pro uced in the lead-poisoned animal. Both ALA and AA
pyrroles are dete mined at an absorption of 553-555 nm, consequently,
AA could influence the final result of the ALA determination by adding to
the total color reaction.
32. AA pyrrole and ALA pyrrole, both formed by the condensation with acetylacetone, are separated from each other by means of an anion AG-1-XS
column. Once the pyrroles have been separated they can be individually
reacted with modified Ehrlich's reagent and ALA can be quantitated by
referring to the ALA standard calibration curve. Aminoacetone is determined mathematically.
33. Urinary AA averages about 2 percent of the total final color of the two
pyrroles added together when reacted with modified Ehrlich's reagent.
It can be concluded that 98 percent of the observed optical density
obtained in the urinary ALA analysis is due to pure ALA and that the
amount of aminoacetone present is there only in insignificant amounts.
34. The percent of final color due to aminoacetone in tissue samples from
lead-poisoned rabbits was determined. The average percent of color
due to AA in the kidney, bone marrow, spleen, and liver averaged 0. 39
percent. The kidney and bone marrow each averaged 0. 01 percent.
The data suggests that the aminoacetone pyrrole does not add any increasec
color to the two tissues suggested for post-mortem analysis of ALA for
lead-poisoning -- namely the bone marrow and the kidney. Aminoacetone,
therefore, can be ruled out as an interfering biological compound.
35. The study of an enzyme of the heme biosynthetic pathway -- namely deltaaminolevulinic acid dehydrase (ALAD) was undertaken in the SpragueDawley rat bearing the Walker 256 Carcinosarcoma. This study was
originated to find some clue to the anemia of cancer and in particular
to determine if ALAD was being inhibited by the growing tumor resulting
in host anemia. The concept of studying a hematopoietic enzyme such as
ALAD appeared to be unique and warranted further investigation.
36. At the time the ALAD studies were initiated in tumor bearing rats a study
of other hematology factors was also begun -- namely determining red
and white cell counts, hemoglobin, hema tocrit, body weight, tumor
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volume and percent reticulocytes. The most significant factor determined
from these other studies was the reticulocyte count.
37. A method was devised for the transplantation of the Walker 256 Carcinosarcoma.
3 8. ALAD enzyme activity was localized to the red blood cell.
39. The growing tumor becomes slightly palpable at 4 days after transplantation and increases to a maximum of 111, 000 cubic millimeters at 16
days after which the tumor becomes inaccurate to measure.
40.

Immediately after trij.'rtsplantation and 4 days before the transplanted
tumor becomes palpabl\, ALAD activity increases over control values
as well as does the reticulocyte count.

41. ALAD activity increased 117 percent over control within 24 hours after
transplantation and rose to 619 percent by day 4, the first day of palpable
tumor growth, to l, 440 percent by day 16, the last day to measure the
tumor accurately, rising to 2, 000 percent over control on day 20, the final
day of the experiment.
42. The reticulocyte count increased 70 percent over control within 24 hours
and rose to 387 percent by day 4, to l, 822 percent by day 16 rising to 2, 30)
percent over control on day 20 after transplantation.
43. Two things are noted about the growth of the Walker tumor in vivo:
1) the similarity and parallelism of the ALAD units curve with the percent
reticulocyte curve, and 2) the immediate and rapid elevation of these
two parameters before any growth of the tumor could be detected as
well as their persistance throughout the time of the growth of the tumor.
44. The concept of the Walker tumor excreting erythropoietin was ruled out
by the fact that at no time, from the moment of transplantation to the
time of death of the tumor host, did the red cell count increase nor did
the hemoglobin or hematocrit levels. All of these factors decreased with
onset of tumor growth and continued to decrease until the animal died.
45. The interesting point is with the onset of increased ALAD activity with
concomitant reticulocytosis correlates closely with the beginning of
rapid host deterioration. An inquiry into the immediate ca,use of this
elevated enzyme and reticulocyte activity might lead to a better understanding of host responses to tumor growth.
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46. The growing tumor studies indicate a positive correlation in the tumor
host between ALAD activity and reticulocytosis.
4 7. A method was developed to isolate cell-free water extracts of the Walker
tumor and of normal liver of the rat. These cell-free extracts were
lyophilized and stored in a dark freezer.
48. A single intra-cardiac injection of 100 mg/kg of the lyophilized Walker
tumor extract resulted in the reticulocyte count being elevated, reaching
the highest value of 12 percent on day 2 after injection while ALAD
activity reached its highest level at day 8 with 13 units of activity.
Both of thes·e parameters returned to normal values by the 20th day of
the experiment.
49. In the lyophilized cell-free tumor extract experiments the body weight,
red and white cell counts as well as the hemoglobin and hematocrit
remain relatively stable and constant with a slight depression in the red
cell count. The increase in ALAD units and reticulocyte percent remain
the only significant parameters affected by the tumor extract.
50. Data from the experiments utilizing lyophilized cell-free water extracts
of normal rat liver indicate there is no change in any of the seven
parameters studied for the 20 days of the experiment.
51.

The immediate and unique elevation of ALAD activity in parallel with
reticulocyte formation before tumor growth becomes palpable suggests an
early tumor- host relationship that may be unique in the early detection
of neoplastic disease.

52. A study to determine if pre-treatment of rats with 100 mg/kg of the lyophilized cell-free water soluble tumor extract would in some way facilitate
or inhibit growth of a transplanted subcutaneous growing Walker tumor
was undertaken. For control purposes a lyophilized cell-free water
soluble extract of normal rat liver was employed. After transplantation,
the volume of the growing subcutaneous tumor was determined on alternate days until the tumor could not be accurately measured or until the
animal died.
53. The data indicates that pre-treatment of the animals with lyophilized
cell-free extracts of the Walker tumor does facilitate the growth of the
subcutaneous growing tumor. On the sixth day after transplantation,
the tumor extract pre-treated animals had a 200 percent increase in tumor
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votme over control. This percentage increased to 29 5 percent by day 12,

54. In contrast, the liver extract pre-treated animals showed very minimal
percent increase in tumor volume over control untreated rats. The
maximum percent of increase in tumor volume was observed on day 10
with a 73 percent increase but this peak in tumor volume was lost by
day 12 when the control tumor volume almost equaled the liver extract
pre-treated animals.
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Figure l
Metabolic fate of ALA: Shemin and Russell (1953) postulated a succinateglycine cycle through which ALA can be oxidized back to succinic acid and
this oxidation would thus provide a pathway for glycine oxidation.

The

first step of this cycle is the deamination of ALA to a-ketoglutaraldehyde
which then releases the ALA-carbon derived from glycine to form succinate.
The ALA-carbon derived from glycine provides the a-carbon a tom to ureido
groups of purines,

the a-carbon atom of serine, the methyl group of methion-

ine, and forms formic acid (She min et al., 195 5).
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Figure 1
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Figure 2
Mechanism of delta-aminolevulinic acid (ALA) accumulation in lead
poisoning: This figure presents, in diagrammatic form, the synthesis of
ALA from glycine plus succinyl-CoAcatalyzed by the rate limiting enzyme of
heme synthesis, ALA synthetase.

The diagram shows the inhibition, by lead,

of ALA dehydrase with the accumulation of ALA resulting from such an
inhibition.

Under normal circumstances, ALA dehydrase catalyzes the

con de nsa ti on of two molecules of ALA to form one molecule of PBG which
then goes on to complete the heme synthetic pathway.
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MECHANISM OF DELTA-AMINOLEVULINIC ACID !ALAI ACCUMULATION IN LEAD POISONING
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Lead poisoning test simple, rapid.

Figure 2

I. Amer.
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Figure 3
Commercially available one-column urinary ALA test for screening
children suspected of being exposed to lead.
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Figure 3
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Fi;ure

4

Individual steps of the test procedure for the rapid analysis of urinary
ALA employing prefilled, dual disposable plastic chromatography columns
arranged in piggyback fashion.
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EFFECT OF SINGLE INTRA-CARDIAC INJECTION OF A WATERSOLUBLE NORMAL LIVER EXTRACT ON THE PERIPHERAL RETICULOCYTE SMEAR*
'

Water-Soluble-Normal-LiverExtract- Injected Animal
Day 2
Depicting 2 Reticulocytes
in the Field (640 X)

Control Animal
Day 0
Depicting 1 Reticulocyte
in the Field (640 X)

Water-Soluble-Normal- LiverExtract- Injected Animal
Day 20
Depicting 1 Reticulocyte
in the Field (640 X)
*Reticulocytes stained with New Methylene Blue-N
Figure 7
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Figure 8
Biosynthesis of Heme: The general scheme of the biosynthesis of heme
whereby Ac =acetate, Pr = propionic acid, and Vi = vinyl.
are required to form one mole of PBG.
uroporphyrinogen.

Two moles of ALA

Four moles of PBG are required to form

In this figure the acetic and prop ionic acid side chains on

uroporphyrinogen III are shown as Ac and Pr. Coproporphyrinogen III results
when the four Ac side chains of uroporphyrinogen III are decarboxyla ted to
yield methyl (CH ) groups.
3

Oxidation and decarboxylation of two of the Pr

groups of coproporphyrinogen III to vinyl groups yields protoporphyrin-9.
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Coulter Counter Coincidence Correction Chart
Count loss due to coincident passage of cells is a function of aperture volume and
:cell concentration • This chart is for use with a 100 micron aperture only and covers
. cell concentrations from 10,300 per ~l to 109,600 per ~1. Only the first three sig·nificant numbers are shown.
If the counters record a count of 26,000, locate 260 on the chart, read the
! Example:
. number in the adjacent column and r-ecord the true count as 27,800 cells per 12rol •
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Figure 10
Conversion Chart for Percent Transmission into Grams Percent Hemoglobin
by the Method of Drabkins: To use this chart one determines the percent
transmission of the reaction mixture at 540 nm using a 13 x 100 cuvette.

One

reads the percent transmission down and across to obtain the grams percent
hemoglobin in the appropriate box.

For example: 35% T

= 15 gm% Hgb.
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Chart 1
Composite chart of three standard calibration curves based on the onecolumn ALA analysis.

The ALA standard curve was prepared in lM sodium

acetate as described in chapter II.

The ALA standard curve prepared in

normal urine used urine, at pH 5. 0, in place of sodium acetate. An
aliquot of the urine representing 1, 5, 10, 20, 30 and 50µg ALA, respectively,
was pipetteted onto individual one-column units.

The ALA was eluted off

with IM sodium acetate and analysis for ALA minus the endogenous urinary
"

ALA proceeded as described in Chapter II.

The ALA standard curve prepared

in water substituted 7.0 ml of pH 4.5 water for the sodium acetate normally
utilized in the pre para ti on of the ALA standard calibration curve. Aliquots
representing l, 5, 10, 20, 3 0 and 50µg ALA, respectively, were pipetted
onto one-column units and the elution of the ALA and analysis for it
proceeded as described in Chapter II.
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Chart 2
Visible spectrum of chromophore resulting from colorimetric analysis
of delta-aminolevulinic acid (ALA): The color curve was formed on heating,
separately, 20µg ALA· HCl and ca ti on-exchange column eluates from urine
and tissue samples of lead-poisoned rabbits with acetylacetone to form a
pyrrole. After coolL1g to room temperature, the color complex was developed
by reacting the pyrroles with DMAB in acid solution.

The reaction conditions

were as follows - The ALA· HCl curve:

20µg ALA ·HCl in 7. 0 ml lM sodium

acetate plus 0. 20 ml. acetylacetone.

The mixture was heated for 10 minutes

at 95 C, afterwhich the mixture was cooled to room temperature.

The

pyrrole was reacted with 7. 0 ml. of fresh, modified Ehrlich's reagent and
full color development was obtained in 15 minutes.

The absorption curve

was made in a Beckman DB-G spectrophotometer and the maximum wavelength of 553 nm was determined.

The column - eluate curve: The ion-

exchange columns were eluted with 7. 0 ml. of lM sodium acetate and the
procedure outlined above was followed.
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Chart 3

Stability of the color developed with modified Ehrlich's reagent for
urinary ALA: Six aliquots of the ALA · HCl stock solution were placed in
test tubes and after appropriate steps, color development was attained
with modified Ehrlich's reagent.

The optical density of each tube, corrected

for the reagent blank, was determined 15 minutes and 2 hours after the addition
of the modified Ehrlich's reagent.
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Chart 4
ALA standard calibration curve: Six aliquots of the ALA· HCl stock
solution (12.5 mg ALA·HCl dissolved in 100 ml. acetate buffer, pH 4.6)
corresponding to l, 5, 10, 20, 30, and 50µg - were pipetted into test tubes
and diluted to 7. 0 ml. with lM sodium acetate.

0. 20 ml. of acetylacetone

was added to each tube and the tubes were placed into a boiling water
bath for 10 minutes. After cooling to room temperature, 7. 0 ml. of fresh,
modified Ehrlich 1 s reagent was added to each tube.
fully within 15 minutes.

The color developed

The optical density of the color reaction was

determined, after correction for the reagent blank, at 553 nm in a spectrophotometer using a l. 0 cm cuvette.
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Chart 5
Recovery of exogenous ALA from 3M tartaric acid preserved urine:
27 Sµg ALA· HCl were added to 12. 5 ml. random urine resulting in a final
concentration of llµg ALA·HCl/O. 5 ml. urine applied to the column.

Endo-

genous ALA was subtracted in determining the amount of ALA recovered.
The preserved urine-ALA mixture was stored, in the dark, at 4 C for a period
of 28 days.

The pH was determined and analysis for urinary ALA was com-

pleted on day 0, 7, 14, 21, and 28 using dual disposable ion-exchange
column chromatography units.
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Chart 6
Visible spectrum of chromophore resulting from colorimetric analysis
of porphobilinogen (PBG): The color curve was produced by adding, separately,
30µg PBG and anion-exchange column eluates from urine and tissue samples
of lead-poisoned rabbits to DMAB in acid solution.
were as follows - the PBG curve:

The reaction conditions

30µg PBG added to 10 ml. of lN acetic

acid. After mixing, the solution was reacted with 10 ml. of fresh, modified
Ehrlich's reagent and full color development was obtained in 15 minutes.
The absorption curve was made in a Beckman DB-G spectrophotometer and
the maximum wavelength of 555 nm was determined.
curve:

The column-eluate

The ion-exchange columns were eluted with 10 ml. of lN acetic acid

and the procedure outlined above was followed.
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Chart 7
Compa-rison of the stability of modified versus unmodified Ehrlich's
reagent in PBG analysis: Two 0. 5 ml. samples from the same random urine
sample received from a patient diagnosed as having acute intermittent
porphyria were carefully pipetted onto two separate anion-exchange columns.
These urine samples were washed with 30 ml. of water and eluted with 10 ml.
of lN acetic acid.

10

\1. of modified Ehrlich's (DMAB,

PCA, acetic acid)

was added to one of the~olumn eluates while unmodified Ehrlich's (DMAB,
HCl) was added to the other eluate.

The optical density of each of the

reactions, corrected for the reagent blank, was determined at 5, 15, 30, 45,
60, 75, and 90 minutes at 555 nm using a spectrophotometer.
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Chart 8
PBG standard calibration curve:

Four aliquots of the PBG stock solution

(O. 05 ml., 0. JO tl., 0. 2 0 ml., and 0. 3 0 ml.) were pipetted into separate
test tubes.

Each was diluted to 10 ml. with lN acetic acid.

10 ml. of

modified Ehrlich's reagent was added to each tube and full color developed
in 15 minutes.

The optical density, corrected for the reagent blank, was

determined at 555 nm in a spectrophotometer.
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Chart 9
Stability of color developed with PBG and modified Ehrlich's reagent:
Four aliquots of the PBG stock solution corresponding to 5, 10, 20 and 30µg
PBG were diluted to 10 ml. with IN acetic acid.

10 ml. of modified Ehrlich's

reagent was added and full color developed in 15 minutes.

The optical

density, corrected for the reagent blank, was determined at 15 minutes and
at 90 minutes at 555 nm in a spectrophotometer.
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Chart 10
Comparison of standard curves obtained from human-extracted PBG
versus synthetic PBG: For the human-extracted PBG curve, four aliquots
of the PBG solution equaling 5, 10, 20, and 25µg were pipetted into 4
separate test tubes and were diluted to 7. 0 ml. with lN acetic acid.

7. 0

ml. of fresh, modified Ehrlich's reagent was added to each tube and full
color developed in 15 minutes.

The optical density, corrected for the reagent

blank, was determined at 5 5 5 nm using a s pee trophotometer.

For the

synthetic PBG curve aliquots from the PBG standard were analyzed as
described above and the results were compared.
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Chart 11
Effect on the stability of PBG in urine preserved with tartaric acid:
378µg PBG were added to 10

m~.

of a random urine sample resulting in a

final concentration of 18. 94µg/0. 5 ml. placed on the column.
urine - P BG mixture was stored for 2 8 days in the dark at 4 C .

The preserved
The pH

was determined and analysis for PBG was completed using disposable ionexchange column chromatography units on day 0, 7, 14, 21, and 28.
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Chart 12
Typical standard calibration curves for ALA and PBG: The ALA and PBG
curves are based on Mg% ALA and PBG in 0. SO ml. of a random urine sample.
The two curves are combined on one chart to study the interrelationships of

the two in reference to the optical denslt( Each point on these charts
represents an average of five ALA and PBG standard calibration curve determinations.
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Chart 12
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Chart 13

Urea standard calibration curve: Crystalline urea was added to 30 ml.
water to make-up standard concentrations ranging from 4 to 15 mg/30 ml.
A yellow-lemon color developed after adding 4 ml. of fresh, modified
Ehrlich's reagent to each tube containing a water-urea solution.

The

optical density was determined, corrected for a reagent blank, at 415 nm
and was plotted against mg urea to produce the standard calibration curve.
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Chart 14
Stability of color developed with urea and modified Ehrlich's reagent:
5 mg crystalline urea was dissolved in 7 .O ml. water and to this was added
2 ml. fresh, modified Ehrlich's reagent. After thorough mixing the optical
density, corrected for a reagent blank, was determined every 5 minutes up
to and including 50 minutes after adding the Ehrlich's reagent.
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Chart 15
9 5 percent confidence limits of human urinary ALA and PBG values: 100
normal medical students each donated a mid-afternoon random urine specimen
for these studies.
these studies.

0. 5 ml. aliquot of the urine specimen was utilized for

The PBG and ALA. were separated from each other by using

dual piggyback, disposable ion-exchange column chromatography units.
PBG was eluted from the anion column by 10 ml. of lN acetic acid. After
addition of 10 ml. of fresh, modified Ehrlich's reagent the PBG color chromophore' s optical density, corrected for a reagent blank, was determined at
555 nm.

The ALA was eluted from the cation column with lM sodium acetate,

heated with acetylacetone to form a pyrrole, and then had added to it
fresh, modified Ehrlich's reagent to form a color chromophore which had
its optical density determined, corrected for a reagent blank, at 553 nm.
The mean for urinary ALA WAS 0.25_±0.14 mg. percent (95% C.L. =0.54 mg%);
n = 100* anrl the mean for urinary PBG was 0 .11_±0.04 mg. percent (95% C. L.
= 0.21mg%);n=100 * .

*Figure depicts values obtainerl from forty of the 100 samples.
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Chart 16
9 5 percent confidence limits of human urinary pH and urea values:
100 normal medical students each donated a mid-afternoon random urine
specimen for these studies.

0. 5 ml. aliquot of the urine specimen was

utilized for the urinary urea studies. The dual piggyback, disposable ionexchange column chromatography units were washed with 30 ml. of water •.
The water eluate was collected and to this was added 4 ml. of fresh,
modified Ehrlich's reagent. After 15 minutes the optical density, corrected
for a reagent blank, of the lemon-yellow colored urea solution was determined
at 415 nm.

The pH was determined electronically after the urine specimen

reached room temperature (25 C) and was mixed thoroughly. The mean for
urinary pH was 6.00

.±

0.44 (95% C.L. = 6.88); n = 100* ano the mean for

*
urinaryureawas 6.97_±4.19 (95%C.L. =15.35);n=l00.

*Figure depicts values obtained from forty of the 100 samples.
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Chart 17
.Excretion of urinary ALA after injection of 200 mg/kg lead acetate via
single subcutaneous dose in adult rabbits: Random urine specimens were
collected, adjust to pH 5 with glacial acetic acid, and O. 5 ml. was analyzed
for ALA using dual disposable ion-exchange column chromatography units
(piggyback columns).

Each point on the chart represents urine specimens

from six lead-poisoned, adult New Zealand white rabbits.

Urine samples

were preserved with acetic acid by the method of Abrahams (1970).
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Chart 18
Control levels of tissue ALA:
were analyzed for tissue ALA.

21 tissues from control, adult rabbits

The cauda epididymis had the highest

concentration of tis sue ALA with 0. 53µg ALA/gm wet weight tissue.

The

least concentration was found in adipose tissue with less than 0. 03µg
ALA/gm.

Each point on the chart represents six control adult New Zealand

white rabbits.

The average concentration of tis sue ALA was 0. 2 0 .± 0. 0 6 µ

gram/gram wet weight.
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Chart 19
µg ALA/gm wet weight tissue in adult lead-poisoned rabbits given single
subcutaneous injection of 200 mg/kg lead acetate: Four tissues were
studied at 20 and 58 days post-injection - the bone marrow, kidney, spleen,
and liver - to determine the effect of lead poisoning.

The tissue ALA

4

concentration was determined utilizing dual piggyback disposable ionexchange column chromatography units.

Each point on the graph represents

an average of six adult lead-poisoned New Zealand white rabbits.
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Chart 20
Levels of ALA in tissues 58 days after a single subcutaneous injection
of 200 mg/kg lead acetate into adult rabbits:
ALA 58 days post-injection of lead acetate.

21 tissues were analyzed for
The bone marrow accumulated

25µg ALA/gm wet weight while the kidney accumulated 10. 8µg ALA.

The

other 19 tissues ranged from an ALA level of 1. 8µg ALA for the spleen down
to 0. 02µg ALA/gm wet weight tissue for adipose tissue.

Each point on the

graph represents an average of six lead-poisoned adult New Zealand white
rabbits.

The average concentration of tis sue ALA for the bone marrow and

kidney was 17. 78

..± 1. 43

µ gram/gram wet weight.

The average concentration

of tissue ALA for all other tis sues was 0. 5 2 .± 0. 06 µ gram/gram wet weight.
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Chart 21
Comparison of lead induced ALA accumulation in tis sues 58 days after
a single subcutaneous injection of 200 mg/kg lead acetate into adult rabbits.
21 tissues were studied for lead induced accumulation of ALA.

The ordinate

represents a ratio of the µg ALA/gm wet weight of lead-poisoned animal over
µg ALA/gm wet weight of control animal.

The highest ratio, approaching 100

occurred with the bone marrow followed by the kidney and the lung at 2 8 and
22, respectively.

The other 18 tissues ranged from less than 8 (heart)

down to l (adipose tissue).

The ALA concentration was determined by using

dual disposable, ion-exchange column chromatography units (piggyback
columns).

Each point on the chart represents an average of six lead-

poisoned adult, New Zealand white rabbits.
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Chart 22
Tissue ALA levels 20 days after single subcutaneous injection of lead
acetate into adult rabbits.

Four tissues - bone marrow, kidney, spleen, and

liver - were analyzed for ALA in rabbits injected with either 200, 400, or
800 mg/kg lead acetate. The µg ALA/gm wet weight of tissue increased as
the dose of lead acetate increased in the bone marrow and the kidney while
there was no effect on the spleen or liver.

Each point on the chart represents

an average of six animals for the 200 mg dose and an average of three leadpoisoned adult, New Zealand white rabbits for the 400 and 800 mg/kg dose.
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Chart 23
Single intraperitoneal injection of 15 mg/kg lead acetate into adult
rats: Two parameters -- ALAD enzyme activity and excretion of urinary
ALA -- represented by the left and right ordinates, respectively, were studied.
150µL of whole blood was utilized for the enzyme experiments while 0. 50
ml. of a random urine sample, adjusted to pH 5 with acetic acid, was
used for the ALA determinations.
average of three adult, male

Each point on the chart represents an
I

Sprague-~ley

rats.
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Chart 24
Effect of tumor growth on reticulocyte count and ALAD activity in adult
rats bearing the Walker 256 Carcinosarcoma: Cell suspensions of the Walker
tumor were transplanted into adult, male Sprague-Dawley rats.
of the tumor was determined by measuring it in 3 dimensions.

The growth
This data is

recorded by the left ordinat;or the enzyme assay 150µ1 of whole blood
was drawn from the tail vein on alternate days up to and including day 20
and is represented by the right ordinate. The reticulocytes were stained
with New Methylene Blue N and 10 fields of 100 red cells per field were
counted so that the number of reticulated red cells per thousand red cells
could be expressed in a percentage.

This data is recorded on the second

ordinate on the right.

The abscissa represents days after transplantation

of the Walker tumor.

Each point on the chart represents an average of six

tumor bearing Sprague-Dawley rats.
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Chart 25
Percent increase in reticulocyte count and ALAD activity over control
in rats bearing the Walker tumor: ALAD enzyme activity and reticulocyte
counts were determined as previously described.

The percent increase in

reticulocyte count is represented by the left ordinate and the percent
increase in enzyme activity is shown by the right ordinate.
is days after transplantation of the Walker tumor.

The abscissa

Each point on the chart

represents an average of six tumor bearing Sprague-Dawley rats.
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Chart 26
Effect of a growing subcutaneous tumor on the host: This chart is
divided into 4 smaller charts -- all with the same abscissa -- days after
transplantation of the Walker tumor.

The top graph compares tumor volume

to body weight; the next chart shows the parallel relationship of ALAD
enzyme activity to percent reticulocytes.

The third chart demonstrates the

falling red cell count with the increased white blood cell count and the
bottom chart shows the parallel decline in hemoglobin and hematocrit in
rel a ti on ship to the gro·;ving subcutaneous Walker tumor.
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Chart 27
Effect of a single cardiac injection of 100 mg/kg of 105, 000 x g unheated
cell-free, lyophilized protein from a water-soluble extract of the Walker
tumor: Reticulocyte counts and enzyme activity were determined as previously
described.

The left ordinate represents enzyme activity while the right

ordinate represents percent reticulocytes.
injection of the lyophilized protein.

The abscissa is days after

Each point on the chart represents

an average of six animals injected with the water-soluble extract of the
tumor.
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WATER-SOLUBLE EXTRACT
effect of single cardiac injection of 100mg/kg
of 105,000 x g unheated, lyophilized protein
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Chart 28
Effect of 105, 000 x g unheated cell-free, lyophilized protein from a
water-soluble extract of the Walker tumor: This chart is divided into 4
charts -- all with the same abscissa -- days after injection of the watersoluble extract of the Walker tumor.

The top chart records the body weight

of the animal while the next chart depicts the parallel rise and fall of ALAD
enzyme activity and percent reticulocytes.

The third chart represents the

effect the water-soluble injection had upon the red and white blood cell
counts while the bottom chart demonstrates the slight effect the tumor
extract had upon the hemoglobin and hematocrit.

Each point on the chart

represents six animals injected with the water-soluble extract of the Walker
tumor.
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105,000 x g unheated, lyophillzed protein
Dose: 100 mg/kg via single cardiac puncture
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Chart 29
Effect of 100 mg/kg single cardiac injection of 105, 000 x g unheated
cell-free lyophilized protein from water-soluble extracts of normal rat
liver: This chart is divided into 4, each chart having the same abscissa -days after injection of the water-soluble liver extract.

The top chart

shows the body weight of the injected rat while the next chart shows the
relationship of enzyme activity to percent reticulocytes.

The third chart

demonstrates the effect on red and white blood cell counts while the bottom
chart represents the effect the normal liver extract had upon hemoglobin
and hematocrit.

Each point on the chart represents an average of six

animals injected with the normal liver extract.
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NORMAL LIVER
WATER-SOLUBLE EXTRACT
105,000 x g unheated, lyophilized protein
Dose:

100 mg/kg via single cardiac puncture
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Chart 30
Comparison of the effect of a single cardiac injection of 100 mg/kg of
105, 000 x g unheated cell-free lyophilized protein from the Walker tumor
extract and from normal liver extract: ALAD enzyme activity and reticulocyte
counts were determined in animals injected with tumor extracts or liver
extracts and the data is compared on this chart. The enzyme activity is
represented by the left ordinate and reticulocyte percent is represented by
the right ordinate while the abscissa is days after injection of the tumor
or liver extract.
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WATER-SOLUBLE EXTRACT
comparison of the effect of a single cardiac
injection of 100 mg1kg of 105,000 x g unheated,
lyophi Ii zed protein from the Walker tumor
extract and from normal liver extract
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Chart 31
Percent increase in tumor volume in animals pre-treated with water
soluble extracts of the Walker tumor or normal liver: Each point on the chart
represents an average of three animals that were pretreated with either water
extracts of the tumor or normal liver. The animals were given the watersoluble extracts and for a period of 20 days after injection had enzyme,
reticulocyte counts, and basic hematology studies performed upon them.
At the conclusion of this experiment, 0. 5 ml. cell suspension of a fresh
7 day old Walker tumor was transplanted to the experimental pretreated
rats.

For control, litter mates of the experimental animals were transplanted

with the same tumor cell suspension. The growth of the tumor was determined
by measuring its volume. The difference in size of the tumor in animals
pretreated was observed and serves as the ordinate on the chart -- percent
increase in tumor volume -- while the abscissa is days after transplantation
of the Walker tumor.
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ANIMALS PRE-TREATED WITH WATER- SOLUBLE
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CHAPTER VIII

TABLES

Table 1

EFFECT OF VARYING THE MESH SIZE OF THE CATION
RESIN IN THE ONE-COLUMN URINARY ALA ANALYSIS
Dual Pigqyback Column Control
Optical Density 553 nm
AG50W-X4~ 100-200 Mesh

One-Column
Optical Density 553 nm
AG50W-X4~ 100-200 Mesh

One-Column
Optical Density 553 nm
AG50W-X4~ 50-100 Mesh

pH

Type Of
Specimen

R.A.

6.0

Normal

0.009

0.008

0.000

G. L.

5.0

Normal

0.030

0. 031

0.010

R.B.

4.5

Norma 1

0.010

0.009

0.000

R.B.

4.5

Normal +
10 µg ALA.HCl

0.270

o. 271

0. 120

12791

5.0

Industrialb
Low ALA

0. 061

0.058

0.020

12785

6.0

Industrialb
Medium Low ALA

0.170

0. 169

0.079

12774

6.3

Industrialb
Medium High ALA

0.429

0.425

0. 105

12916

6.0

Industrialb
Very High ALA

0.660

0.657

0.270

Specimen

a. Analytical grade cation exchanqe resin, hydrogen ionic form, Bio-Rad Corp., Richmond, California.
b. Industrial urines supplied through courtesy of automotive industry.

N
<.D
~
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Table 2

COMPARISON OF THE DUAL PIGGYBACK COLUMN AND ONE-COLUMN
METHODS FOR DETERMINATION OF URINARY ALA

Sample

Piggyback Columna
Optical Density
553 nm

One-Columnb
(4.0 x 0.6 cm bed resin)
Optical Density 553 nm

One-ColumnC
(2.0 x 0.6 cm bed resin)
Optical Density 553 nm

Norma 1 Uri ned
(No ALA Added)

0.044

0.041

0.044

Normal Urine
1 µg ALA Addede

0.052

0.043

0.050

Normal Urine
5 µg ALA Addede

0.185

o. 169

o. 186

Normal Urine
10 µg ALA Addede

0.379

0.349

0.380

Normal Urine
20 µg ALA Addede

0.660

0.659

0.660

Normal Urine
30 µg ALA Addede

0.990

0.845

0.980

Normal Urine
50 µg ALA Addede

1. 490

1. 500

1. 500

a. Commercial dual piggyback column, AG50W-X4 analytical grade resin, 100-200
mesh, H+ ionic form, Bio-Rad Corp., Richmond, California.
b. One-column unit, 4.0 x 0.6 cm bed resin, AG50W-X4, 100-200 mesh, H+ ionic
form.
c. One-column unit, ~O x 0.6 cm bed resin, AG50W-X4, 100-200 mesh, H+ ionic
form.
d. Normal random urine, pH adjusted to 5.0.
e. ALA.HCl added to urine specimen so that 0.50 ml urine would contain l, 5,
10, 20, 30 or 50 µg ALA.

Table 4

COMPARISON OF DUAL PIGGYBACK COLUMN VERSUS ONE-COLUMN METHOD
FOR ~ETERMINATION OF ALA ADDED TO NORMAL URINE
A.
ALA Added
{µg)

B.
Endogenous
ALA {µq)

ALA Recovered
One-Column Methoda
µg
% Recovered

ALA Recovered
Pigqyback Methodb
µg
%Recovered

5.20

0.20

5

4.9

98

5

5.20

0.20

5

4.8

96

4.5

90

10.20

0.20

10

10.0

100

10. 3

103

10.20

0.20

10

9.8

98

9. 1

91

20.20

0.20

20

18.8

94

19

95

20.20

0.20

20

19.0

95

18. 5

93

30.20

0.20

30

27.4

91

27.7

92

30.20

0.20

30

28.0

93

27.4

91

40.20

0.20

40

36.5

91

36

90

40.20

0.20

40

36.0

90

36.3

90

ALA To Be
Recovered (A-B)

100

a. Column size 2.0 x 0.6 cm bed resin, AG50W-X4, 100-200 mesh, H+ ionic form.
b. Commercially available piggyback column.

N

c.o
'1

Table

5

EFFECT OF STORAGE OF RANDOM URINE SPECIMENS PRESERVED
WITH TARTARIC ACID ON THE STABILITY OF URINARY ALA
COMPARISON OF DUAL PIGGYBACK COLUMN TO ONE-COLUMN ALA METHOD
DAY 0

DAY 7

Optical Density
OpticJl Density
553 nm
553 nm
Piggyback Column (P.BJC One Column (O.C.)d

0. D.
(P.B:)

0. D.
(0. c.)

DAY 14
0. D.
(P. B.)

0. D.
(0. c.)

DAY 28

DAY 21
0. D.
(P. B.)

O.D.
(0. c.)

0. D.
( p. B. )

0
(0

Jri ne Preserved
lith 3 MTartarica

0.460
( 11. 85) .

0.459
(11.81)

0.445 0.450
( 11. 53) ( 11. 60)

0.450 0.449
( 11. 60) ( 11. 59)

0.440 0.443
( 11. 35) (11. 50)

0.430 0.
(11.10) (11

Jri ne Preserved
lith Glacial Acetica,b

0.462
( 11. 87)

0.460
( 11. 85)

0.450 0.452
(11. 60) (11.63)

0.425 0.430
( 10. 90) ( 11 . 10)

0.435 0.425
(11.25) (10.90)

0.410 o.
( 10. 50) ( 10

) = µg ALA recovered.
t.

10 ml of fresh random urine, 260 µg ALA.HCl added to 10 ml urine, final concentration
pH 8.3 before being added to preservative.

>.

0.10 ml glacial acetic added to 10 ml random urine.

= 13 µg ALA/0.50 ml, adjusted to

Commercial piggyback column.

L 2.0 x 0.6 cm bed resin column, AG50W-X4, 100-200 mesh, H+ ionic form.
N

c.o
co

Table 6

EFFECT OF INCREASING THE VOLUME OF WATER TO WASH NORMAL
URINARY UREA THROUGH THE ONE-COLUMN IN THE ALA DETERMINATION
UREA DATA
Volume of Water Op ti cal Density
Passed Throuqh
Urea+ Ehrlich's
415 nmC
Th2 Column (~

ALA COLUMN DATA
0.D. ALA Pyrrole
553 nm

µg ALA
Recovered

Recovery
%

Pigg~back

Columna:
5 µg ALA in 0.5 ml urine

30

0.025

0. 161

4.50

90

One-Columnb:
5 µg ALA in 0.5 ml urine

21

0.085

0.167

4.75

92

5 µg ALA in 0.5 ml urine

28

0.037

0.158

4.45

87

5 µg ALA in 0.5 ml urine

30

0.017

4.45

87

5 µg ALA in 0.5 ml urine

35

0.013

o. 158
o. 157

4.45

87

a. Commercial piggyback column, washed with 30 ml distilled water as directed in the ALA kit.
b. 2.0 x 0.6 cm resin bed size, AG50W-X4, 100-200 mesh, H+ ionic form.
c. Urea 0.D. determined using DB-G spectrophotometer. The O.D. of the eluted ALA (converted
to a pyrrole) and any remaining urea washed from the column with the ALA elution was determined when reacted with modified Ehrlich's reagent.
N
lD
lD

Table 7

STANDARD CALIBRATION CURVE FOR ALA, PREPARED ACCORDING TO THE DIRECTIONS
FOR PERFORMING THE SIMPLIFIED, ONE-COLUMN TEST FOR URINARY ALA
Trial #1
One Test Tube Data

Trial #2
One Test Tube Data

Trial #3
One Test Tube Data

0. D.
553 nm

O.D.
553 nm

0. D.
553 nm

0.031

0. 031

0.035

0.032

5 µg

0.180

0. 190

0.189

o. 186

10 µg

0.405

0.400

0.400

0.401

20 µg

0.799

0.800

0.800

0.799

30 µg

1. 100

1. 100

1. 280

1. 160

50 µg

1. 500

1. 500

1. 500

1. 500

µg ALA
1 µg

/

Average O.D.
For Three Trials

w
0
0

Table 8

STANDARD CALIBRATION CURVE FOR ALA PREPARED IN NORMAL URINE*
THROUGH THE ONE COLUMN TEST FOR URINARY ALA
Trial #1

Trial #2

One Column Data

One Column Data

------~--

µg ALA
Applied To
Column/0.50 ml Urine

----

Trial #3
-·-

One Co 1- umn Data

~

-

---·

-···-

--· ·-

O.D.**
553 nm

O.D.**
553 nm

O.D.**
553 nm

Averaqe O.D.
For Three Trials

0.029

0.026

0.026

0.027

o. 163

0. 161

o. 160

o. 161

10 µg

0.343

0.346

0.340

0.343

20 µg

0.704

0.700

0.701

0. 701

30 µg

1. 249

1. 100

1. 111

1. 155

50 µg

1.505

1. 505

l. 505

1.505

l µg
5 µg

/

* Normal random urine adjusted to pH 5.0 before ALA added.
** Endogenous urinary ALA subtracted from experimentally recovered ALA added to urine
specimen.
Note:

Average 0.D. for normal urinary ALA content was 0.048.

w
0

......

Table 9

STANDARD CALIBRATION CURVE FOR ALA PREPARED IN WATER*
THROUGH THE ONE COLUMN TEST FOR URINARY ALA
Trial #2

Trial #3

One Column Data

One Column Data

One Column Data
Average O.D.
For Three Trials

0. D.
553 nm

0. D.
553 nm

O.D.
553 nm

1 µg

0.025

0.025

0.025

0.025

5 µg

0.170

o. 161')

0.155

o. 161

10 µg

0.350

0.347

0.347

0.347

20 µg

0.666

0.666

0.660

0.664

30 µg

1. 100

1. 100

1. 100

1. 100

50 µg

1 . 50()

1. 500

1. 500

1. 500

µg ALA
AeElied To Column

~

Trial #1

*Distilled water pH adjusted to 5.0 before ALA added.

w
0
N
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Table 10

EFFECT OF URINE pH ON RECOVERY OF ALA FROM COLUMNSt
Optical Density At 553 nm*
Urine Adjusted
With HCl or NaOH

Urine Adjusted
With HCl or NH40H

Urine Adjusted
With HCl or Na2C03

1. 0

0.250

0.271

0. 241

2.0

0.245

0.289

0.252

3.0

0.232

0.260

0.256

4.0

0.249

0.273

0.230

5.0

0.225

0.260

0.230

6.0

0.232

0.240

0.228

7.0

0.210

0.225

0.212

8.0

0.188

o. 161

0.200

9.0

o. 127

0.022

0.095

pH

* 0.20 ml (lOOµq) of ALA.HCl was added to each of 9 test
tubes. 9.80 ml of normal urine, adjusted to the pH
indicated was added and mixed well. The pH of each
tube was checked before a 0.50 ml aliquot of udne was
added to individual piqqyback columns. The optical
density of the eluted ALA was determined at 553 nm.

t Abrahams, R.H.
Chicago, 1970.

Ph.D. Dissertation, Loyola University of

(
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Table 11

INTERPRETATION OF URINARY ALA LEVELS IN T~RMS
OF THEIR RELATIONSHIP TO LEAD EXPOSURE
Urinary ALA Range
(mg/100 ml)

Urinary ALA
Code

Relationship To
Lead Exposure*

0.00-0.99

Normal

None

l. 00- l. 49

l+

Moderate

1. 50-1. 99

2+

Heavy

2.00-2.99

3+

Severe

3:00-5.99

4+

Critical

6.00-10.00

5+

Overwhelming

*Terms employed were arbitrarily selected.
t Abrahams, R.H. Ph.D. Dissertation, Loyola University
of Chicaqo, 1970.
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Table 12

EFFECT ON pH OF URINE PRESERVED WITH
3 MOXALIC, BORIC, CITRIC, OR TARTARIC ACID
Urine ~He
0 Hours

12 Hoursa

24 Hoursa

1. Oxalic Acidb

4.20

4.20
(Very Cloudy)

4.20
(Heavy Precipitate)

2. Boric Acidb

8.30

**

**

3. Citric Acidb

3.00

3.70
(Cloudy)

3.80
(Heavy Precipitate)

4.30

4.30

Sample

4. Tartaric Acidb 4.30

** pH not further determined due to initial pH of urine sample
being above the maximum allowable for recovery of urinary
ALA.

a. Urine samples stored at 4°C, in the dark.
b. 10 ml normal urine adjusted with Na2C03 to pH 9.0 before
being added to 15 ml screw-capped bottle containing 0.20
ml of the indicated 3 Mpreservative.
c. pH determined electronically at 23°C.

\

Table lJ

EFFECT OF 3 MTARTARIC ACID ON THE pH OF RANDOM
URINE SPECIMENS STORED AT 4°C IN THE DARK

Urine
Sample

Initi a1 pH
Of Urine
~)pecimena

Urine pH After
Adjusting ~ith
1 MNa2C03

Urine pH After
pH of Urine
Adding To PresSpecimend
ervative (Day O)d (Day 14)

pH of Urine
Specimend
(Day 28)

Normal Urine
(No Preservative)

6.0

**

**

6.95

7.01

Normal Urine
Preserved with 0.10
ml tartaric acid

6.0

8.30

5.60

6.30

6.40

Normal Urine
Preserved with 0.20
ml tartaric acid

6.0

8.30

4.11

4.15

4. 17

Normal UrineC
Preserved with 0.10
ml glacial acetic acid

6.0

8.30

4.50

4. 51

4.60

** Urine not adjusted to pH 8.30 nor added to container with preservative, it was stored as an
unpreserved, random urine specimen at 4°C, in the dark.
a. Fresh voided normal urine,)TI"id-afternoon sample, pH determined electronically at 23°C.
b. All urine specimens were adjusted with 1 MNa2C03 (except for control) and then were added
to the bottles containing dried down 3M tartaric acid. pH determined electronically at 23°C.
c. Glacial acetic acid used as an internal control to compare current data to that obtained from
the preservation of urine as directed in the commercial ALA test kit.
d. Urine pH determined electronically at 23°C.

w
0
Q)

Table 14

EFFECT OF VARIOUS VOLUMES OF 3 MTARTARIC
ACID ON FINAL pH OF MID-AFTERNOON URINE SPECIMENS

Volume of 3 M
Tartaric Acida

pH of Urine Specimen
After Adjugtment With
1 MNa2C03

307

pH of Urine Specimen
After Adding to Bottle
Containing Tartaric Acidc

0.10 ml

9.0

5.5

0.20 ml

9.0

4.4

0.40 ml

9.0

3.4

a. Appropriate volume of 3 M tartaric acid was pipetted
into individual 15 ml glass, screw-capped bottles and
heated for 60 minutes at 75°C. This resulted in a
bottle containing a dry, clear film of tartaric acid
adhering to the walls and bottom of the bottle.
b. 12.5 ml of normal random urine was used per bottle.
c. Average pH of three experiments per volume of tartaric
acid. Urine pH determined electronically at 23°C.
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Table

15

EFFECT OF STORAGE ON RECOVERY OF ALA FROM RANDOM
URINE SPECIMENS PRESERVED WITH 3 MTARTARIC ACID
Time Of
Samplin~

(Days)

µg ALA
Recoveredd

Percent of Original
ALA Remaining
(%)

Specimenb
#1
8.0 µg ALA

0
14
28

7.8
7.6
7.4

100
97
95

Specimenc
#2
11.0 µg ALA

0
14
21
28

10.8
10.7
1o.7
10.6

1on
99
99
98

a. 12.5 ml random urine.
the dark.

ALA mixture stored at 4°C, in

b. 200 µg ALA added per 12.50 ml random urine resulting
in a final concentration of 8 µq ALA/0.50 ml urin~
applied to the dual piggyback column.
c. 275 µg ALA added per 12.50 ml random urine resulting
in a final concentration of 11 µg ALA/0.50 ml urine
applied to the dual piggyback column.
d. ALA.HCl added to normal random urine sample before
being preserved with tartaric acid. 0.50 ml aliquot
applied to the dual piggyback column and urinary ALA
was eluted off. Urinary ALA recovered minus endogenous
ALA was considered to be equal to 100% on day 0. All
subsequent determinations were compared to this 0 day
value (percent of original ALA remaining - %).
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Table 16

COMPARISON OF THE pH OF STORED RANDOM URINE SPECIMENS
PRESERVED WITH TARTARIC ACID OR GLACIAL ACETIC ACID
Time of Sampl in~
of Random Urine

pH of Tartaric
Acid breserved
Urine

pH of Glacial
Acetic Acid
Preserved Urinec

0 Days

3.87

4.39

7 Days

4.00

4.46

14 Days

3.95

4.42

21 Days

4.00

4.50

28 Days

4.00

4.50

a. Urine stored at 4°C, in the dark.
b. Initial random urine specimen adjusted to pH 8.3
with 1 MNa2C03 before being added to bottle containing urine preservative.
c. pH determined electronically at room temperature.
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Table 17

EXPECTED RESULTS USING THE MODIFIED METHOD
FOR THE DETERMINATION OF URINARY PBG

Limit of detectability of PBG in urine ........ 0.02 mg%
Sensitivity of test ........................... 0.15 µg
Variation between duplicate samples ........... ± 2%
Recovery of PBG from distilled water ..........

88%

Recovery of PBG from urine ....................

83%
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Table 18

INTERPRETATION OF URINARY PBG LEVELS IN TERMS
OF THEIR RELATIONSHIP TO PORPHYRIA
Urinary PBG Range
(mg/l 00 ml)

Urinary PBG
Code

Relationship To
Porphyri a*

0.00-0.03

Normal

None

0.04-0. 19

Trace

Slight

0.20-0.49

l+

Moderate

0. 50-1. 99

2+

Heavy

2.00-3.99

3+

Severe

4.00-5.99

4+

Critical

6.00-10.00

5+

Overwhelming

* Terms employed were arbitrarily selected.

)
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Table 19

STABILITY OF PBGa IN RANDOM UR~NE
PRESERVED WITH TARTARIC ACID
DAY
2

DAY
5

DAY
6

DAY
7

µq PBG
Recovered 14.45 13. 90 13.40 13.40 12.80 11. 6

10.7

10.4

DAY
0

% Loss From
Day Oc
0%
Urine pHd

3.20

DAY
1

4%
3.20

DAY
3

DAY
4

8%

8%

12%

20%

26%

28%

3. 15

3. 19

3.20

3.20

3.25

3.23

a. 378 µg PBG added to 10 ml random urine before urine added to
preservative. Final concentration equals 18.94 µg PBG/0.50 ml
urine applied to the dual piggyback column.
b. 0.20 ml 3 M tartaric, in 15 ml glass screw-capped bottle, dried
at 75°C for 60 minutes.
c. Calculated from the µg PBG recovered from the elution of the
dual piggyback column on day 0. Day 0 recovery is considered
to be 0% loss and all subsequent determinations were compared
to this day 0 value.
·
d. Urine pH determined e1ectron i ca 11 y at 23° C.

/
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Table 20

EFFECT OF URINE pH AND STORAGE TIME ON STABILITY
OF PBG IN RANDOM URINE SPECIMENS
DAYc

pH 5.0
0 µg PBG Recovered a 15.5

pH 6.0
16. 4

URINE ~Hb
pH 7.0
16.2

pH 8.0
15. 6

pH 9.0
16.4

1 µq PBG Recovered
%Loss From Day 0

14.6
6%

15.5
5%

15. 4
5%

15. 5
1%

16.3
1%

2 µg PBG Recovered
% Loss From Day 0

13.85
11%

14.65
11%

15.20
6%

15.40
1%

16.2
1%

3 µg PBG Recovered
% Loss From Day 0

13.1
15%

14.40
12%

14.50
10%

14. 50
7%

14. 7
10%

4 µg PBG Recovered
% Loss From Day 0

12. 9
17%

14. 40
12%

14.40
11%

14.00
10%

14. 40
12%

5 µg PBG Recovered
% Loss From Day 0

10.9
30%

12.9
21%

12.9
20%

13.4
14%

13.7
16%

6 µg PBG Recovered
% Loss From Day 0

10.0
35%

12. 65
23%

12.80
21%

12.80
21%

12.65
23%

7 µg PBG Recovered
% Loss From Day 0

10.0
35%

12. 65
23%

12. 65
22%

12.65
19%

12.70
23%

a. 18.94 µg PBG/0.50 ml urine anplied to dual piggyback column, µq
recovered is the PBG eluted from the piggyback column unit and is
considered to be 0% loss on day 0.
b. pH adjusted with acetic acid or Na 2co 3 and determined electronically
at 23°C.
c. Urine stored at 4°C, in the dark.

--------

RECOMMENDED PROCEDURE FOR COLIECTION AND STORAGF. OF RANDOM
URINE SAMPLES FOR THE DETECTION OF I.EAD POISONING (URINARY
ALA) AND PROPHYRIA (URINARY PBG)
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FOR PBG SAMPLES TO BE ANALYZED WITHIN 24 HOURS OF URINE COLLECTION

TIME~.~ALA CAN BE ANALYZED FOLLOWING THESE DIRECTIONS, UP TO A

PERIOD OF FOUR MONTHS
1.

Collect a random urine sample. Note1 It is advisable not to
use the first voided morning specimen, late evening specimens
after 8100 pm, or specimens obtained following excessive
fluid intake.

2.

Add approximately 10 ml of the random urine sample to the
bottle containing the dried layer of tartaric acid, replace
the cap and gently mix.

J. Place the bottle in a dark refrigerator or freezer as soon as
possible up to 8 hours after collection. The urinary ALA
content of samples stored in a dark refrigerator will remain
constant up to 4 months while urinary PBG stored in the acid
urine, in a dark refrigerator, will remain constant for a
period of 24 hours. Frozen urinary ALA samples will remain
constant up to a year while frozen PBG samples, in acid urine,
will remain stable for a month.
FOR PEG SAMPLES TO BE ANALYZED WITHIN 72 HOURS AFI'ER URINE COLLECTION*
1.

Collect a random urine sample as directed above in direction #1.

2.

Add approximately 10 ml of the random urine sample to the amber
15 ml screwcapped bottle. Carefully add powdered anhydrous,
sodium carbonate (Na2C03) to raise the pH to approximately 8.o.
One can easily acco;npllsh this pH adjustment by checking the
changing pH with each addition of Na2C01 with pHydrion paper.
(Micro Essential Laboratory, Inc., Brooklyn, N.Y.)

J. Place the bottle in a dark refrigerator or freezer as soon as
possible, after collection and pH adjustment, up to 8 hours after
urine collection. The refrigerated urinary PEG will remain
constant up to 72 hours while frozen urinary ?BG in alkaline
urine will remain constant in the dark up to 8 months.
4.

When removed from storage just prior to performing the PBG analysis,
the urine in the screwcapped bottle should be gently shaken to
provide a homogenous sample from which to pipet the 0.50 ml aliquot
required for the urinary PBG determination.

*

Since urinary ALA is unstable at pH 8.0, this method of sample
collection designed for the preservation of urinary PEG for
72 hours does not permit the measurement of urinary ALA in the
urine specimen to which sodium carbonate has been added.

Optical Density
555 nm

(

Mg % Mg
ALAa
PBG

S

Optical Density
555 nm

Mg % Mg ~
ALAa
PBG

0.010

0.03

0.11

0. 140

0.70

2.47

0.020

0.08

0.28

0.150

0.75

2.65

0.030

o. 13

0.46

0.160

0.80

2.82

0.040

0.20

0. 71

0. 170

0.85

3.00

0.050

0.25

0.88

0.180

0.90

2. 18

0.060

0.30

1. 06

0.190

0.95

3.35

0.070

0.35

1. 24

0.200

1. 00

3.53

0.080

0.40

1. 41

0.220

1. 12

3.95

0.090

0.45

1. 59

0.240

1. 22

4. 31

0. 100

0.50

1. 77

0.260

1. 32

4.66

o. 120

0.60

2. 12

0.280

1. 42

5.01

0.130

0.65

2.29

0.300

1. 52

4.37

a. Mg % ALA per 14.2 ml final reaction volume.
b. Mg % PBG per 20.0 ml final reaction volume.

* To convert mg % ALA to mg % PBG, multiply mg % ALA (determined

from ALA standard calibration curve) by 3.53. Therefore, mg %
PBG =mg % ALA x 3.53.
To use this table, one determines the O.D. at 555 nm of the PBG
sample and reads the corresponding value from the column headed
mg % PBG.

w
.......
C.11
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Table 23

METHOD TO DETERMINE URINARY UREA

0.50 ml
RANDOM URINE SAMPLE
Apply to the top column
of a dual piggyback column
unit.
WASH COLUMN UNIT
WITH 30 ml WATER

30 ml WATER
ELUATE
Add 4.0 ml fresh, modified
Ehrlich's reagent and mix
well.
Allow for full color
development (15 minutes).
LEMON-YELLOW SOLUTION
Determine O.D. at 415 nm in
a standard laboratory colorimeter against a reagent blank.
QUANTITATE UREA
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METHOD FOR DETERMINATION OF TISSUE LEVELS OF DELTA-AMINOLEVULINIC ACID (ALA)
I om tissue

!

homogenize in 9 ml of cold 0.001 N HAc

HOMOGENATE
add 0.1 ml of 5 % TCA, miK and let stand for 10 min, and
centrifuge at 600 K o for 20 min at roam temperature

PRECIPITATE

SUPERNATANT

/'

wash twice with 2 ml of
0. 001 N HAc and centrifuge
at 600KO for 10 min
/

1

·
WASH-

combine

/

/

/

l

l

C0
2
3
and freeze overnight in the dark

FROZEN SUPERNATANT
defrost in a 45 C water bath and mix
DEFROSTED SUPERNATANT
heat in a 45 C water bath for 5 min, cool
to room temperature and then centrifuge
at 600 x o for 20 min

*

PRECIPITATE
wash twice with
2 ml distilled H 2 o
and centrifuge
I
WASH- _

adjust to pH 5.0 with solid Na

c~mbine _ J

1
/

SUPERNATANT
I add to lop column of tandem
dual column chromatography unit
analyze for ALA

+

(DAVIS, J.R. !! al., Arch Environ Health,
17: 164, 1968)

Table

co
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r-1
CV)

METHOD FOR DETERMINATION OF TISSUE BLANK IN THE DELTA-AMINOLEVULINIC ACID (ALA) ANALYSIS

ELUTED SAMPLE FROM THE CATION COLUMN

~

(From the addition of combined supernatants
to the tandem dual column chromatography unit)

7.0 ml of ELUATE
I

Divide into two 3,0 ml fractions

+

TISSUE BLANK
Add 3.0 ml of fresh Ehrlich's
reagent.
Determine optical density at 553 mµ
after 15 minutes, reading the sample
against a distilled water blank.

•

ALA DETERMINATION
Add 0.10 ml acetylacetone.
Boil in a water bath for 10
minutes, cool to room temperature.
Add 3.0 ml of fresh Ehrlich's
reagent.
Determine optical density at
553 mp after 15 minutes,
reading the sample against a
distilled water blank.

O'>
r-1

M

Table 26

RECOVERY OF DELTA-AMINOLEVULINIC ACID (ALA) FROM RAT LIVER

Sample

pg Endogenous
ALA

Total µg
ALA Expected

Total µg
ALA Recovered

1.0 gm liver
plus 2.50 µg ALA

0.07

2.57

2.34

91

1.0 gm liver
plus 5.00 µg ALA

0.07

5.07

4.66

92

1.0 gm liver
plus 10.00 pg ALA

0.07

10.07

9.26

92

1.0 gm liver
plus 20.00 pg ALA

0.07

20.07

18.46

92

-----

%

Recovery
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Table 27

THE EFFECT OF A SUBCUTANEOUS INJECTION OF LEAD
ACETATE ON THE ACCUMULATION OF ALA IN THE BONE
MARROW AND KIDNEY OF THE ADULT MALE RABBIT

BONE MARROW

CONTROL
µg ALA/gm

20 DAYS
µg ALA/gm

58 DAYS
µg ALA/gm

0.25

4.50

24. 63 --

FOLD INCREASE
KIDNEY
FOLD INCREASE

0.40

18

98.52

3.49

10.92

8.73

27.30

Table 28
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THE EFFECT OF A SUBCUTANEOUS INJECTION OF LEAD
ACETATE ON THE ACCUMULATION OF PBG IN THE BONE
MARROW AND KIDNEY OF THE ADULT MALE RABBIT

BONE MARROW

CONTROL
µg PBG/gm

20 DAYS
µg PBG/gm

58 DAYS
µg PBG/gm

0.20

10.00

8.00

50.00

40.00

13. 75

21. 13

55.00

84.52

FOLD INCREASE
KIDNEY
FOLD INCREASE

0.25

Table 29

METHOD* TO SEPARATE AMINOACETONE (AA) FROM
DELTA-AMINOLEVULINIC ACID (ALA)
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SUPERNATANT FROM TISSUE HOMOGENIZATION
Add to dual piggyback column unit
and wash with 30 ml water.
From the cation AG50W-X4 column,
elute the ALA and AA with 1 MNa
acetate.
Convert to pyrroles by Knorr-type
condensation with acetylacetone
and heat.
ALA AND AA PYRROLES
Apply the pyrroles to an anionic
AG-l-X8 column, 100-200 mesh,
acetate form.
Elute the AA pyrrole with 10 ml of
n-butanol containing 0.01 MNH 40H.
AMINOACETONE PYRROLE

fI

Add equal volume of fresh
modified Ehrlich's reagent.

AA-PYRROLE EHRLICH'S REACTION
Allow to stand for 10 minutes
at room temperature.
Determine optical density at
555 nm in a standard laboratory
·colorimeter.
QUANTITATE FOR AA

DELTA-AMINOLEVULINIC ACID PYRROLE
(Remaining on the column)
Wash column with 10 ml of 1 M
acetic acid.
Elute ALA pyrrole with 10 ml of
a mixture of glacial acetic acid
and methanol (1 :2).
ALA PYRROLE
Add equal volume of fresh
tI modified
Ehrlich's reagent.
ALA-PYRROLE EHRLICH'S REACTION
Allow to stand for 15 minutes at
room temperature.
Determine optical density at 553 nm
in a standard laboratory colorimeter
QUANTITATE FOR ALA

* Marver, et al. Anal. Biochem. l.1_:53-60, 1966.

Table JO
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TOTAL PERCENT OF FINAL COLOR DUE TO AMINOACETONE
IN A URINE SPECIMEN FROM A LEAD POISONED RABBITd

Method

ALA
{Mg %)

AA
{Mg %)C

Total % Of Color
Due To Aminoacetone

Urinary ALA (Davis)a

3.50

0.07

2.00 %

Urinary ALA (Marver)b

3.42

0.07

2.01 %

a. ALA eluted from cation ionic column with 1 MNa-acetate, the ALA converted
to a pyrrole by a Knorr-type condensation with acetylacetone and heat. ALA
pyrrole reacted with modified Ehrl,ch s and determined at 553 nm. ALA quantitated by referring to a standard calibration curve.
1

b. ALA converted to a pyrrole by a Knorr-type condensation with acetylacetone
and heat. The ALA pyrrole is added to an anionic AG-l-X8 column and ALA
pyrrole is eluted (after AA pyrrole) with a mixture of glacial acetic acid
and methanol (1 :2). The eluted ALA pyrrole is reacted with modified Ehrlich's
and determined at 556 nm. ALA quantitated by referring to a standard calibration curve.
c. AA pyrrole eluted from anionic AG-l-X8 column with 10 ml n-butanol containing
0.01 M ammonium hydroxide. The AA pyrrole is mixed with an equal volume of
modified Ehrlich's reagent. The AA pyrrole is determined at 555 nm at exactly
10 minutes. (Marver, et al. Anal. Biochem. 14:53-60, 1966).
d. Rabbit given single subcutaneous dose of 200 mg/kg body weight of lead acetate.

I
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Table Jl

TOTAL PERCENT OF FINAL COLOR DUE TO AMINOACETONE
IN TISSUE SAMPLES FROM A LEAD POISONED RABBIT*

Tissue
Kidney

µg ALA/gm Tissue µg AA/gm Tissue

Total % of Color
Due to Aminoacetone

1. 75

0.025

0.01 %

12.84

0.140

0. 01 %

Spleen

2.50

o. 157

0.06 %

Liver

0.67

0.010

1.49 %

Bone Marrow

* Rabbit given single subcutaneous dose of 200 mg/kg body weight
of lead acetate.
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METHOD FOR TRANSPLANTING THE
WALKER 256 CARCINOSARCOMA

60 DAY OLD SPRAGUE-DAWLEY RAT BEARING
A 7 DAY OLD SUBCUTANEOUS TUMOR

Sacrifice by decapitation.
Surgically remove the subcutaneous tumor.
Place in a sterile petri dish and wash with
sterile saline.
Transfer the cleaned tumor to a second sterile
petri dish and finely mince 2 gm of tumor by
repeated cutting with sterile scissors.
MINCED WALKER 'fUMOR

Add minced tumor to a sterile tissue press
fitted with a fine sieve covered with a 90-mesh
stainless steel screen.
Under pressure force the tumor cells through
the sieve into 5 ml sterile saline.

PELLET

WALKER TUMOR CELL SUSPENSION

(Connective tissue and cell
debris - DISCARD)

Inject 0. 5 ml subcutaneously
in the region of the lower
abdomen la tera.l to the Linea
Alba.
~~

INJECTED RAT BEARING THE WALKER TUMOR
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Table JJ

DETERMINATION OF ALAD ACTIVITY IN
RAT WHOLE BLOOD

0. 15 ml WHOLE BLOOD

l

Add I .45 ml distilled water.

HEMOLYSATE

Add 1 • 0 ml fresh 0. 01 M ALA, pH 7 . 0-7. 4
Incubate at 37 C for 60 minutes
INCUBATION MIXTURE

Stop reaction by adding 1 ml of 10%
trichloroacetic acid and 0. 05 ml of
saturated copper sulfate solution.
Centrifuge at room temperature at
600 x g for 10 min.
PELLET
(Discard)

UPERNATANT
2 ml supernatant added to 2 ml
modified Ehrlich's reagent.
Allow 2 min. for full development
of color after mixing.
Measure absorbance in a standard
laboratory colorimeter at 555 mµ
against a reagent blank.
CALCULATE ALAD UNITS
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Table )4

FORMULA FOR DETERMINING ALAD ACTIVITY

0060 - ODo

Where 0060

44.61

=

100

x Hct x 44.61

=

Units of ALAD*

=

Optical density after 1 hour at 37°C.

=

Optical density at 0 time (it was measured
in samples to which trichloroacetic acid
and copper sulfate were added to the incubation mixture before the addition of blood;
it was consistently found to be 0).

Incubation Volume (3.65 ml)
1
X b
2
Blood Volume (0. 15 ml)
X 60 (time) X 2a X 0.036 (PBG ext. coeff)

a. The first calculation is multiplied by 2 because one ml aliquot of this
incubation mixture is mixed with an equal part of Ehrlich's reagent.
b. The final answer is multiplied by 2 to represent the fact that the enzyme
activity is defined as the amount of enzyme necessary to convert 1 µ mole
of ALA to PBG. It is necessary that 2µmoles of ALA are utilized to synthesize one µmoles of PBG.
* A unit of ALAD activity is defined as the amount of enzyme necessary to
convert 1 µmole per milliliter per minute of ALA to PBG per milliliter
of red blood cells.
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Table

35

DETERMINATION OF ALAD ACTIVITY IN
WHOLE BLOOD* VERSUS PLASMA

Sample

ALAD Units

Sample

ALAD Units

50 µL whole blood

13.97

50 µL plasma

0

100 µL whole blood

18. 18

100 µL plasma

0

200 µL whole blood

24.11

200 µL plasma

0

* Blood and plasma taken from same patient and from the same
ml blood sample.

10
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Table 36

STABILITY OF THE COLOR REACTION DEVELOPED
IN THE ANALYSIS OF ALA DEHYDRASE (ALAD)
Time Color Reaction
Exposed To Light
(Minutes)

Opt i ca 1 Density
555 nm

Percent
Color Remaining

Percent
Color Loss

2

0. 129

100

0

5

0.127

98.45

1. 55

10

0. 122

94.57

5.43

15

0. 121

93.79

6.21

20

0. 119

92.25

7.75

25

0.118

91. 47

8.53

30

90.69

9.31

89.92

10.08

88.37

11. 63

45

o. 117
o. 116
o. 114
o. 110

85.27

14.73

50

0. 108

83.27

16.28

55

0. 106

82.17

17.83

60

0.106

82.17

17. 83

35
40

400 µl whole blood from tail vein of control 60 day old rat.
Ehrlich's reagent= 1 gm DMAB dissolved in 34 ml glacial acetic acid
to which is added 16 ml of 70% perchloric acid.
Reaction conditions = 2.0 ml of supernatant from the incubation
reaction plus 2.0 ml of fresh Ehrlich's reagent.
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Table 37

METHOD FOR PREPARING A WATER EXTRACT
OF THE WALKER CARCINOSARCOMA

3 0 gm TUMOR (7 days after transplantation)

l

Homogenize in 1 SO ml cold
dis tilled water

1: S (W:V) HOMOGENATE

Swirl for 30 min. at 4 C and
centrifuge at 10, 000 x g for
3 0 min • a t 4 C .

PELLET

SUPERNATANT

(Discard)

Centrifuge at 600 x g for 10 min.
at room temp.
PELLET

SUPERNATANT

(Discard)

Centrifuge at 1 OS, 000 x g
for 60 min. at 4 C.

+---------.

PELLET

SUPERNATANT

(Discard)

1

Lyophilize for
24 hours

LYOPHILIZED TUMOR EXTRACT
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Table J8

METHOD FOR PREPARING A WATER EXTRACT
OF NORMAL RAT LIVER

8. 0 gm NORMAL LIVER

1 :5 0N:V)

1

Homogenize in 40 ml cold
distilled water.

HOMOGENATE

Swirl for 30 min. at 4 C and
centrifuge at 10, 000 x g for 30 min.
at 4 C.
PELLET

SUPERNATANT

(Discard)

'
PELLET
(Discard)

Centrifuge at 105, 000 x g
for 60 min. at 4 C

SUPERNATANT
Lyophilize for
24 hours

LYOPHILIZED LIVER EXTRACT

CHARACTERISTIC FEATURES OF LEAD POISONING COMPARED WITH SEVERAL TYPES OF PORPHYRIAS
ERYTHROPOI ETI C
Characteristics

Lead
Poisoning

Uroporphyria

Protoporphyrin

Acute
Intermittent

HEPATIC
Porphyri a
Variegata

Inheritance

None

Recessive

Dominant

Dominant

Dominant

Dominant

Sex

Both

Both

Both

Both

Both

Both

Age of onset

Any age

0 -

0 - 5

12 - 40

20 - 30

10 - 30

Latent Acute

Latent Acute

Latent Acute

Phases of the
disease
Photos ens iti vity
cutaneous lesions

5

---

---

Cutanea
Tarda

++++

++

0

0

++

++++

0

0 or +

0

0

0

+++

+

++++

0

+

N

Red

N

N

Red

N

N

N

N or Red

ALA

++++

N

N

+

+++

+

++

N

++

PBG

N

N

N

+ or ++

++++

+ or ++

++++

N

+

Uroporphyrin

+

++++

N

++

+++

N to +

+++

N

++++

++

++

N

++

++

N to +

++

N

+++

N

Abdominal, phychic
and/or neurologic
++
symptoms
URINE:
Color

Coproporphyrin

N .... Norma 1
+ .... Increased
++++
Greatly Increased

0 .... Absent
ALA .. Delta-Aminolevulinic Acid
PBG .. Porphobilinogen

w
w
N
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Table 40

CHEMICALS THAT INDUCE PORPHYRIN FORMATION IN PRIMARY
CULTURES OF CHICK EMBRYO LIVER CELLS*
Chemical

Chemical

Allylisopropylacetamide

Phenobarbital-Na

Ami nopyri ne

Grislofulvin

Bemegride

Progesterone

Theophylline

05 -Pregnenolone

Orinase

Testosterone

Meprobamate

Ethinyl Estradiol

Sul fona l

Estradiol

Glutethimide

Norethandrolene

Mesantoin

Estrone

Dilantin

Menthol

Trimethadione

Diallybarbituric Acid

Chloramphenicol
* Granick, S.

J. Biol. Chem. 241 :1359-1375, 1966.
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